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Arteriosclerotic peripheral arterial disease (PAD) is a major health 
care problem among the elderly in the Western society. The estimated 
prevalence of PAD in the general population is in the range of 3% to 
10%, which increases up to 15-20% in persons over 70 years (1-4). In 
the Netherlands, the estimated prevalence among persons over 55 years 
is 19.1%, ranging from 8.1% at the age of 55-59 years towards 55.8% in 
persons over 85 years (5). The prevalence in males and females is 
roughly the same in the Netherlands (16.9% versus 20.5%, respectively), 
although men are more prone to develop symptomatic PAD (6). 
PAD is an expression of generalized arteriosclerosis, caused by 
well-known risk factors like smoking, diabetes mellitus, hypertension, 
dyslipidemia and hyperhomocysteinemia (4), and clinical symptoms are 
the result of compromised arterial flow to the lower extremities due to 
obstructive peripheral arterial lesions (figure 1). Besides obstructive 
arterial lesions at the macrovascular level, i.e. lesions of the large 
conduit arteries of the lower extremities, disorders might also be pre-
sent at the microvascular level, in which small arteries, arterioles and 
capillaries are affected. Microvascular disease comprises endothelial and 
vascular smooth muscle cell dysfunction and inflammation, which 
results in a disturbed production of vaso-active substances, leading to 
increased vascular tone and damage (1, 7-10). Microvascular disease is 
most pronounced in the majority of the subgroup of PAD patients with 
diabetes mellitus, whereas macrovascular disease is the major cause of 
symptoms in non-diabetic PAD patients (1, 7-10). 
Symptoms in PAD range from intermittent claudication, commonly 
defined as pain and / or cramping of the calf musculature in response to 
exercise, relieved by a short period of rest, to critical limb ischemia, 
defined as ischemic rest pain, ulceration or gangrene (11). Although 
intermittent claudication is the most common clinical expression of PAD, 
the vast majority of PAD patients are asymptomatic (symptomatic versus 
asymptomatic ratio is in the range of 1:3 to 1:4) and unknown to clini-
cians (4, 11). Nevertheless, some patients with asymptomatic PAD may 
have greater functional impairment and more adverse pathophysiologi-
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cal findings in calf muscles and lower extremity nerves compared to PAD 
patients with intermittent claudication (12). 
Although PAD frequently is a pro-
gressive disease, only a fraction of asymp-
tomatic subjects harboring the disease will 
ever become symptomatic. In approxi-
mately three quarters of the patients with 
intermittent claudication clinical symptoms 
are stable over time, which may be due to 
the development of new arterial structures, 
bypassing the original obstructed artery, 
the so-called collateral arteries (13). 
Collateral artery formation following 
peripheral ischemia is a complex process, 
the details of which are increasingly being 
elucidated (14). However, in depth research 
studies in human PAD patients on the 
potential vascular mechanisms underlying 
rehabilitation are limited and have provid-
ed conflicting results up to now (13). The 
formation of collateral arteries could thus 
far not be visualized or quantified and their 
specific contribution has not been conclu-
sively determined. The exact mechanisms 
underlying collateral formation are still 
unknown, as well as the reasons why the 
extent of collateral formation can differ 
from one patient to another. In 25% of the 
patients with intermittent claudication 
symptoms will significantly deteriorate, 
most frequently during the first year after 
the diagnosis (4). However, the prognosis 
is generally good and less than 2% of 
patients with PAD will end-up with major 
limb amputations, which is a major fear of 
 
 
 
Figure 1. Contrast-enhanced MR 
angiography of the peripheral 
arterial tree in a patient with 
PAD. There are numerous 
occlusions (arrowheads) and 
stenosis (arrows) present in the 
right leg, whereas the arteries of 
the left leg show signs of arterial 
disease as well. 
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many patients (4, 15). Unfortunately, to date it is difficult to predict 
which PAD patients will significantly deteriorate, although it is known 
that continuing smoking and diabetes mellitus have a negative impact 
on the prognosis of PAD patients. 
Diagnosis and treatment of peripheral arterial disease 
The diagnosis of PAD is made on the basis of the typical clinical 
history, palpation of pedal pulsations and by measurement of the ankle-
brachial index (ABI) (4, 16). Once established, the severity of PAD is 
graded by using either the Fontaine or Rutherford classifications (table 
1) (12, 17, 18). Measurement of ABI is a cheap and ubiquitously availa-
ble screening tool in the high-risk, asymptomatic population to confirm 
the presence of PAD, and is clinically relevant because of the strong 
association with underlying but clinically silent coronary artery disease 
(4, 11, 19). 
The treatment of PAD is primarily aimed at relieving symptoms. 
Given the relative benign course of PAD, today’s consensus on the best 
initial approach is optimized medical treatment in asymptomatic sub-
Fontaine classification  Rutherford classification 
Stage Symptoms  Grade Category Symptoms 
I Asymptomatic  0 0 Asymptomatic 
IIa Mild claudication*  I 1 Mild claudication* 
IIb 
Moderate – severe* 
claudication 
 I 2 Moderate claudication* 
 I 3 Severe claudication* 
III Ischemic rest pain  II 4 Ischemic rest pain 
IV Ulceration or gangrene  III 5 Tissue ulceration 
   IV 6 Tissue loss/gangrene 
Table 1. Overview of the Fontaine and Rutherford classification system. 
* Mild, moderate and severe claudication are not further specified for the Rutherford 
 classification, whereas in the Fontaine classification mild and moderate to severe 
 claudication differ in a pain free walking distance of more (mild claudication) or less 
 (moderate to severe claudication) than 200 meters. 
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jects (detected by screening) and, in addition, supervised exercise 
training in patients with intermittent claudication. For asymptomatic 
patients treatment comprises risk factor modification to prevent further 
progression of PAD (4, 11). In patients with intermittent claudication, 
the aim of treatment is improvement of exercise performance and daily 
functional abilities, which can be accomplished by structured exercise 
therapy (4, 13, 20, 21). Only when a patient’s complaints do not im-
prove under conservative treatment, or even deteriorate, imaging and 
invasive therapy (i.e. endovascular or surgical revascularization) are 
considered (4, 11). 
Besides the aforementioned therapies, a whole range of novel 
therapeutic strategies are being developed - primarily for patients with 
severe PAD unable or unlikely to benefit from conventional approaches - 
which include administration of growth factors and stem cells (22-25). 
Similar to exercise therapy, those new therapies aim to ameliorate 
symptoms by stimulation of vascular adaptations, both at the macro- 
and microvascular levels (13, 26-29). At the macrovascular level, these 
adaptations include the formation or further maturation of collateral 
arteries and to increase of capacity of existing arteries. Unfortunately, it 
is unknown to what extent exercise therapy as well as the above men-
tioned novel therapeutic options contribute to the process of collateral 
formation, nor is it known if and to what extent these collaterals add to 
functional improvement in patients. These uncertainties are partly the 
result of a lack of non-invasive diagnostic methods to visualize and 
quantify this complex biological process. 
Imaging of PAD 
As outlined above, the diagnosis of PAD can be established with 
virtual certainty based on patient history, clinical symptoms and nonin-
vasive tests like ABI. Consequently, imaging of the peripheral vascular 
tree is only preserved for patients being considered for invasive therapy 
with the aim to localize arterial lesions and to plan the correct approach 
for the intervention (figure 1) (4, 11, 30). Today, the most reliable non-
invasive imaging techniques for this purpose are computed tomographic 
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angiography (CTA) and magnetic resonance angiography (MRA) (31). 
Intra-arterial digital subtraction angiography (DSA), the traditional 
reference standard, is used less and less for planning purposes due to 
its invasiveness. Both CTA and MRA techniques yield highly accurate 
morphologic data on the macrovascular status in PAD patients and 
facilitate assessment of the suitability of lesions for intervention, with-
out the need for invasive DSA (32-34). Major advantages of CTA are 
high spatial and contrast resolution and fast acquisition times, whereas 
the most important disadvantages of CTA are the dependency on poten-
tial harmful radiation and contrast agents. It is known that many PAD 
patients suffer from renal artery stenosis as well as renal dysfunction 
which, with regards to contrast agents, makes CTA a less attractive 
alternative compared to MRA (35). 
MRA, on the other hand, is a relatively new imaging modality for 
PAD, which has important advantages over CTA. In contrast to CTA, 
there is no use of iodinated contrast agents, nor is ionizing radiation 
used. Over the past decade contrast-enhanced MRA (CE-MRA) has 
established itself as a highly accurate non-invasive diagnostic imaging 
method for morphological evaluation of the large conduit arteries in 
PAD patients. Sensitivity and specificity of CE-MRA are comparable with 
those of invasive intra-arterial DSA (33, 36, 37). Recently introduced 
blood pool contrast agents, which reversely bind with blood plasma 
albumin molecules, thereby limiting extravasation of contrast agent into 
the interstitial space, increase the temporal imaging window for CE-
MRA. This allows ultra-high spatial resolution CE-MRA acquisitions and 
whole-body CE-MRA examinations to be performed with even better 
diagnostic accuracy (38-42). 
Although DSA, CTA and MRA all provide very accurate morpholog-
ic information concerning the vascular status, the first two modalities 
are inherently limited because they only provide morphologic images 
and little or no information on the hemodynamic consequences of 
obstructive vascular lesions in PAD patients. Figure 2 for example shows 
a CE-MRA reconstruction of the superficial femoral artery in a patient 
with an occluded artery and with extensive collateral artery formation.  
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Based on this morphologic 
image, it is not possible to 
determine the contribution 
of these collateral arteries 
to the blood flow towards 
the distal lower limb. To 
supplement morphologic 
information, it would be 
highly desirable to use non-
invasive imaging tools to 
determine the hemodynamic 
significance of arterial 
stenoses and occlusions as 
well as the impact of vascu-
lar adaptations resulting 
from different treatment 
strategies. Combined 
morphologic and functional 
methods to visualize and 
quantify vascular status in 
PAD patients are useful for 
several reasons: (i) to 
confirm the diagnosis and 
grade the hemodynamic 
severity of PAD, (ii) for 
patient follow-up and 
therapy monitoring, (iii) for 
studying the mechanisms of underlying vascular adaptations, such as 
collateral artery formation, and (iv) for studying the effect of present and 
future therapeutic options. The most attractive imaging modality that 
has the potential to satisfy all these requirements is MRI. There are 
numerous MRI techniques besides MRA that are suitable to obtain 
information on vascular function (43-46). MRI-based functional meas-
urements have the advantage that they can be applied repeatedly 
 
Figure 2. Contrast-enhanced MR angiography of 
the upper leg of a patient with severe PAD. The 
superficial femoral artery at both sides is occluded 
(arrowheads mark occlusion at the right side), 
whereas especially in the right leg extensive 
collateral arteries are visible (encircled). 
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without detrimental side effects and are relatively easy to add to clinical 
routine CE-MRA examinations. 
Functional MRI in PAD 
One of the most widely used functional MRI measurements at the 
macrovascular level relevant to PAD is quantitative 2D cine MR phase 
contrast imaging (PCI) (44). The temporal variations of both the MR 
signal phase, induced by the pulsatile arterial blood flow of arteries, are 
used to obtain quantitative information about blood velocity and flow. 
The accumulated phase shift is the result of magnetic spins moving 
along the axis of a flow-encoding magnetic gradient (47, 48). PCI 
detects these phase shifts, which are proportional to blood velocity (44, 
49), and can provide a waveform of blood velocity over the cardiac cycle. 
The blood flow through a blood vessel can then be calculated by sum-
ming all velocity values, parallel to the cylinder axis, over all pixel 
positions of the cross-sectional vessel area depicted in the image. 
At the microvascular level, MRI can be used to measure end-organ 
perfusion utilizing dynamic contrast-enhanced (DCE) MRI, as well as 
tissue oxygenation using dynamic blood oxygen level-dependent (BOLD) 
MRI (43, 45). DCE MRI is able to determine regional perfusion in skeletal 
muscle tissue (50, 51). By dynamically recording enhancement of muscle 
tissue during injection of contrast medium and measuring the signal in 
the arteries supplying those muscles, quantitative information on the 
microcirculation can be obtained. When a small molecular contrast agent 
is used, the wash-in rate of the tissue is relatively fast and primarily 
determined by microvascular flow (and not by vessel wall permeability 
issues). Using a two-compartment pharmacokinetic model that relates 
arterial concentration to the tissue concentration, the dynamic transfer 
of the contrast agent from the blood space to the tissue can be quanti-
fied in terms of the unidirectional influx constant, which is a surrogate 
quantity for microvascular flow. 
In contrast to DCE MRI, BOLD MRI is a non-contrast enhanced 
functional MRI technique to measure perfusion. The BOLD phenomenon 
is based on local susceptibility changes due to changes in blood oxy-
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genation and BOLD MRI is sensitive to the concentration of paramagnet-
ic deoxyhemoglobin. When the oxygenation state of a certain tissue is 
altered, the ratio between oxyhemoglobin and deoxyhemoglobin con-
centrations will change accordingly, which results in a local change in 
magnetic susceptibility. The presence of deoxyhemoglobin in blood 
results in a mismatch between the magnetic susceptibility of tissue and 
blood and thereby shortens the T2* relaxation time of blood and its 
immediate surroundings (45, 49). Increase of oxygenation increases the 
measured signal intensity due to the higher oxyhemoglobin and/or 
lower deoxyhemoglobin concentration. This can be observed under 
hyperemic (increased blood flow) circumstances, such as reactive hyper-
emia. Lower signal intensity on the other hand is expected under more 
ischemic conditions, in which the concentration of deoxyhemoglobin will 
rise (45, 49, 52-57). 
Functional MRI measurements as described above could in theory 
provide useful additional quantitative information on the muscle perfu-
sion status in the evaluation of PAD. However, to date the additional 
value or clinical reproducibility of functional MRI measurements is 
unknown for PAD. 
Objectives 
Main objective of the current thesis was to determine and optimize 
the suitability of morphologic and functional vascular MRI for diagnosis 
and longitudinal follow up of PAD patients. To achieve this objective we 
first determined the reproducibility of CE-MRA as well as the above-
mentioned functional MRI techniques in PAD patients, non-PAD subjects 
and healthy controls. We also assessed the discriminative capability of 
these techniques to differentiate between PAD patients and non-PAD 
subjects. Based upon these results, improvements of functional vascular 
MRI techniques and an optimal clinical implementation are proposed 
and tested in practice. Finally, morphologic and functional vascular MRI 
was used to evaluate vascular changes over time in PAD patients under-
going supervised exercise therapy. 
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Outline of the thesis 
o In chapter 2 the reproducibility of morphologic and functional 
vascular MRI is evaluated in PAD patients as well as in healthy con-
trol subjects. In addition, differences between PAD patients and 
healthy control subjects are investigated. 
o In chapter 3 measures at different levels of the peripheral arterial 
vasculature in a large population of PAD and non-PAD patients are 
evaluated to determine the best location to measure the arterial 
peak flow (APF) in order to facilitate clinical standardization. 
o In chapter 4 the APF, success rates and discriminative capability of 
APF are compared with ABI measurements in a large population of 
PAD patients. 
o In chapter 5 reference values for the APF in patients with PAD and 
non-PAD subjects are established and the influence of disease se-
verity (intermittent claudication versus critical ischemia), presence of 
diabetes mellitus and age on APF is evaluated. 
o In chapter 6 the results of a longitudinal follow-up study using CE-
MRA and quantitative PCI to study the effect of supervised exercise 
therapy on vascular changes in PAD patients are presented. 
o In chapter 7 a technique is presented to measure arterial flow 
reserve by quantitative PCI to improve the sensitivity of the APF to 
differentiate between PAD patients and healthy controls. 
o In chapter 8 we demonstrate the feasibility of DCE MRI of the calf 
musculature of PAD patients and healthy control subjects using a 
blood pool contrast agent. 
o Chapter 9 comprises general conclusions of this thesis. 
o Chapter 10 is the summary of the thesis. 
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Abstract 
Objectives 
The aim of the current study was to test the reproducibility of dif-
ferent quantitative MRI methods to assess the morphological and func-
tional peripheral vascular status and vascular adaptations over time in 
patients with peripheral arterial disease (PAD). 
Materials and methods 
Ten patients with proven PAD (intermittent claudication) and arte-
rial collateral formation within the upper leg and 10 healthy volunteers 
were included. All subjects underwent two identical MR examinations of 
the lower extremities on a clinical 1.5T MR system, with a time interval 
of at least 3 days. The MR protocol consisted of 3D contrast-enhanced 
MR angiography (CE-MRA) to quantify the number of arteries and artery 
diameters of the upper leg, 2D cine MR phase contrast angiography 
(PCA) flow measurements in the popliteal artery, dynamic contrast-
enhanced (DCE) perfusion imaging to determine the influx constant and 
area-under-curve and dynamic blood oxygen level-dependent (BOLD) 
imaging in calf muscle to measure maximal relative T2* changes and 
time-to-peak. Data were analyzed by two independent MRI readers. 
Interscan and interreader reproducibility were determined as outcome 
measures and expressed as the coefficient of variation (CV). 
Results 
Quantification of the number of arteries, artery diameter and 
blood flow proved highly reproducible in patients (CV 2.6, 4.5 and 15.8% 
respectively at interscan level and 9.0, 8.2 and 7.0% at interreader level). 
Reproducibility of DCE and BOLD MRI was poor in patients with a CV up 
to 50.9%. 
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Conclusion 
Quantification of the morphological vascular status by CE-MRA, as 
well as PCA MRI to assess macrovascular blood flow proved highly 
reproducible in both PAD patients and healthy volunteers and might 
therefore be helpful in studying the development of collateral arteries in 
PAD patients and in unraveling the mechanisms underlying this process. 
Functional assessment of the microvascular status using DCE and BOLD 
MRI did not prove reproducible at 1.5 T and is therefore currently not 
suitable for (clinical) application in PAD. 
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Introduction 
Peripheral arterial disease (PAD), characterized by arteriosclerotic 
stenosis or occlusion of pelvic and/or lower extremity arteries, may 
manifest clinically as intermittent claudication or critical limb ischemia 
(1). The primary treatment for patients with intermittent claudication is 
supervised exercise therapy, which may stimulate collateral blood artery 
formation to increase muscle perfusion (1-3). Stimulation of collateral 
blood vessel growth is also the main target of angiogenic growth factor 
or stem cell administration to improve tissue oxygenation in patients 
with critical limb ischemia (4-6). The exact mechanisms underlying this 
process are presently unknown, but are thought to involve both adapta-
tion of existing arteries and the formation of new collateral arteries over 
time (7). Furthermore, it is presently unknown to what extent different 
therapeutic options contribute to these vascular adaptive responses, and 
to what extent functional improvement of patients is related to such 
vascular adaptations (1, 8). 
Uncertainties concerning the exact type and extent of vascular ad-
aptations in humans are partly due to the lack of non-invasive diagnos-
tic methods to visualize and quantify these processes. Quantitative non-
invasive imaging tools that can be used to study the process of vascular 
adaptation and to monitor the effectiveness of vessel-stimulating 
therapies are therefore highly desirable. Magnetic resonance imaging 
(MRI) techniques are attractive for this purpose, as they provide high 
spatial resolution to visualize the entire peripheral vascular tree, includ-
ing small collateral arteries. Furthermore, MRI techniques are suitable to 
obtain information on vascular morphology and function and allow 
repeated measurements without ionizing radiation exposure (9-15). 
However, for evaluation of vascular responses over time it is crucial that 
MRI provides reproducible quantitative measures. 
The aim of the current study was to test the reproducibility of dif-
ferent MRI methods to assess the morphological and functional vascular 
status and adaptations of the peripheral vasculature over time. Morpho-
logically, the reproducibility was determined of a method to quantify the 
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number of arteries in the upper leg, visualized by contrast-enhanced MR 
angiography (CE-MRA). Development of collateral arteries might result 
in an increased blood supply to and subsequent enlargement of the 
collateral re-entrance zone. This collateral re-entrance zone represents 
the level at which collaterals re-enter the large native conduit artery 
distal to an occluded segment of the arterial tree (distal superficial 
femoral or popliteal artery in our study), For this, the reproducibility of 
diameter measurements of the distal conduit artery was also assessed. 
Functional vascular status was determined both at macro- and micro-
vascular level. Reproducibility of macrovascular function was studied by 
measuring peak arterial blood flow in the popliteal artery (PA) with 
quantitative 2D cine MR phase contrast angiography (PCA) (10, 16-19). 
Reproducibility of microvascular function was determined in the calf 
musculature by perfusion measurements using dynamic contrast-
enhanced (DCE) MRI (9, 20, 21) as well as the blood oxygenation meas-
urements using dynamic blood oxygen level-dependent (BOLD) MRI (13, 
22-27). All measurements were performed in a group of PAD patients 
with proven extensive collateral artery formation and a group of healthy 
volunteers. 
Materials and methods 
Phantom study 
A vessel phantom was used to determine the diameter of the 
smallest arteries that can be detected with our clinically used CE-MRA 
protocol. This phantom consisted of ten tubes with varying inner diame-
ters: 6.00, 2.03, 1.57, 1.40, 1.01, 0.76, 0.51, 0.25, 0.18 and 0.13 mm. 
These tubes were filled with the same gadolinium-based contrast agent 
as used in the patient study (gadopentetate dimeglumine, (Magnevist), 
Bayer HealthCare Pharmaceuticals, Berlin, Germany), with a concentra-
tion of 11 mmol/L, which is representative of the peak arterial concen-
tration in our human study. Tubes were immersed in a muscle tissue 
mimicking fluid (T1 = 800 ms, 0.2 mmol/L gadopentetate dimeglumine 
solution). 
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MRI was performed using the same acquisition protocol as used in 
the human studies detailed below. Scan parameters are given in table 1. 
Acquired voxel sizes were 1.22 x 1.52 x 2.4 mm. Subsequently, voxels 
were interpolated to 0.92 x 0.92 x 1.2 mm during reconstruction by 
zero-filling. The phantom was positioned slightly angulated with respect 
to the z-axis of the MRI scanner to average the signal over many sub-
voxel positions. 
For image analysis, a line segment perpendicularly intersecting the 
depicted tubes was manually drawn. The intensity profile along this line 
was analyzed to determine the smallest detectable tube diameter by 
counting the number of peaks in the signal intensity profile. 
Human study 
Over a period of 6 months, 10 patients (mean age 64.7 ± 6.1 
years; range 57 to 73 years; 9 men and 1 woman) with proven PAD 
(intermittent claudication, Fontaine stage II, Rutherford stage 1-3) and 
arterial collateral vessel formation within the upper leg and 10 healthy 
volunteers without signs and symptoms of PAD (mean age 26.7 ± 11.5 
years; range 18 to 50 years; 2 men and 8 women) were included. PAD 
patients were eligible for the study if peripheral CE-MRA examinations 
as part of routine diagnostic work-up confirmed the presence of super-
ficial femoral artery (SFA) occlusion with a collateral arterial network in 
the upper leg. Patients with contra-indications to MRA, including claus-
trophobia, known gadolinium based contrast agent allergy, and low 
estimated glomerular filtration rate (< 30 mL/kg/1.73 m2) were exclud-
ed from participation. The study was approved by the institutional 
medical ethics committee and all patients and healthy controls gave 
written informed consent before inclusion. 
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Magnetic Resonance Imaging 
All subjects underwent two MRI examinations on different days 
(mean interval 14.6 days, range 3 - 68 days). An overview of the imag-
ing protocol is given in figure 1. The entire examination lasted one hour. 
Patients received no treatment between both examinations. All exami-
nations were performed on a 1.5-T commercially available system 
(Intera, Philips Medical Systems, Best, The Netherlands). For signal 
reception we used a dedicated 12-element phased-array peripheral 
vascular coil with a craniocaudal coverage of 128 cm (Philips Medical 
Systems, Best, The Netherlands). Subjects were imaged in the supine 
position and care was taken not to deform calf muscle by calf-bed 
contact. All subjects were lying in this position for at least 15 minutes 
before the first measurement was started. Scan parameters for all 
acquisitions are given in table 1. 
Contrast. For CE-MRA and DCE MRI a dose of respectively 30 and 
15 mL gadopentetate dimeglumine (Magnevist, Bayer HealthCare Phar-
maceuticals, Berlin, Germany) was injected intravenously as a single 
biphasic bolus in the cubital vein, using a remote controlled injection 
system (Medrad Spectris, Indianola, PA). Although CE-MRA for this study 
comprised only one station (upper leg), an injection of 30 mL of contrast 
agent was chosen for best comparison of image quality with common 
clinical three-station peripheral CE-MRA, for which we normally admin-
ister a single bolus of 30 mL. After contrast medium administration, 20 
mL of saline was injected. Real time bolus monitoring software (Bolus-
Trak, Philips Medical Systems, Best, The Netherlands) was used to 
visualize the arrival of the bolus in the proximal SFA with a refresh rate 
of proximally 1 frame/sec. Upon first sight of contrast arrival in the 
proximal SFA, image acquisition for the CE-MRA sequence was started. 
For DCE MRI, cuff inflation (see below) was immediately followed by a 
single bolus of 15 mL contrast agent, allowing systemic contrast equili-
bration in the arterial blood pool proximal to the occlusion during cuff 
compression. 
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Cuff paradigm. For DCE and BOLD MRI, postischemic reactive hy-
peremia was provoked in both lower legs using inflatable cuffs (Medrad, 
Indianola, PA). Reactive hyperemia was provoked to ensure measurable 
signal alterations in DCE and BOLD MRI and to ensure a most reproduci-
ble state of vasodilatation for both examinations for each patient (13). A 
cuff paradigm was chosen, as this method was believed to be more 
reproducible and suitable for MRI in comparison with muscle exercise 
and less invasive in comparison with drug induced vasodilation. Besides, 
a cuff paradigm ensures a vascular step-input function of contrast 
agent, as preferred for DCE MRI (9). The cuffs were placed at mid-thigh 
level and manually inflated to suprasystolic values (> 50 mmHg above 
brachial systolic blood pressure) during 6 minutes prior to BOLD and 
DCE MRI, ensuring total arterial occlusion (13). 
Survey. A non-enhanced time-of-flight (TOF) scan of the pelvic, 
upper and lower leg station was acquired to prescribe the imaging 
volumes of interest for morphological and functional imaging. A turbo 
field echo (TFE) pulse sequence was used with a 180° inversion prepulse 
to suppress stationary tissues. Thirty-one axial slices per station were 
acquired with 3.3-mm slice thickness and 11-mm interslice gap, and an 
inferiorly concatenated saturation band. The standard quadrature body 
coil was used for signal transmission and reception. For positioning of 
the 3D CE-MRA volumes maximum intensity projections (MIP) were 
generated in 3 orthogonal directions. 
CE-MRA. An one-station 3D CE-MRA was performed with voxel 
sizes identical of the phantom study. Whereas clinical CE-MRA examina-
tions are usually limited to visualization of a thin anteroposterior imag-
ing volume only including the large conduit arteries in the upper leg (i.e. 
SFA and PA), for this study the entire muscular volume of the upper leg 
was imaged to visualize all the arteries including any collateral branches 
within the upper leg. Prior to contrast medium administration, a non-
enhanced ‘mask’ image data set was acquired with exactly the same 
acquisition parameters as the CE-MRA, enabling background tissue 
suppression by image subtraction. 
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PCA MRI. Blood flow data were obtained in the PA (distal to the 
vascular lesion in the SFA in patients). A single slice was positioned 
perpendicular to the course of the PA. Twenty cardiac phases were 
acquired over the R-R interval with an encoding velocity (venc) of 100 
cm/s in the craniocaudal direction. VCG-tracing was used for retrospec-
tive cardiac synchronization. The nominal duration of this acquisition 
was 136 seconds at a heart rate of 60 beats per minute. 
DCE MRI. DCE-MRI was preceded by T1 mapping to determine 
pre-contrast T1 relaxation times before contrast enhancement, using a 
scan sequence with identical contrast parameters and geometry as for 
the subsequent DCE acquisitions, but with variable flip angles (2, 5, 10, 
15, 25 and 35°) (9, 28). A dynamic 3D T1-weighted gradient echo 
sequence was used for DCE MRI (table 1). Slices were positioned at the 
maximum diameter of the calf. Five dummy scans were acquired before 
the actual measurement to avoid varying T1 saturation effects. The 
acquisition started 330 seconds after cuff inflation. The cuff was then 
rapidly deflated (within 2 seconds) together with the start of the 6th 
dynamic scan. 
BOLD MRI. For BOLD imaging, a multi-shot single-echo echo pla-
nar imaging (EPI) sequence with fat suppression (spectral presaturation 
with inversion recovery, SPIR) was used to detect the T2* responses to 
oxyhemoglobin changes. Slices were also positioned at the maximum 
diameter of the calf. The first 1:30 minutes of the measurement were 
used to obtain baseline values. The cuff was then inflated for 6 minutes, 
while the measurement continued (data not used for analysis) and after 
cuff deflation the measurement continued for approximately 6 minutes. 
The dynamic study was preceded by a series of EPI sequences to deter-
mine the T2* relaxation time of muscle tissue, using the same parame-
ters and geometry but increasing echo times of 10, 15, 20, 30, 40 and 
50 ms. 
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Image analysis 
In patients the most symptomatic leg was analyzed for all meas-
urements. In healthy volunteers reproducibility measures were deter-
mined for both legs separately and these measures were subsequently 
averaged. Two independent MRI readers (ME and BV) analyzed all da-
tasets, blinded for each other’s results and the order of the examina-
tions. 
Vascular morphology 
CE-MRA. Image analysis was performed on a dedicated image post 
processing workstation (MacPro, running OS X, version 10.5.4, Apple 
Inc., Cupertino, CA). Both source images and subtracted images were 
analyzed to ensure that no collateral arteries were missed due to mis-
registration artifacts between the source and mask images. 
The MRI readers manually quantified the number of collaterals by 
counting the total number of arteries crossing transverse planes in the 
upper leg at five different levels. In patients, arteries were counted at 
 
Figure 2. Maximum intensity projection 
(MIP) after background subtraction of a CE-
MRA in a PAD patient with segmental 
occlusion of the superficial femoral artery 
with extensive collateral blood vessel 
formation. The image shows the location of 
the five transverse planes, represented by 
the five horizontal lines, at which quantifi-
cation of the number of arteries was 
manually performed. This MIP image is 
used to demonstrate the locations of the 
measurements; the actual measurements 
were performed using the 3D image data 
set. 
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the following levels: 5 cm below, exactly at and 5, 10, and 15 cm above 
the location where the SFA was reconstituted distal to the occlusion 
(figure 2). In volunteers these planes were located at 10, 15, 20, 25 and 
30 cm above the distal margin of the femoral condyls, as this corre-
sponded best to the levels used in patients. In volunteers both legs were 
analyzed, whereas in patients only the most symptomatic leg (i.e. with 
clinically significant vascular pathology) was analyzed. 
Arteries were counted using the open source DICOM viewer OsiriX 
(OsiriX, Geneva, Switzerland, version 3.5.1, http://www.osirix-
viewer.com/), using the original source images as well as coronal and 
sagittal multiplanar reconstructions (MPR). Identification of the correct 
counting plane was ensured by placing a crosshair at the anatomical 
landmarks as described above. Subsequently, the total number of 
arteries intersecting the five planes was determined, including conduit 
arteries (SFA or PA), terminal muscle branches and any collateral arter-
ies. Arteries were distinguished from veins by scrolling through source 
images and MPR stacks when it was necessary to find an upstream 
connection to a named artery. 
Diameter of the collateral re-entrance zone and image quality, in 
terms of contrast-to-noise ratio (CNR), were assessed on source imag-
es. Artery diameter and CNR were determined below the vascular lesion 
at the level of the collateral re-entrance zone (distal SFA or proximal PA 
in PAD patients or at the level of the PA in healthy volunteers). Artery 
diameter was measured at the coronal source images by manually 
drawing a line segment perpendicular to the artery at the same location 
as the most inferior transverse plane, used for counting the arteries. 
Next, the intensity profile along this line was obtained to determine the 
full-width-at-half-maximum of the arterial lumen, which represented 
the arterial diameter. Image quality of vascular depiction was expressed 
as the contrast-to-noise ratio (CNR), which was defined as the differ-
ence between signal intensity within the vessel and a similarly sized 
region of interest directly adjacent to the vessel. 
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Vascular function 
PCA MRI. Modulus and phase images were reconstructed from the 
PCA data. The image software application MRIcro (MRIcro, 
http://www.mricro.com/) was used to manually draw a region of inter-
est (ROI) covering the entire visible surface of the PA on each of the 20 
reconstructed modulus images spanning the R-R interval. These regions 
of interest (ROI’s) were analyzed, using self-written software code 
(Matlab, The Mathworks inc., Natick, MA) to obtain velocity and flow 
waveforms from the phase images. Reproducibility was determined for 
the peak flow (unit: mL/s), as flow has been shown to be a more reliable 
parameter compared to velocity and peak values have shown larger 
differences between patients and healthy volunteers and proven to be 
more reliable compared to mean values for small arteries like the PA 
(10). 
DCE MRI. MRIcro was used to manually draw large ROI’s covering 
the entire cross-section of the calf muscle (including vessels) in four 
successive slices. Special attention was given to draw ROI’s of both 
scans for every subject at the same location. 
Self-written Matlab software code was used for the analysis of T1-
weighted signal intensity time-courses for each ROI. Individual signal 
time-courses were normalized with respect to resting values, measured 
prior to contrast agent arrival and converted to contrast agent concen-
tration, using the relation between T1 relaxation time and the signal 
intensity for a spoiled gradient echo pulse sequence. Signal to contrast 
agent concentration conversion was applied to correct for the presence 
of residual contrast agent from the CE-MRA, which may vary between 
patients and healthy volunteers. In addition, contrast concentration is 
less scan technique dependent compared to signal intensity. 
A vascular input function could not be obtained in every patient. 
Therefore a predefined step-wise vascular input function (VIF) with a 
maximum (i.e. step size) concentration of 0.45 mM was used for data 
analysis (9). The influx constant (Ki, unit: min-1) and area-under-curve 
(AUC, unit: mMs) up to 90 seconds after contrast arrival were calculated 
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as surrogate markers of microvascular blood flow (9). Reproducibility 
was determined for both Ki and AUC. 
BOLD MRI. Analogous to DCE MRI, a large ROI, covering the entire 
cross-section of the calf muscle was drawn in the 4 acquired slices to 
assess skeletal muscle oxygenation. Self-developed Matlab software 
code was used for analysis of the T2* signal intensity time courses for 
each of the ROI’s. Individual T2* time courses were divided by the aver-
age T2* values measured prior to cuff inflation. The maximum relative 
T2* change after cuff deflation relative to the resting condition value 
(rT2max, unit: %) and TTP (unit: s) were determined (13). rT2max and TTP 
were both used to determine the reproducibility of the BOLD technique. 
Statistical analysis 
To determine reproducibility, two agreement measures, being the 
coefficient of variation (CV in %) and the repeatability coefficient (RC), 
and a measure for reliability, the intra-class correlation coefficient (ICC) 
were determined. The CV was derived by dividing the overall mean 
within-subject standard deviation (SDws) by the mean measurement 
value over all subjects. The RC gives the smallest noticeable difference 
that can be detected beyond measurement error and is defined as 
1.96⋅√2⋅SDws (29, 30). The difference between 2 measurements in the 
same subject is expected to be less than the RC in 95% of the observa-
tions in cases where the measured quantity remains unchanged over 
time. A value of RC (or CV) lower than absolute (or relative) difference 
between mean values in patients and controls indicates good agree-
ment. The ICC was calculated using a 1-way random model, according 
to ICC = SDbs2 / (SDbs2 + SDws2), where SDbs represents the standard 
deviation between subjects. The ICC is the fraction of total variance due 
to variation between subjects, rather than measurement error, and 
ranges between 0 and 1. If the measurement error is small compared to 
the variation between subjects, the ICC approaches 1, i.e. reliability is 
very high. 
Figure 3 schematically illustrates how interscan and interreader 
reproducibility were defined. Interscan reproducibility is influenced by 
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contrast injection, vascular opacification, positioning of the patient 
within the coil or magnet, preparation of the patient, physiological 
variances within the patient, and reader errors. Interscan reproducibility 
is mainly influenced by scan related inconsistencies and was calculated 
by averaging the results of both MRI readers for each scan (mean of MRI 
1 for reader A and B versus the mean of MRI 2 for reader A and B in 
figure 3). Interreader reproducibility is an indicator of image reading 
error and is primarily influenced by reader experience. Interreader 
reproducibility was calculated by averaging the results of both scans for 
each MRI reader (mean of reader A for MRI 1 and MRI 2 versus the mean 
of reader B for MRI 1 and MRI 2 in figure 3). 
Secondary to the reproducibility, an independent-samples t-test 
was performed to test the significance of differences in parameters 
between patients and healthy volunteers. P < 0.05 was considered 
statistically significant. All statistical analyses were performed with 
commercially available statistical software (SPSS 16.0, SPSS Inc., Chicago, 
IL). 
 
 
Figure 3. Schematic overview to define the interscan and interreader reproducibility. 
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Results 
Vessel phantom 
Figure 4 displays a thin-slab maximum intensity projection (MIP) 
image of the vessel phantom. The smallest tube visualized had a diame-
ter of 0.51 mm. The smallest peak visible in the signal intensity profile 
matched the smallest tube visible on the MR angiogram. 
Subjects 
All patients and healthy 
volunteers underwent both MRI 
examinations without experi-
encing side effects or adverse 
events. In one patient there 
were severe subtraction mis-
registration artifacts in CE-MRA 
due to patient movement 
between acquisition of the 
mask and the contrast-
enhanced data sets. For this 
patient only the original con-
trast-enhanced images were 
analyzed. Reactive hyperemia 
could not be provoked in two 
out of ten patients as the cuff 
broke during cuff inflation. 
There were no side effects or 
adverse events in any of the 
study subjects. Severe discom-
fort due to cuff inflation was 
reported in 3 out of the 8 
patients and 3 out of the 10 
volunteers. 
 
Figure 4. Thin slab (5 slices) maximum intensity 
projection (MIP) image showing the tubes with 
various diameters. Seven out of ten tubes can be 
distinguished. Graph shows the signal intensity 
profile measured at the level of the dotted line in 
the MIP image. The 6 mm tube with the highest 
signal intensity has been removed from the 
image to improve contrast. 
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  Patients Volunteers 
 Source images Subtracted images Source images Subtracted images 
 (n = 10) (n = 9) (n = 10) (n = 10) 
Arteries per plane 15.7 ± 3.5 14.5 ± 3.2a 12.9 ± 2.5 13.1 ± 2.3b 
Interscan reproducibility    
CV % 2.6 6.1 2.8 3.1 
RC  1.1 2.5 1.0 1.1 
ICC (95% CI) 0.99 (0.95 - 0.99) 0.92 (0.75- 0.98) 0.98 (0.90 - 0.99) 0.97 (0.89- 0.99) 
Interreader reproducibility    
CV % 9.0 10.1 11.1 10.0 
RC  3.9 4.1 3.9 4.5 
ICC (95% CI) 0.85 (0.56 - 0.96) 0.81 (0.44 - 0.95) 0.73 (0.12 - 0.95) 0.74 (0.18 - 0.94) 
Table 2. Numbers of arteries per plane and reproducibility of artery count. 
Number of arteries is expressed as mean ± SD. CV, coefficient of variance; RC, repeatabil-
ity coefficient; ICC, intraclass correlation coefficient; 95% CI, 95% confidence interval. a p = 
0.19, b p = 0.43. 
Vascular morphology 
Artery count. Table 2 lists the number of arteries and reproduci-
bility measures for source and subtracted images in patients and volun-
teers. Interscan and interreader reproducibility were better for source 
images compared to subtracted images for both groups. Furthermore, 
RC at interscan level was roughly 4 times lower than the RC at in-
terreader level, indicating better agreement at interscan level. There 
were no relevant differences in reproducibility measures between pa-
tients and volunteers, both at interscan and interreader level. In figure 5 
Bland-Altman plots are shown for artery count on CE-MRA source 
images for interscan and interreader variations (31). Both for patients 
and volunteers, the range between the 95% limits of agreement is much 
narrower, and therefore better, at interscan level compared to in-
terreader level. 
No significant differences were found in mean number of arteries 
per plane between the source and subtracted images in both patients 
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and volunteers. The number of arteries per plane was significantly 
higher in patients compared to volunteers for CE-MRA (p < 0.05). 
Artery diameter. In table 3 results of the arterial diameters of the 
collateral re-entrance zone in patients and PA in volunteers are listed. 
Analogous to the artery count, the interscan RC in patients was better 
than interreader RC, whereas in volunteers the reverse was found. This 
was the case true for the CV in patients and volunteers. ICC was low in 
 
Figure 5. Interscan and interreader reproducibility of number of arteries per plane in PAD 
patients and volunteers. Bland-Altman plots showing difference in number of arteries 
between scans (interscan) or readers (interreader) (y-axis) against mean number of 
arteries (x-axis). Absolute mean difference is represented by the solid line and 95% 
confidence interval is given by the two dashed lines. 
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volunteers with respect to interscan level reproducibility. In figure 6 
Bland-Altman plots are shown for the collateral re-entrance zone on 
source images at interscan and interreader level for both patients and 
healthy volunteers (31). The 95% limits of agreement show no large 
differences between interscan and interreader diameters for both pa-
tients as well as volunteers. 
 
 
Figure 6. Interscan and interreader reproducibility of diameters of the conduit artery near 
the collateral re-entrance zone in PAD patients and of the popliteal artery in volunteers. 
Bland-Altman plots showing difference in diameter between scans (interscan) or readers 
(interreader) (y-axis) against mean vessel diameter (x-axis). Absolute mean difference is 
represented by the solid line and 95% confidence interval is given by the two dashed 
lines. 
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Table 3. Artery diameter, reproducibility and contrast-to-noise ratio. 
Arterial diameter is expressed as mean ± SD. CNR, contrast-to-noise ratio. a p = 0.43, b p 
< 0.05. 
 
 
  Patients Volunteers 
   (n = 10) (n = 10) 
Peak flow mL/s 3.15 ± 1.40 9.77 ± 2.06a 
Interscan reproducibility   
 CV % 15.8 6.8 
 RC mL/s 1.4 1.9 
 ICC (95% CI) 0.94 (0.76 - 0.98) 0.89 (0.77- 0.97) 
Interreader reproducibility   
 CV % 7.0 5.9 
 RC mL/s 0.6 1.6 
 ICC (95% CI) 0.98 (0.95 - 0.99) 0.92 (0.51 - 0.93) 
Table 4. Reproducibility of PCA MRI in the popliteal artery. 
Values are presented as mean ± SD.ap < 0.01. 
No significant differences were found in artery diameters between 
patients and volunteers (p = 0.43). 
   Patients Volunteers 
   (n = 10) (n = 10) 
Arterial diameter mm 6.9 ± 1.2 7.0 ± 0.7a 
Interscan reproducibility   
 CV % 4.5 5.6 
 RC mm 0.8 1.1 
 ICC (95% CI) 0.94 (0.79 - 0.98) 0.71 (0.39- 0.88) 
Interreader reproducibility   
 CV % 8.2 4.0 
 RC mm 1.5 0.8 
 ICC (95% CI) 0.79 (0.44 - 0.94) 0.84 (0.63 - 0.94) 
CNR   64 ± 31 84 ± 31b 
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Image quality. CNR values of the CE-MRA images are listed in ta-
ble 3 as well. Patients showed a significantly lower CNR compared to 
volunteers (p < 0.05). 
Vascular function 
PCA MRI. Examples of measured waveforms are shown in figure 7. 
In table 4 the results of the reproducibility of the flow assessment are 
listed. In general, reproducibility of peak flow was good according to all 
different measures of agreement and reliability, with an interscan CV in 
patients up to 15.8%. Interreader reproducibility was better than the 
interscan reproducibility, especially for the patient group.  
Flow waveforms in patients were either bi- (n = 3) or monophasic 
(n = 7), whereas triphasic flow waveforms were obtained in all volun-
teers (figure 7). The peak flow in the PA of patients was less than 1/3 
compared to peak flow of healthy volunteers (p < 0.01). For PCA MRI, 
there was no relevant difference in any of the reproducibility measures 
between patients and healthy volunteers. 
 
 
Figure 7. PCA modulus image (left panel) of the knee in a 68-year old patient suffering 
from Fontaine stage II PAD with a black square marking the popliteal artery. Typical flow 
waveforms of the popliteal artery are shown in a patient (center panel) and 24-year old 
healthy volunteer (right panel) at two different time points show excellent reproducibility 
over time. Note loss of tri-phasic flow waveform and a decrease in peak flow in the patient 
with PAD compared to the healthy volunteer. 
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Figure 8. Example of DCE image (left panel) in a 68-year old patient suffering from 
Fontaine stage II PAD. Reproducibility was determined for a ROI covering the entire 
muscular volume (area between the black dotted contours). Graphics show the signal 
intensity converted to contrast agent concentration over time directly after cuff deflation in 
a PAD patient (center panel) and healthy volunteer (right panel) for both sessions. Note the 
interscan variability in PAD patients and healthy volunteers. 
 
 
Figure 9. Example of BOLD image (left panel) in a 68-year old patient with Fontaine stage 
II PAD. Reproducibility was determined for a ROI covering the entire muscular volume (area 
between the black dotted contours). Graphics show the normalized T2* over time directly 
after cuff deflation in a PAD patient (center panel) and healthy volunteer (right panel) for 
both sessions. Note the large interscan variability in PAD patients (center panel) and 
healthy volunteers (right panel). 
DCE MRI. Examples of DCE MRI derived time courses are shown in 
figure 8. DCE-MRI interscan reproducibility was poor in patients for both 
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Ki and AUC with interscan CV values up to 51% (table 5). Interreader 
reproducibility, on the contrary, was good with a low CV and RC, indi-
cating a strong agreement between the readers, and a high ICC, indicat-
ing good interreader reliability. Interreader reproducibility was 
comparable between patients and healthy volunteers. 
Ki of the entire cross-section muscular volume showed a trend of 
lower perfusion values in the calf of patients compared to healthy 
volunteers (p = 0.07), whereas the AUC showed a trend of higher values 
in patients(p = 0.09).  
    
   Patients Volunteers 
   (n = 8) (n = 10) 
Ki min-1 0.64 ± 0.22 0.84 ± 0.26a 
Interscan reproducibility   
 CV % 50.9 17.7 
 RC min-1 0.9 0.4 
 ICC (95% CI) 0.00 (0.00 - 0.65) 0.71 (0.22 - 0.92) 
Interreader reproducibility   
 CV % 6.3 3.5 
 RC min-1 0.1 0.1 
 ICC (95% CI) 0.97 (0.86 - 0.99) 0.99 (0.95 - 0.99) 
AUC mMs 4.18 ± 1.26 3.53 ± 1.24b 
Interscan reproducibility   
 CV % 26.1 10.7 
 RC mMs 3.0 1.0 
 ICC (95% CI) 0.45 (0.00 - 0.86) 0.69 (0.17 - 0.91) 
Interreader reproducibility   
 CV % 4.2 6.2 
 RC mMs 0.5 0.6 
 ICC 95% CI 0.98 (0.92 - 0.99) 0.97 (0.89 - 0.99) 
Table 5. Reproducibility of DCE MRI in the calf. 
Values are presented as mean ± SD; Ki, influx constant; AUC, area under the curve; ap = 
0.07; bp = 0.09. 
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BOLD MRI. Examples of BOLD time-courses are shown in figure 9. 
In patients BOLD derived parameters had interscan CV values in rT2max 
and TTP of up to 27% and 11% respectively and these results were 
comparable with those found in healthy volunteers (table 6). The in-
terreader reproducibility was better in patients for both BOLD parame-
ters and had CV values of up to 1.5 % for rT2max and 11.3 % for TTP 
(table 6). 
TTP was delayed (p < 0.01) in the patient group compared to the 
volunteers, whereas the rT2max was nearly equal (p = 0.97). 
     
   Patients Volunteers 
   (n = 8) (n = 10) 
rT2max % 13.2 ± 6.4 13.3 ± 5.9a 
Interscan reproducibility   
 CV % 26.7 21.5 
 RC % 9.7 7.9 
 ICC (95% CI) 0.71 (0.13 - 0.93) 0.79 (0.38 - 0.94) 
Interreader reproducibility   
 CV % 1.5 4.3 
 RC % 0.5 1.6 
 ICC (95% CI) 0.99 (0.95 - 0.99) 0.99 (0.97 - 0.99) 
TTP s 116 ± 26.8 60.7 ± 15.9b 
Interscan reproducibility   
 CV % 10.6 15.9 
 RC s 33.8 26.7 
 ICC (95% CI) 0.80 (0.35 - 0.96) 0.69 (0.18 - 0.91) 
Interreader reproducibility   
 CV % 11.3 18.8 
 RC s 36.1 31.4 
 ICC (95% CI) 0.78 (0.28 - 0.95) 0.59 (0.01 - 0.88) 
Table 6. Reproducibility of BOLD MRI in the calf. 
Values are presented as mean ± SD; rT2max, relative change in T2*; TTP, time-to-peak;  
ap = 0.97; bp < 0.01. 
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Discussion 
The reproducibility of morphological and functional MRI tech-
niques able to assess the vascular status in patients with PAD and 
healthy volunteers was evaluated. At morphological level we presented 
an easy and reproducible method to quantify the number of arteries 
with a detection limit of 0.5 mm and a method to assess the diameter of 
the collateral re-entrance zone in the upper leg. For vascular function 
we investigated the reproducibility of three different MRI techniques to 
assess macrovascular popliteal artery blood flow and microvascular calf 
muscle perfusion and blood oxygenation. Measurement of peak arterial 
flow in the PA proved reproducible, whereas all DCE MRI-derived param-
eters and the rT2max parameter for BOLD MRI in the lower leg are poorly 
reproducible in PAD patients. TTP in BOLD MRI was identified as a fairly 
reproducible microvascular parameter. 
Objective assessment of the hemodynamic consequences of ste-
noses and occlusions in the peripheral arterial tree remains an area of 
high interest in the diagnostic workup and treatment of patients with 
PAD. A simple and cost-effective way to assess the functional severity of 
PAD is the ankle-brachial index (ABI), which is the ratio of the systolic 
blood pressures measured at the level of the ankle and the upper arm 
(32). However, the ABI is a relatively crude parameter as it is not able to 
pinpoint the exact location of a stenosis, is unreliable in patients with an 
uncompressible vessel wall due to arterial calcifications, and shows a 
large interobserver variability (33). 
Other known techniques to determine vascular function are Dop-
pler based flow measurements, plethysmography, skin perfusion pres-
sure measurements, positron emission tomography (PET), contrast-
enhanced ultrasound (CEUS) and intra-arterial pressure and/or flow 
measurements (34-43). Unfortunately, these methods either lack the 
spatial resolution or coverage to directly measure the effect of vascular 
adaptations (e.g. collateral vessel formation or changes in microcircula-
tion), or are unfavorable for repeated measurements for instance in the 
context of therapy monitoring due to invasiveness, use of ionizing 
REPRODUCIBILITY OF MORPHOLOGIC AND FUNCTIONAL VASCULAR MRI 
49 
radiation, or large interobserver variability (33). MRI has the potential to 
overcome these limitations and can facilitate a variety of functional 
measurements at both the macro- and microvascular level. In particular, 
MRI may enable comprehensive diagnostic imaging of both the anatomy 
of the peripheral vascular tree as well as vascular function in terms of 
macrovascular flow and surrogate parameters of tissue perfusion and 
oxygenation (9, 10, 13, 21, 25, 44, 45). MRI-based functional measure-
ments have the advantage that they can be applied repeatedly without 
detrimental side effects and are easy to add to clinical routine CE-MRA 
examinations. 
We sought to investigate whether MRI can be used to combine its 
well known high-quality depiction of peripheral vascular anatomy with 
non-invasive assessment of macrovascular and microvascular hemody-
namics (12). Combined assessment of vascular morphology and function 
using one non-invasive accurate MRI exam is of high clinical interest for 
the diagnostic workup as well as for monitoring the effects of novel 
therapeutic strategies in patients with PAD. Although all of the MRI 
techniques as applied in this study have been described previously (9-
11, 13), little is known about the reproducibility of flow, perfusion and 
oxygenation sensitive MRI in the lower extremity. To our knowledge, 
this is the first study on interscan and interreader reproducibility of 
quantitative MRI derived morphological and functional measures in the 
context of PAD. 
Vascular morphology 
Artery count. Interscan reproducibility for the artery count, as ex-
pressed by various measures of agreement and reliability, was high in 
both patients and healthy volunteers. The RC indicates the smallest 
noticeable increase in the number of visualized arteries that can be 
confidently determined by the current combination of image acquisition 
and analysis methods. Lower RC values signify the capability to detect 
smaller differences in (longitudinal) follow-up studies. In both patients 
and volunteers the interscan RC was approximately 1 artery per plane, 
meaning that a mean increase of one or more artery per plane obtained 
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at two different time-points can be detected beyond measurement 
error. In other words, any additionally formed or sufficiently matured 
artery, exceeding a diameter of 0.5 mm, will be detectable during 
treatment monitoring in PAD patients, using the sequence parameters as 
described above. 
The RC at interreader level was roughly four times as high as the 
RC at interscan level. This indicates that when different readers are used 
and an increase of less than four collateral arteries is detected, it cannot 
be concluded with certainty that this increase represents a real change. 
This larger RC at interreader level is probably the result of differences in 
experience of the MRI readers and in reading conditions. Given the 
larger RC at interreader level, it would be advisable to use the same 
observer at different points in time. This is not a surprising finding as 
advanced post-processing techniques are often dependent on the 
experience of the observer performing the measurements, as has also 
been demonstrated for abdominal aortic neck volumetry and diameter 
assessment, which shows good intra-observer, but poor interobserver 
reliability (46). 
The interreader ICC was evidently lower in healthy volunteers 
compared to patients. A low ICC is unfavorable, as it compromises 
reproducibility. However, the lower ICC for healthy volunteers can be 
explained by the fact that these volunteers represent a more homoge-
nous group of subjects, with lower SDbs (table 2), as opposed to patients 
harboring a wider range of vascular pathology. Because of this lower 
SDbs and comparable SDws for patients and volunteers, the SDws has more 
influence on the ICC and the proportion of total variance that is ex-
plained by SDbs is smaller. A significantly higher number of arteries per 
plane was found in patients with PAD compared to healthy volunteers. 
This was to be expected, as patients were selected for this study based 
on the presence of collateral arteries. Volunteers did not suffer from 
PAD and did not have an extensive collateral network. Instead, only the 
terminal muscular branches of the deep femoral artery were counted. In 
this study we therefore studied the two extremes of the possible spec-
trum of disease that may be encountered in clinical practice: a patho-
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logic vascular system with diseased conduit arteries, muscular branches 
and extensive collateralization versus a healthy vascular tree with patent 
conduit arteries and muscular branches but lacking collateral arteries. 
For determination of reproducibility of artery count, which was the 
primary aim of this study, these differences appeared to be of only 
minimal influence, indicating the robustness of this method. 
Artery diameter. Interscan reproducibility was reasonable for di-
ameter assessment in patients and volunteers, with an average RC of 
approximately 1 mm. A better RC would not have been realistic given 
the voxel sizes used in the imaging protocol. Interreader reproducibility 
in patients was less favorable than interscan reproducibility, as was the 
case for the artery count. Therefore, in patients, for follow-up studies 
the same image reader for one patient is advised. Nevertheless, in 
absolute terms the differences between interscan and interreader 
reproducibility were very small. In patients the RC at both interscan and 
interreader level differed only 0.7 mm, which is actually lower than the 
resolution of the images. In volunteers, interreader reproducibility was 
equal to or slightly better than interscan reproducibility. This can be 
explained by the fact that the physiological variance in volunteers with 
healthy arteries (which influences interscan reproducibility) is somewhat 
higher than interreader variance. 
Given the good reproducibility and especially the low RC values, 
diameter assessment of the collateral re-entrance zone may help to 
study morphologic changes due to collateral formation, as we expect an 
increase in diameter over time of this re-entrance zone when collateral 
arteries are developing and blood supply distal to a high-grade stenosis 
or occlusion improves. 
In this study we did not find a significant difference in artery di-
ameter between patients and volunteers, although a smaller diameter in 
patients might have been expected. This finding may be explained by a 
difference in location at which the diameter was assessed between 
subjects. In volunteers the measurement was always performed 10 cm 
above the distal margin of the femoral condyls, whereas in patients the 
assessment was performed 5 cm distal to the vascular lesion (in most 
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cases the popliteal artery), resulting in a large variance. More important-
ly, however, is the fact that we only included patients with already well-
developed collateral arteries, that reconstituted the main conduit artery 
distal to the occlusion to a near-normal diameter. 
Image quality. All examinations were of sufficient quality for anal-
ysis, with the exception of one subtracted image stack in a PAD patient. 
A lower CNR in patients is most likely inherent to the presence of PAD, 
as impaired flow due to vascular lesions will result in lower signal 
intensity in the vessels distal to vascular lesions. In addition, for patients 
it is often harder to lie perfectly still during the examination, which 
results in increased noise levels due to subtraction misregistration. 
Source versus subtracted images. An important insight from this 
study is the finding that image subtraction leads to a deterioration of 
the reproducibility of the artery count compared to the detection of 
small arteries on source images. This is surprising because image 
subtraction leads to better background suppression and better visuali-
zation of small vascular structures (47), and is therefore widely applied 
in clinical practice. A possible explanation for this finding is that small 
subtraction misregistration errors as well as the well-known √2 increase 
in image noise after subtraction apparently do not disturb qualitative 
evaluation of peripheral MR angiograms for purposes of stenosis detec-
tion, but do influence quantitative assessment of the number of arteries 
as well as arterial diameter. 
Vascular function 
PCA MRI. We found favorable values for the interscan and in-
terreader reproducibility measures for the peak arterial flow in the 
popliteal artery in both patients and healthy volunteers, indicating good 
reproducibility of PCA MRI over a broad range of flow conditions. Alt-
hough the interscan CV in patients run up to 15.8%, both CV and RC 
were clearly lower than the relative and absolute differences in peak flow 
between PAD patients and healthy volunteers, making the PCA derived 
peak flow perfectly suitable for a reliable, objective gauge of PAD se-
verity and therapy monitoring. Minor variations in interscan results are 
REPRODUCIBILITY OF MORPHOLOGIC AND FUNCTIONAL VASCULAR MRI 
53 
probably the result of biologic variation in popliteal artery flow over time 
and small differences in scan geometry between the two examinations in 
the subjects. 
DCE MRI. In contrast to PCA MRI, the interscan reproducibility of 
DCE MRI was poor in patients, with a CV and RC evidently larger than the 
relative and absolute differences between patients and healthy volun-
teers. This implies that repeated measurements over time cannot pro-
vide reliable information on small changes in DCE MRI derived calf 
muscle perfusion using the imaging protocol described in this study. 
Reproducibility studies in skeletal muscle are unfortunately scarce. 
Previous DCE MRI studies in various tumor types and skeletal muscle 
performed under resting conditions also reported unfavorable repro-
ducibility measures, particularly for muscle tissue (9, 21). In agreement 
with our study, the AUC parameter appeared to be more reproducible 
than the corresponding Ki (proportional to Ktrans in Ref (19)). In the study 
by Galbraith et al the flow level of resting state muscle was low and 
likely prone to large day-to-day variations in the endothelial function 
(i.e. endothelial permeability and bioavailability of nitric oxide) (21, 48). 
Indeed, T1 values, as determined during the pre-contrast T1 mapping, 
showed high interscan reproducibility in both patients (mean T1 578 ± 
148 ms, CV 2.7%, RC 43 ms and ICC 0.99) and healthy volunteers (mean 
T1 480 ± 28 ms, CV 3.1%, RC 42 ms and ICC 0.71), indicating that the 
technique itself was reproducible. However, the physiologic process we 
studied was not. To obtain a higher flow level, which better represented 
physical activity, we used a cuff inflation-deflation protocol to measure 
muscle perfusion under reactive hyperemia conditions. Application of 
such a cuff-compression technique is likely to be more reproducible 
than exercise paradigms, because this paradigm is independent of the 
patient’s compliance, can be standardized, is less hampered by motion 
artifacts of the leg, and induces a general reactive hyperemia in all calf 
muscles in contrast to exercise paradigms which activate specific calf 
muscles (13). Despite these advantages, the interscan reproducibility 
revealed large day-to-day variations. 
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Interreader reproducibility proved high, indicating a low reader 
dependency of the measurement, which is desirable for application in 
therapy monitoring and follow-up studies. 
BOLD MRI. Although better than the interscan reproducibility of 
DCE MRI, the interscan reproducibility for rT2max in BOLD MRI was also 
found to be poor. TTP, however, was fairly reproducible in both patients 
and healthy volunteers. Analogous to DCE MRI, the BOLD technique 
showed good interscan reproducibility, as proven by the interscan 
reproducibility of T2* relaxation times, prior to the actual BOLD MRI 
(mean T2* 24.5 ± 1.2 ms, CV 3.7%, RC 2.5 ms and ICC 0.47 in patients 
and 23.1 ± 3.5 ms, CV 12.3%, RC 8 ms and ICC 0.31 in healthy volun-
teers respectively), indicating large biologic day-to-day variation in 
muscle tissue oxygenation, resulting in poor interscan reproducibility 
for rT2max in the dynamic BOLD measurement. This means that small 
changes in muscle tissue oxygenation, as reflected by changes in rT2max 
cannot be measured reliably with BOLD MRI. 
Macrovascular versus microvascular reproducibility. In this study 
we found that macrovascular flow can be reliably determined by PCA 
MRI, whereas methods used to measure microvascular function were 
subject to large interscan variations, with the exception of the TTP in 
BOLD MRI. These results corroborate to the findings of Wu et al showing 
variations in the perfusion of the soleus muscle of healthy volunteers of 
up to 20% within one hour using a similar cuff compression method and 
arterial spin labeling at 3 Tesla (34). 
Our observation of poor microvascular interscan reproducibility is 
remarkable given the reproducible PA flow, and thus blood supply to 
calf muscle. There might be two underlying reasons for this apparent 
discrepancy. First, the microcirculation of the calf muscle itself is likely 
more prone to day-to-day variations than macrovascular flow as the 
microcirculation and endothelial function are influenced by many intrin-
sic (i.e. hormonal and circadian cycles, insulin supply, shunting and 
rerouting of blood) and extrinsic (i.e. outside temperature, season, time 
of the day, food, pharmacologic) factors (49). Many of these factors are 
susceptible to day-to-day variations and will therefore inevitably nega-
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tively impact reproducibility of microvascular function. A second factor 
that might partly explain our findings is that microvascular function was 
assessed under reactive hyperemic conditions, where as the PA flow was 
measured under resting conditions. 
The better interscan reproducibility of BOLD MRI over DCE MRI 
might be explained by the fact that DCE MRI parameters (Ki and AUC) 
are determined by processes that occur within a very short period of 
time (less than 20 seconds) and depend on endothelial function to a 
large extent (i.e. extravasation of contrast agent), whereas TTP for BOLD 
MRI is a much slower process (taking up to two minutes) not depending 
on endothelial leakage, indicating that the endothelial function has less 
influence on the results. 
Clinical perspective 
Reproducible non-invasive imaging tools are needed for studying 
the processes of vascular adaptations and collateral development in 
patients with PAD. Our method can be used to visualize and reproduci-
bly quantify collateral vessel formation over time for monitoring vascular 
adaptive responses to various treatments in patients with PAD. As 
interscan reproducibility was evidently better compared to the in-
terreader reproducibility for both artery count and diameter assessment 
in most cases, it would be advisable to use the same image reader in 
follow-up studies. Under these conditions, the sensitivity of CE-MRA for 
the detection of new collateral arteries is very high and allows the 
detection of an increase of more than one vessel per plane or an in-
crease of more than 1 mm in diameter of the collateral re-entrance zone 
beyond measurement error. 
At functional level, we demonstrated that PCA MRI can reproduci-
bly determine peak blood flow in the popliteal artery and can reliably 
detect changes in macrovascular blood flow over time. Although our 
data are not directly comparable to those of previous studies, who 
mainly focused on mean flow (16, 18), we confirmed the findings of 
Mohajer et al, by detecting a decrease in blood flow distal to vascular 
lesions in the superficial femoral artery in patients (10). The high in-
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terreader reproducibility, indicating a low observer dependency of the 
measurements, and short acquisition duration, allow easy implementa-
tion of flow measurements combined with routine CE-MRA examinations 
in clinical practice. Further studies are needed to determine the potential 
of this technique to discriminate between normal and clinically relevant 
low flow levels in relation to functional parameters such as walking 
distance and quality of life. 
Taken together, the results of the DCE and BOLD MRI indicate that 
the perfusion responses in the calf muscles of patients with PAD were 
slower compared to healthy volunteers. However, detecting perfusion 
differences between patients and healthy volunteers was not the primary 
goal of this study. Such observable differences will strongly depend on 
the type of patients and controls included. Anyhow, this finding demon-
strates the potential of these MRI techniques to distinguish between 
different perfusion levels and supports the findings of previous studies 
comparing patients and controls. Despite the discriminative ability of 
microvascular functional MRI, DCE MRI does not appear to be a reliable 
method to quantify changes in the functional status of the microcircula-
tion over time. Additional studies are required to investigate whether 
better standardization of patient conditions and/or protocols will im-
prove the reproducibility of functional MRI techniques and to determine 
the clinical applicability of microvascular MRI to assess skeletal muscle 
perfusion. 
Study limitations 
The presented method for the artery count allows quantification of 
the total number of arteries in the upper leg, although it cannot differ-
entiate between pre-existing large conduit arteries, muscular branches 
and collateral arteries. This method may well be used for follow-up 
studies evaluating the effectiveness of therapies that stimulate collateral 
vessel formation, since even a very small increase in the number of 
collateral arteries, with a caliber exceeding 0.5 mm, will be detectable. 
Furthermore, review of the source images allows easy identification of 
the large named arteries in the upper leg. 
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A comparison between conventional digital subtraction angi-
ography (DSA) and CE-MRA to quantify the number of collaterals would 
have been useful. Unfortunately for most patients no DSA images were 
available. Previous results of our research group in animal models show 
that DSA consistently identifies more and smaller collateral arteries (50). 
However, in the study by De Lussanet it is argued that these small 
collateral arteries do not add substantially to the blood supply (50). 
In clinical practice, MRA examinations of PAD patients are used to 
visualize the entire peripheral arterial tree from the infrarenal aorta 
down to the feet. Although most collaterals of the upper leg are located 
near the adductor canal as previously found by Wecksell et al (51), we 
imaged the entire volume of the thigh for maximal axial coverage. This 
resulted in increased acquisition duration of the upper leg station (on 
average 40 - 50 seconds instead of the usual 10 - 15 seconds). Also, we 
did not assess reproducibility of the measurement in the pelvic and 
lower leg stations in this study. A future improvement could be the use 
of a blood pool contrast agent as this would allow a first-pass CE-MRA 
of the upper leg using our extended field of view for artery quantifica-
tion, followed by high-resolution steady-state images of the total 
peripheral arterial tree for clinical assessment of the peripheral vascula-
ture (52, 53). A disadvantage of this approach is the venous enhance-
ment during the steady state, however, due to the high resolution easy 
differentiation between arteries and veins is possible (52, 53). 
For analysis of DCE MRI data we used a standardized vascular in-
put function (VIF). Although an individual VIF could potentially be more 
accurate, we were not able to identify suitable arteries in the majority of 
the patients (5 out of 8) and in 2 healthy volunteers. Low spatial resolu-
tion most likely explains the failure to identify a suitable artery in these 
subjects. Although increased spatial resolution might improve the 
determination of an individual VIF, it would directly worsen the signal-
to-noise ratio and the temporal sampling conditions of the rapidly 
increasing MRI signal. Furthermore, reproducibility measures were even 
worse in selected cases where an individual VIF could be determined 
(data not shown). 
CHAPTER 2 
58 
Conclusion 
In conclusion, quantification of the morphological vascular status 
by CE-MRA, as well as PCA MRI to assess macrovascular blood flow 
proved highly reproducible in both PAD patients and healthy volunteers 
and might therefore be helpful in studying the development of collateral 
arteries in PAD patients and in unraveling the mechanisms underlying 
this process. 
Functional assessment of the microvascular status using DCE and 
BOLD MRI did not prove reproducible and is therefore currently not 
suitable for clinical monitoring in PAD. 
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Abstract 
Objectives 
In patients with peripheral arterial disease, it would be clinically 
desirable to have a standardized arterial position to measure the arterial 
peak flow (APF) independent of the location of obstructive arterial 
lesions with well-known reference values and high ability to differentiate 
between diseased and healthy arterial vasculature. The purpose of this 
study was to determine the best location to measure the APF in order to 
facilitate clinical standardization. 
Materials and Methods 
259 patients with varying degrees of peripheral artery disease 
(PAD) and 48 patients without PAD were included. All subjects under-
went vector cardiography-synchronized quantitative 2D cine MR phase-
contrast velocity imaging at three predefined arterial positions (i.e. 
common femoral artery (CFA), superficial femoral artery (SFA) and 
popliteal artery (PA)). APF values of PAD patients with clinically relevant 
stenosis according to MRA were compared with non-PAD patients. 
Discriminative ability to identify PAD was evaluated by means of receiv-
er-operatoring characteristic (ROC) curves and the corresponding areas 
under the curve (AUC). Furthermore, failure and success rates of APF 
measurements at all arterial positions were evaluated. 
Results 
Mean APF values in PAD patients were reduced by 42%, 55% and 
59% compared to non-PAD patients for respectively the CFA, SFA and PA 
(p < 0.01). The AUC’s were 0.84, 0.92 and 0.93 for CFA, SFA and PA, 
respectively. Success rates of the measurements in both PAD and non-
PAD patients were 90%, 91% and 93% for CFA, SFA and PA, respectively. 
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Conclusions 
To conclude, the APF measured in the PA and SFA show large dif-
ferences between PAD and non-PAD patients, strong discriminative 
ability and high success rates as compared to measurements in the CFS. 
For the location distal to the majority of arterial lesions, the preferred 
position for a standardized APF measurement in PAD patients is the PA. 
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Introduction 
MR angiography (MRA) has established itself as a highly accurate 
non-invasive diagnostic imaging method for the morphological evalua-
tion of the peripheral conduit arteries in patients with peripheral arterial 
disease (PAD) (1-4). Given the progressive character of PAD, an increas-
ing number of patients nowadays undergoes multiple MRA examinations 
during lifetime for treatment planning and/or therapy monitoring. For 
those patients, a fast and simple functional MRI derived measure, such 
as the arterial peak flow (APF), which is suitable to objectively quantify 
the vascular status and to monitor the progression of PAD over time, 
might be a valuable addition to MRA (5, 6). Numerous other non-
invasive functional diagnostic tools are available for this purpose, such 
as ankle-brachial pressure index (ABI), duplex ultrasonography and 
laser Doppler measurements (7-10). APF measurements, however, have 
the advantage of being a fast, reproducible and highly automated MRI 
technique, with acquisition times well below one minute, that can easily 
be added to existing MRA-protocols to obtain morphologic information 
together with functional vascular status during the same examination (5, 
6, 11-13). 
Previous studies demonstrated good reproducibility for APF meas-
urements and lower APF values in PAD patients compared to healthy 
control subjects (5, 6). For clinical practice, it would be desirable to have 
a standardized arterial position to measure the APF, comparable to ABI 
measurements, independent of the location of obstructive arterial 
lesions, but with high ability to differentiate between a diseased and 
healthy arterial vasculature and with well-known reference values. 
Therefore, in this study the APF was acquired at three distinctive and 
standardized arterial positions in a large group of PAD and non-PAD 
patients to determine the location that differentiates best between PAD 
and non-PAD patients. 
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Materials and Methods 
Study population 
MR cine phase-contrast imaging flow measurements are a stand-
ard addition to contrast-enhanced MR angiography (CE-MRA) at our 
institution in all patients scheduled for CE-MRA of the peripheral arter-
ies. The ethics committee waived the need for informed consent for 
patients, as flow measurements are part of the standard imaging proto-
col at our institution. Patients with (partial) lower extremity amputations 
were not included in this study. Otherwise there were no exclusion 
criteria. Patients referred for CE-MRA of the peripheral arterial tree to 
rule out deep vein thrombosis or in the pre-operative workup for recon-
structive surgery using lower extremity tissue flaps with no clinical 
symptoms of PAD nor signs of PAD on CE-MRA, were used as reference 
in this study. Patient characteristics were retrieved from the patients’ 
records and are summarized in table 1. 
   
 PAD patients  Non-PAD patients  
Number 259 48 
Males (%) / Females (%) 147 (57%) / 112 (43%) 23 (48%) / 25 (52%) 
Age (years) 67 ± 13.1  53 ± 16.4 * 
Heart rate (bpm) 71 ± 13 75 ± 14 
Bodyweight (kg) 77.1 ± 15.1  75.7 ± 16.4 
IC/CI 137 (53%) / 122 (47%) - 
Diabetics (%) 120 (54%)a 5 (13%)b 
Table 1. Patient characteristics. 
Values are presented as mean ± SD. Bpm, beats per minute; kg, kilogram; IC, intermittent 
claudication; CI, critical ischemia.* p < 0.01 
a Diabetic status could only be retrieved in 221 out of 259 PAD patients. bDiabetic status 
could only be retrieved in 38 out of 48 non-PAD patients. 
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MRI protocol 
All patients underwent a three-station CE-MRA protocol of the pe-
ripheral arteries (14), followed by quantitative MR cine phase-contrast 
imaging flow measurements at three distinctive arterial positions as 
described below. Flow data were used to obtain the APF in PAD and 
non-PAD patients (15). A schematic overview of the scan protocol is 
given in figure 1. All examinations were performed using a 1.5-T MRI 
system (Intera, Philips Medical Systems, Best, The Netherlands). For 
signal reception we used a dedicated 12-element phased-array periph-
eral vascular coil with a craniocaudal coverage of 128 cm (Philips Medi-
cal Systems). Patients were imaged in supine position and were in this 
position for approximately 30 minutes before the flow measurements 
were started. During this period the CE-MRA examination was per-
formed, using a fixed dose of 10 mL gadofosveset trisodium (Ablavar®, 
Lantheus Medical Imaging, Billerica, MA) as contrast agent. 
 
Figure 1. Overview of imaging protocol and the approximate duration of each scan 
sequence. Contrast-enhanced MR angiography (CE-MRA) was combined with cine phase-
contrast imaging (PCI) MRI. Total MRI examination, including patient positioning, table 
movements and MRI scans, took approximately 35 minutes. 
Survey. A non-enhanced time-of-flight (TOF) scan of the pelvic, 
upper and lower leg station was performed to prescribe the imaging 
volumes of interest for morphological and functional imaging. For this, a 
turbo field echo pulse sequence was used with a 180° inversion prepulse 
to suppress stationary tissues. Thirty-one axial slices per station were 
acquired with 3.3-mm slice thickness and 11-mm interslice gap, and an 
inferiorly concatenated saturation band. The standard quadrature body 
coil was used for signal transmission and reception. For positioning of 
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the 3D CE-MRA volumes, maximum intensity projections (MIP) were 
generated in 3 orthogonal directions. 
 
Figure 2. Maximum intensity reconstructions of a CE-MRA acquisitions in a PAD patient 
with a significant arterial stenosis in the right common femoral artery (CFA), indicated by 
the arrow. The predefined locations of the arterial peak flow (APF) measurements are 
indicated by, i.e. the proximal common femoral artery, proximal superficial femoral artery 
(SFA) and P2-segment of the popliteal artery (PA). The graphics show examples of flow 
wave forms in this particular patient. The black dotted line in each graphic indicates the 
level of the APF.  
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CE-MRA. A three-station 3D gradient-echo (fast field echo) MRA 
sequence was performed as previously described (2, 14). Acquisition 
parameters were as follows: TR 4.8 ms, TE 1.45 ms, flip angle 40°, FOV 
470 mm, matrix 480, and voxel dimensions (reconstructed) 0.92 x 0.92 
x 1.20 mm. Prior to contrast agent administration, a non-enhanced 
‘mask’ image data set was acquired with exactly the same acquisition 
parameters as the CE-MRA, enabling background tissue suppression by 
image subtraction. 
Flow MRI. For quantitative cine phase-contrast imaging we used a 
2D gradient-echo (fast field echo) scan technique with the following 
acquisition parameters: TR 9.7 ms, TE 5.8 ms, flip angle 30°, FOV 380 
mm, matrix 384, and reconstructed voxel dimensions of 0.99 x 0.99 x 
6.00 mm. Fifteen dynamic phases were acquired during the cardiac 
cycle. Measurements were performed at the level of the proximal com-
mon femoral artery (CFA), the proximal superficial femoral artery (SFA) 
and the P2-segment of the popliteal artery (PA) (figure 2). The phase 
encoding velocity was set to 100 cm/s in the craniocaudal direction for 
CFA and SFA measurements and 60 cm/s for PA measurements (5, 15). 
Vector cardiography (VCG) triggering was used for retrospective cardiac 
synchronization. Parallel imaging (sensitivity encoding, SENSE) was 
applied to reduce scan time (SENSE acceleration factor 2 in the anterior-
posterior direction) (16). At a mean heart rate of 60 beats per minute, 
the nominal acquisition time was 1 minute. Coronal and sagittal MIP 
reconstructions of CE-MRA recordings were used for accurate angula-
tion of the slice, perpendicular to the direction of the vessel of interest. 
Angiographic reading 
All CE-MRA datasets were analyzed by a well-trained radiologist 
with over 5 years of experience in MRA of the peripheral vasculature. For 
this study, CE-MRA data were used to determine the presence and 
severity of obstructive arterial lesions in PAD and to exclude presence of 
obstructive arterial lesions or arterial malformations in the group of 
non-PAD patients. 
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Flow analysis 
Modulus and phase images were reconstructed from the cine flow 
data. A quantitative flow analysis package (QFlow) included with the 
software release (R11.4.14, Philips Medical Systems) of the MRI hard-
ware was used for analysis of the flow data directly after the acquisition. 
Using this software, a region of interest (ROI) covering the entire visible 
cross-section of the artery of interest was accurately drawn manually 
using a modulus image at peak systole and then automatically propa-
gated to the remaining cardiac phases using an active contour algo-
rithm. Although peak systolic phase only is sufficient to calculate the 
APF, ROI’s were propagated to the remaining cardiac phases to obtain 
flow wave forms, which were visually analyzed to reassure the chosen 
cardiac phase was indeed at peak systole and to detect possible aliasing 
effects. If detected, the measurement was repeated with sufficiently 
higher phase encoding velocity. 
APF analysis 
APF was determined in the most symptomatic leg in patients with 
PAD and in the right leg in non-PAD patients. If both legs were equally 
affected in patients with PAD, the right leg APF was used for analysis. 
Using CE-MRA data, patients with PAD were divided into two subgroups, 
i.e. patients with and without relevant arterial stenoses in the peripheral 
arterial tree. A relevant stenosis was defined as > 50% stenosis in the 
iliac artery, CFA, SFA or PA, independent of the extensiveness and 
location of the lesion and/or > 50% stenosis in at least two out of three 
main arteries of the lower leg. Stenosis grade of the peripheral arterial 
tree below < 50%, was considered not relevant. A comparison of APF 
values was made between PAD patients with and without relevant 
stenoses in the peripheral arterial tree and non-PAD patients at the level 
of the CFA, SFA and PA. Also, the ability to discriminate between PAD 
and non-PAD patients at each level was determined. Furthermore, APF 
values in PAD patients with arterial lesions limited to the lower leg were 
compared with non-PAD patients to determine whether APF measure-
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ments are sensitive for lesions in the out-flow trajectory. Success rates 
of APF measurements and causes of failure at the distinctive arterial 
positions were determined and compared. 
Statistical analysis 
Statistical analysis was performed with commercially available sta-
tistical software (SPSS 16.0, SPSS Inc., Chicago, IL) and STATA (11.2, 
StataCorp LP., Texas). Mean values between groups were tested for 
statistical significance using a t-test for independent samples. The 
ability of APF measurements to discriminate between PAD and non-PAD 
patients was compared using receiver operating characteristic (ROC) 
curves and areas under the curve (AUC). Differences between the AUCs 
were tested for statistical significance using the method described by 
Hanley and McNeil, which accounts for the fact that the AUCs were 
derived from the same sample of patients (17). In all analysis, p-values 
< 0.05 were considered to indicate statistical significance. 
Results 
A total of 307 consecutive patients undergoing CE-MRA of the pe-
ripheral arteries at our institution as part of a clinical routine examina-
tion between January and December 2010 were considered eligible for 
analysis in this study. Presence of PAD was confirmed by CE-MRA in 259 
PAD-patients. Relevant stenoses were present anywhere within the 
peripheral arterial tree in 238 out of 259 patients with PAD according to 
CE-MRA, whereas no relevant stenoses were found in 21 patients 
initially diagnosed with PAD. 
In 48 patients CE-MRA was indicated to rule out deep vein throm-
bosis or acquired in the pre-operative workup of patients scheduled for 
reconstructive surgery with lower extremity tissue serving as donor site. 
APF values in patients with PAD with and without relevant stenoses 
and non-PAD patients are given in table 2. Mean APF values in PAD 
patients with relevant stenosis were reduced by 42%, 55% and 59% 
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compared to non-PAD patients for CFA, SFA and PA, respectively (p < 
0.01 at all levels). Differences between PAD patients with and without 
relevant stenosis were significant at all arterial positions (p < 0.01). 
Differences between PAD patients without relevant stenosis and non-
PAD patients were significant as well (p = 0.03, p < 0.01 and p = 0.01 
for CFA, SFA and PA, respectively). 
   
 PAD patients Non-PAD patients 
Relevant stenosis No relevant stenosis   
 APF (mL/s) n APF (mL/s) n APF (mL/s)  
CFA 17.9 ± 9.3 212 24.9 ± 9.0 19 30.6 ± 9.1 45 
SFA   9.0 ± 6.8 211 15.8 ± 5.5 20 20.2 ± 6.4 48 
PA   4.6 ± 3.0 218   8.7 ± 3.8 21 11.3 ± 3.8 45 
Table 2. Arterial peak flow in PAD and non-PAD patients. 
Values are presented as mean ± SD. APF, arterial peak flow; CFA, common femoral artery; 
SFA, superficial femoral artery; PA, popliteal artery. 
In 14 PAD patients arterial lesions were limited to the lower leg 
(i.e. more than 50% stenosis in at least two out of the three main arteries 
of the lower leg). In these patients, APF was 25.4 ± 9.7 mL/s, 13.6 ± 4.6 
mL/s and 7.6 ± 4.4 mL/s in the CFA, SFA and PA, respectively. The APF 
in these patients was significantly lower compared to non-PAD patients 
for the SFA (33%, p < 0.01) and PA (33%, p < 0.01), whereas a similar 
trend was found for the CFA (17%, p = 0.07). 
The distribution of APF values of the (most) symptomatic leg of 
PAD patients with relevant stenosis and the right leg of non-PAD pa-
tients at the level of the CFA, SFA and PA is graphically displayed in 
figure 3. In general, APF values in PAD patients were lower compared to 
non-PAD patients, although some overlap exists. Relative differences 
between PAD and non-PAD patients were larger if the measurement was 
performed more distally within the peripheral arterial tree. 
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Figure 3. Histograms showing the distribution of arterial peak flow values among a PAD 
and non-PAD patient population at the level of the common femoral artery (CFA), 
superficial femoral artery (SFA), and popliteal artery (PA). 
The discriminative ability of APF measurements in the CFA, SFA 
and PA is presented by the ROC curves (figure 4). The area-under-the-
curve (AUC) at the level of the CFA was 0.84 with a 95% confidence 
interval (CI) between 0.78 - 0.89. At the level of the SFA and PA, AUC’s 
were 0.92 (95% CI 0.88 - 0.96) and 0.92 (95% CI 0.88 - 0.95), respec-
tively. The AUC at the level of the CFA was significantly lower compared 
to AUC’s at the level of the SFA and PA, whereas no statistically signifi-
cant difference was found between the level of the SFA and PA. 
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Causes of failure of APF measurements are given in table 3. Op-
erator errors mainly consisted of wrong localization of the slices of the 
flow measurements. 
    
Arterial position PAD patients Non-PAD patients Total 
CFA 28 (11 %) 3 (6 %)  31 (10 %) 
 Operator error 10 2 12 
 Occlusion  14 0 14 
 Orthopedic prothesis  4 0 4 
SFA  28 (12 %) 0 (0 %) 28 (9 %) 
 Operator error 2 0 2 
 Occlusion 24 0 24 
 Orthopedic prothesis 2 0 2 
PA 20 (8 %) 3 (6 %) 23 (7 %) 
 Operator error 2 2 4 
 Occlusion 12 0 12 
 Orthopedic prothesis 4 1 5 
 Bypass 2 0 2 
Total 76 (10 %) 6 (4 %) 82 (9 %) 
Table 3. Main causes of failure for the APF measurements. 
APF, arterial peak flow; CFA, common femoral artery; SFA, superficial femoral artery; PA, 
popliteal artery. 
Discussion 
It is clinically desirable to have a standardized arterial position to 
measure the APF, preferably independent of the location of obstructive 
arterial lesions, with well-known reference values and high ability to 
differentiate between diseased and healthy arterial vasculature. The 
most suitable location for this purpose was expected to be the popliteal 
artery, as this is the most distally located large conduit artery of the 
peripheral arterial tree and therefore situated distally from the majority 
of the obstructive arterial lesions. According to the results of this study, 
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the APF acquired in the popliteal artery indeed shows the largest differ-
ences between PAD and non-PAD patients (i.e. 59% lower APF values in 
PAD patients), high discriminative ability (AUC of 0.92) and highest 
success rates of the measurement (up to 92% in PAD patients). 
Objective assessment of the functional consequences of stenoses 
and occlusions in the peripheral arterial tree is a necessity in diagnosis 
and longitudinal follow up or therapy monitoring of patients with PAD. 
Currently, the ankle-brachial index (ABI) measurement is the most 
recognized and most widely applied functional measurement used for 
diagnosis and therapy monitoring (4, 18, 19). ABI measurements, 
however, are hampered by poor reproducibility and cannot be deter-
mined accurately in patients with heavily calcified arteries (20-22). 
Other known techniques to determine vascular function are Doppler 
based flow measurements, plethysmography, skin perfusion pressure 
measurements, positron emission tomography (PET), contrast-enhanced 
ultrasound (CEUS) and intra-arterial pressure and/or flow measurements 
(23-32). These techniques, however, may lack spatial resolution or 
coverage to directly measure the effect of vascular adaptations (e.g. 
collateral vessel formation or changes in microcirculation), or are unfa-
vorable for repeated measurements for instance in the context of 
therapy monitoring due to invasiveness, use of ionizing radiation, or 
large interobserver variability (7). 
MRA has established itself as a highly accurate non-invasive diag-
nostic imaging method and is widely applied for diagnosis and treat-
ment planning in PAD (1-4). Due to the progressive character of PAD, an 
increasing number of patients with PAD undergo multiple MR angio-
graphic examinations during lifetime. For those patients MRI can also be 
used to obtain objective functional vascular information, for example by 
measuring arterial peak flow (APF). The APF is defined as the maximum 
systolic flow and is an attractive arterial flow measure, as the APF is an 
important determinant of the systolic blood pressure (33), which previ-
ously showed relatively large differences between PAD patients and 
control subjects and proved highly reproducible (5, 6, 15). 
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One of the strengths of other functional tests, for example ABI 
measurements, is a high degree of standardization, meaning that for 
example the ABI is measured at the same location with the same tech-
nique for every patient. Such a standardized protocol is a necessity for 
functional measurements to be suitable for longitudinal follow-up or 
therapy monitoring in patients. As APF measurements are relatively new 
and not yet widely applied, currently no such standardized protocol 
does exist, nor are there reference values known. Although APF meas-
urements are relatively fast, it is highly desirable to have a single, 
predefined location to measure the APF in all patients with PAD, at which 
the ability to differentiate between diseased and normal vasculature is 
best. 
In this study we demonstrated a standardized approach in which 
the APF was measured in the proximal CFA, proximal SFA and P2 seg-
ment of the PA in patients with PAD, independent from the location of 
obstructive arterial lesions, and in non-PAD patients. As expected, mean 
APF values in PAD were significantly lower compared to non-PAD pa-
tients at all arterial levels. The largest decrease in APF was found at the 
level of the PA in patients with PAD with a clinically relevant stenosis, 
were the average APF was 59% lower compared to non-PAD patients. A 
simple explanation for this finding is that flow in PA reflects all proximal 
obstructive arterial lesions. Interestingly, APF measured in the SFA and 
PA are both sensitive for proximal disease as well as disease distal to 
the position of the measurement. 
A distinction was made between PAD patients with and without 
relevant stenoses, as those patients without relevant stenosis were 
expected to have higher APF values, while therapeutic options in these 
patients differ from those patients with relevant stenosis. Results of our 
study confirm this assumption, as APF in PAD patients with relevant 
stenoses was significantly lower compared to those without stenoses. 
Due to the large differences in APF between PAD and non-PAD pa-
tients, the discriminative ability of APF measurements as shown by the 
ROC curves of figure 4 was excellent. The largest AUC was found at the 
level of the PA (0.93) again, although the difference with the SFA (0.92) 
CHAPTER 3 
80 
was small. The average success rate of APF measurements was high (on 
average 91% for all subjects in this study) and best at the level of the PA 
in both PAD and non-PAD patients. 
 
Figure 4. Receiver operating characteristic (ROC) curves among a PAD and non-PAD 
patient population at the level of the common femoral artery (CFA), superficial femoral 
artery (SFA), and popliteal artery (PA). 
SFA and PA are both excellent positions to measure the APF, inde-
pendent from the location of obstructive arterial lesions. Nevertheless, 
we would prefer to measure the APF in the PA as results at this position 
were only slightly, but consistently, better and the PA is situated distally 
from the majority of the obstructive arterial lesions. 
There are some limitations in this study. Only patients with PAD 
scheduled for MRA were included. Although this resulted in a selected 
study population, this population was considered to be clinically the 
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most relevant as far as APF measurements are concerned, as MRI-based 
APF measurements are not (yet) suitable for screening purposes due to 
the limited availability of MRI systems or magnet time and associated 
costs. Also, as the selected population comprised consecutive patients 
undergoing CE-MRA, it is a clinically representative group as far as 
disease severity is concerned. Nevertheless, this implies that current 
findings do not necessarily apply for all PAD patients. The group of non-
PAD patients who were used as control subjects were free from PAD, 
according to CE-MRA and anamnesis, but not free from vascular dis-
ease, as the majority of the non-PAD patients had deep vein thrombosis. 
Nevertheless, APF measures of these non-PAD patients were comparable 
with healthy controls from previous studies (5, 6). 
Although clinically relevant, APF was not measured at the level of 
the main arteries of the lower leg as the current spatial resolution would 
have been insufficient to accurately measure the APF in these small 
arteries (13, 34, 35), whereas increasing spatial resolution would have 
resulted in unsatisfactory acquisition times for clinical practice. Yet, as 
our results have shown, APF measurements at the level of the SFA and 
PA proved sensitive for arterial stenosis in the lower leg. 
To conclude, the APF measured in the PA and SFA show large dif-
ferences between PAD and non-PAD patients, strong discriminative 
ability and high success rates as compared to measurements in the CFS. 
For the location distal to the majority of arterial lesions, the preferred 
position for a standardized APF measurement in PAD patients is the PA. 
CHAPTER 3 
82 
References 
1. de Vries M, de Koning PJ, de Haan MW, et al. Accuracy of semiautomated 
analysis of 3D contrast-enhanced magnetic resonance angiography for 
detection and quantification of aortoiliac stenoses. Invest Radiol. 
2005;40(8):495-503. 
2. de Vries M, Nijenhuis RJ, Hoogeveen RM, et al. Contrast-enhanced periph-
eral MR angiography using SENSE in multiple stations: feasibility study. J 
Magn Reson Imaging. 2005;21(1):37-45. 
3. Leiner T, Kessels AG, Nelemans PJ, et al. Peripheral arterial disease: 
comparison of color duplex US and contrast-enhanced MR angiography 
for diagnosis. Radiology. 2005;235(2):699-708. 
4. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the 
Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 
Suppl S:S5-67. 
5. Versluis B, Backes WH, van Eupen MG, et al. Magnetic resonance imaging 
in peripheral arterial disease: reproducibility of the assessment of mor-
phological and functional vascular status. Invest Radiol. 2011;46(1):11-
24. 
6. Versluis B, Dremmen MH, Nelemans PJ, et al. MRI of arterial flow reserve in 
patients with intermittent claudication: feasibility and initial experience. 
PLoS One. 2012;7(3):e31514. 
7. van Langen H, van Gurp J,Rubbens L. Interobserver variability of ankle-
brachial index measurements at rest and post exercise in patients with 
intermittent claudication. Vasc Med. 2009;14(3):221-6. 
8. Begelman SM, Jaff MR. Noninvasive diagnostic strategies for peripheral 
arterial disease. Cleve Clin J Med. 2006;73 Suppl 4:S22-9. 
9. Corcoran HA, Smith BE, Mathers P, et al. Laser Doppler imaging of reactive 
hyperemia exposes blood flow deficits in a rat model of experimental limb 
ischemia. J Cardiovasc Pharmacol. 2009;53(6):446-51. 
10. Kido M, Takeuchi S, Hayashida S, et al. Assessment of abnormal blood 
flow and efficacy of treatment in patients with systemic sclerosis using a 
newly developed microwireless laser Doppler flowmeter and arm-raising 
test. Br J Dermatol. 2007;157(4):690-7. 
11. Dumoulin CL. Phase contrast MR angiography techniques. Magn Reson 
Imaging Clin N Am. 1995;3(3):399-411. 
TOWARDS A STANDARDIZED ARTERIAL PEAK FLOW MEASUREMENT 
83 
12. Walker MF, Souza SP, Dumoulin CL. Quantitative flow measurement in 
phase contrast MR angiography. J Comput Assist Tomogr. 
1988;12(2):304-13. 
13. Bakker CJ, Hoogeveen RM,Viergever MA. Construction of a protocol for 
measuring blood flow by two-dimensional phase-contrast MRA. J Magn 
Reson Imaging. 1999;9(1):119-27. 
14. Leiner T, Nijenhuis RJ, Maki JH, et al. Use of a three-station phased array 
coil to improve peripheral contrast-enhanced magnetic resonance angi-
ography. J Magn Reson Imaging. 2004;20(3):417-25. 
15. Mohajer K, Zhang H, Gurell D, et al. Superficial femoral artery occlusive 
disease severity correlates with MR cine phase-contrast flow measure-
ments. J Magn Reson Imaging. 2006;23(3):355-60. 
16. Prakash A, Garg R, Marcus EN, et al. Faster flow quantification using 
sensitivity encoding for velocity-encoded cine magnetic resonance imag-
ing: in vitro and in vivo validation. J Magn Reson Imaging. 
2006;24(3):676-82. 
17. Hanley JA, McNeil BJ. A method of comparing the areas under receiver 
operating characteristic curves derived from the same cases. Radiology. 
1983;148(3):839-43. 
18. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines 
for the management of patients with peripheral arterial disease (lower ex-
tremity, renal, mesenteric, and abdominal aortic): a collaborative report 
from the American Association for Vascular Surgery/Society for Vascular 
Surgery, Society for Cardiovascular Angiography and Interventions, Socie-
ty for Vascular Medicine and Biology, Society of Interventional Radiology, 
and the ACC/AHA Task Force on Practice Guidelines (Writing Committee 
to Develop Guidelines for the Management of Patients With Peripheral Ar-
terial Disease): endorsed by the American Association of Cardiovascular 
and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; 
Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and 
Vascular Disease Foundation. Circulation. 2006;113(11):e463-654. 
19. Creager MA. Clinical assessment of the patient with claudication: the role 
of the vascular laboratory. Vasc Med. 1997;2(3):231-7. 
20. Lindner JR, Womack L, Barrett EJ, et al. Limb stress-rest perfusion imaging 
with contrast ultrasound for the assessment of peripheral arterial disease 
severity. JACC Cardiovasc Imaging. 2008;1(3):343-50. 
CHAPTER 3 
84 
21. Stein R, Hriljac I, Halperin JL, et al. Limitation of the resting ankle-brachial 
index in symptomatic patients with peripheral arterial disease. Vasc Med. 
2006;11(1):29-33. 
22. Al-Qaisi M, Nott DM, King DH, et al. Ankle brachial pressure index (ABPI): 
An update for practitioners. Vasc Health Risk Manag. 2009;5:833-41. 
23. Wu WC, Wang J, Detre JA, et al. Hyperemic flow heterogeneity within the 
calf, foot, and forearm measured with continuous arterial spin labeling 
MRI. Am J Physiol Heart Circ Physiol. 2008;294(5):H2129-36. 
24. Burchert W, Schellong S, van den Hoff J, et al. Oxygen-15-water PET 
assessment of muscular blood flow in peripheral vascular disease. J Nucl 
Med. 1997;38(1):93-8. 
25. Bragadeesh T, Sari I, Pascotto M, et al. Detection of peripheral vascular 
stenosis by assessing skeletal muscle flow reserve. J Am Coll Cardiol. 
2005;45(5):780-5. 
26. Peetrons P. Ultrasound of muscles. Eur Radiol. 2002;12(1):35-43. 
27. Chloros GD, Smerlis NN, Li Z, et al. Noninvasive evaluation of upper-
extremity vascular perfusion. J Hand Surg Am. 2008;33(4):591-600. 
28. Weber MA, Krix M, Delorme S. Quantitative evaluation of muscle perfusion 
with CEUS and with MR. Eur Radiol. 2007;17(10):2663-74. 
29. Ludman PF, Volterrani M, Clark AL, et al. Skeletal muscle blood flow in 
heart failure measured by ultrafast computed tomography: validation by 
comparison with plethysmography. Cardiovasc Res. 1993;27(6):1109-15. 
30. Duet M, Virally M, Bailliart O, et al. Whole-body (201)Tl scintigraphy can 
detect exercise lower limb perfusion abnormalities in asymptomatic dia-
betic patients with normal Doppler pressure indices. Nucl Med Commun. 
2001;22(9):949-54. 
31. Ament W, Lubbers J, Rakhorst G, et al. Skeletal muscle perfusion meas-
ured by positron emission tomography during exercise. Pflugers Arch. 
1998;436(5):653-8. 
32. Fleischer AC, Niermann KJ, Donnelly EF, et al. Sonographic depiction of 
microvessel perfusion: principles and potential. J Ultrasound Med. 
2004;23(11):1499-506. 
33. Bishara RA, Taha W, Alfarouk MO, et al. Duplex detected ankle peak 
systolic velocity: a new parameter for the assessment of degree of periph-
eralischemia. Int Angiol. 2004;23(4):368-72. 
34. Hoogeveen RM, Bakker CJ, Viergever MA. MR phase-contrast flow meas-
urement with limited spatial resolution in small vessels: value of model-
based image analysis. Magn Reson Med. 1999;41(3):520-8. 
TOWARDS A STANDARDIZED ARTERIAL PEAK FLOW MEASUREMENT 
85 
35. Machida H, Komori Y, Ueno E, et al. Accurate measurement of pulsatile 
flow velocity in a small tube phantom: comparison of phase-contrast cine 
magnetic resonance imaging and intraluminal Doppler guidewire. Jpn J 
Radiol. 2010;28(8):571-7. 
 
  

  
CHAPTER 4 
Functional MRI in peripheral arterial disease: 
Arterial peak flow versus ankle-brachial index 
 
 
 
 
 
 
B. Versluis, P.J. Nelemans, R. Brans, J.E. Wildberger, G.W.H. Schurink,  
T. Leiner, W.H. Backes 
Published at PLoS One, 2014: 
Versluis B, Nelemans PJ, Brans R, et al. Functional MRI in Peripheral 
Arterial Disease: Arterial Peak Flow versus Ankle-Brachial Index. PLoS 
One. 2014;9(2):e88471 
87 
CHAPTER 4 
88 
Abstract 
Objectives 
The purpose of this study was to compare the success rate of suc-
cessful arterial peak flow (APF) and ankle-brachial index (ABI) measure-
ments in patients with suspected or known peripheral arterial disease 
(PAD). In addition the discriminative capabilities for disease severity of 
the APF and ABI measurements were compared. 
 Materials and Methods 
183 patients with varying degrees of PAD were included. All sub-
jects underwent ABI measurements and vectorcardiography-
synchronized quantitative 2D cine MR phase-contrast imaging of the 
popliteal artery to determine APF. Proportions of patients with success-
ful APF and ABI measurements were compared and the discriminative 
capability was evaluated to correctly classify disease severity of both 
methods by means of receiver-operator characteristic (ROC) curves and 
the corresponding areas under the curve (AUC). 
Results 
APF was successfully measured in 91% of the patients, whereas the 
ABI could be determined in 71% of the patients (p < 0.01). Success rates 
of APF and ABI were significantly higher in patients with intermittent 
claudication (95% and 80%, respectively) than in patients with critical 
ischemia (87% and 62%, respectively). The AUCs for APF and ABI meas-
urements were 0.74 and 0.75, respectively, which were not significantly 
different (p = 0.90). 
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Conclusions 
Compared to the assessment of PAD severity with ABI, the success 
rate of MRI-based APF measurements is 20 % higher, with similar dis-
criminatory capacity for disease severity. Therefore, APF is a valuable 
measure to assess PAD severity in patients in whom ABI cannot be 
reliably determined, and is especially convenient in patients already 
scheduled to undergo MR angiography. 
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Introduction 
Peripheral arterial disease (PAD) is a highly prevalent condition in 
industrialized societies (1, 2), affecting up to 7% of the general popula-
tion over the age of 70 years (2). The diagnosis of PAD is based on the 
typical clinical history, physical examination with palpation of pedal 
pulse and by measuring the ankle-brachial index (ABI) (3-6). The ABI is 
a fast, widely available and cost-effective test for this purpose  
(7-12). Sensitivity of ABI measurements for diagnosing PAD is high and 
the ABI can be used to determine the severity and progression of PAD 
over time (11, 13-15). Unfortunately, ABI measurements also suffer 
from certain limitations such as inability to reliably acquire the ABI in 
many patients with stiff and uncompressible ankle arteries due to severe 
arterial wall calcifications and poor interobserver variability (16-18). For 
example, studies have shown that the ABI cannot be measured in at 
least 5 – 10% of the diabetic population (12, 15, 18-23). 
In addition to ABI measurements, diagnostic (imaging) tools such 
as duplex ultrasonography (DUS), magnetic resonance angiography 
(MRA), computed tomography angiography (CTA) or invasive angi-
ography are available for diagnosis, treatment planning and longitudinal 
follow-up of patients with PAD (2). Except DUS, all of these imaging 
modalities are accurate for visualizing the vascular morphology (24-26), 
but generally do not provide functional information, which makes it 
difficult to quantify and evaluate hemodynamic consequences over time, 
as is easily done by ABI measurements. MRI, however, can also be used 
to evaluate vascular function, for example by measuring arterial peak 
flow (APF) with quantitative MR phase-contrast imaging (PCI) (27). The 
APF is a highly reproducible (27, 28), fast and simple measurement, 
which is not hampered by uncompressible arteries, like in ABI measure-
ments. For those PAD patients scheduled to undergo a MRA examination 
and in whom the ABI cannot be determined, the combination of mor-
phologic MRA and functional vascular MRI might help in the objective 
assessment of vascular status and be helpful in the follow-up of PAD 
patients, especially as (due to the progressive character of PAD) many 
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patients will repeatedly undergo MRA examinations during lifetime. APF 
measurements in that respect are most promising if the proportion of 
successful APF measurements is markedly higher as compared to ABI 
measurements in this group of patients with PAD. 
Therefore, the purpose of this study was to compare the propor-
tions of a large group of patients scheduled for MRA with successful APF 
and ABI measurements. In addition, we determined the influence of 
disease severity (intermittent claudication versus critical ischemia), 
presence of diabetes mellitus and the location of arterial lesions on the 
success rates of APF and ABI measurements. Also the discriminative 
capability for disease severity of the APF and ABI measurements was 
determined. 
Materials and Methods 
Study population 
This study was approved by the institutional medical ethics com-
mittee. Considering the retrospective nature of the study the ethics 
committee waived the need for informed consent. The APF is routinely 
measured at our institution in every patient scheduled for contrast-
enhanced MR angiography (CE-MRA) of the peripheral arteries. There-
fore, 210 consecutive patients undergoing CE-MRA of the peripheral 
arteries at our institution as part of a clinical routine examination 
between January and June 2010 were considered suitable for analysis in 
this study. In 27 patients CE-MRA was performed to rule out deep 
venous thrombosis (n = 16), or as part of the pre-operative visualization 
of the vasculature in patients scheduled for reconstructive surgery, with 
the lower leg serving as donor site (n = 11). After exclusion of these 27 
patients, who did not undergo ABI measurements, 183 patients were 
further analyzed in this study. Patient characteristics are presented in 
table 1. Diabetes mellitus was present in 48% of all patients (table 1). In 
17 patients the diabetic status could not be established definitively. 
These patients were referred to our institution for diagnostic purposes 
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only and no full clinical history was present. These patients were ex-
cluded from relevant analysis. Distinction between intermittent claudica-
tion and critical ischemia was based on clinical symptoms as recorded 
by the referring vascular surgeon and retrieved from patient records. 
    
 Intermittent claudi-
cation 
Critical ischemia All patients 
Patients 94 89 183 
Males (%) / Females (%) 58 (62%) / 36 (38%) 45 (51%) / 44 (49%) 103 (56%) / 80 (44%) 
Age (years)  64 ± 12  69 ± 11 67 ± 12 
Diabetics (%) 42 (48%)a 38 (48%)b 80 (48%) 
APF (mL/s) 5.8 ± 3.1 3.9 ± 2.8 * 4.9 ± 3.1 
ABI 0.74 ± 0.22 0.52 ± 0.24 * 0.65 ± 0.25 
Table 1. Patient characteristics. 
Values are presented as mean ± SD. APF, arterial peak flow; ABI, ankle-brachial index. 
a Diabetic status was confirmed in 87 out of 94 patients. bDiabetic status was confirmed in 
79 out of 89 patients. 
*  p < 0.01. 
MRI protocol 
All patients underwent quantitative cine PCI flow measurement of 
the popliteal artery (PA) to obtain flow wave forms, as required to 
determine the APF. PCI was preceded by a three-station CE-MRA proto-
col of the peripheral arteries. A schematic overview of the scan protocol 
is given in figure 1. All examinations were performed on a 1.5-T MRI 
system (Intera, Philips Medical Systems, Best, The Netherlands). Patients 
were imaged in supine position and had been in this position for ap-
proximately 30 minutes before the flow measurement was started. 
During this time the CE-MRA was acquired, using a fixed dose of 10 mL 
gadofosveset trisodium (Ablavar®, Lantheus Medical Imaging, Billerica, 
MA) as contrast agent. 
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Figure 1. Overview of imaging protocol and the approximate duration of each acquired 
sequence. Contrast-enhanced MR angiography (CE-MRA) was combined with phase-
contrast imaging (PCI) flow MRI. Total MRI examination time, including patient positioning, 
table movements and MRI scans, was approximately 35 minutes. 
MR angiography. A three-station 3D gradient-echo (fast field 
echo) MRA sequence was performed as previously described (25, 29). 
Acquisition parameters were as follows: TR 4.8 ms, TE 1.45 ms, flip 
angle 40°, FOV 470 mm, matrix 480, and voxel dimensions (recon-
structed) 0.92 x 0.92 x 1.20 mm. Prior to contrast agent administration, 
a non-enhanced ‘mask’ image data set was acquired with exactly the 
same acquisition parameters as the CE-MRA, enabling background 
tissue suppression by image subtraction. 
Flow MRI. For quantitative cine phase-contrast imaging we used a 
2D gradient-echo (fast field echo) scan technique with the following 
acquisition parameters: TR 9.7 ms, TE 5.8 ms, flip angle 30°, FOV 380 
mm, matrix 384, and reconstructed voxel dimensions of 0.99 x 0.99 x 
6.00 mm. Fifteen dynamic phases were acquired to obtain the waveform 
that spanned the cardiac cycle. The phase encoding velocity was set to 
100 cm/s in the craniocaudal direction (27, 30). Vector cardiography 
(VCG) triggering was used for retrospective cardiac synchronization. 
Parallel imaging (sensitivity encoding, SENSE) was applied to reduce scan 
time (SENSE acceleration factor 2 in the anterior-posterior direction) 
(31). At a mean heart rate of 60 beats per minute, nominal acquisition 
time was 1 minute. 
Angiographic reading 
All angiographic datasets were analyzed by one well-trained radi-
ologist with over 5 years of experience in CE-MRA of the peripheral 
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vasculature. For this study, CE-MRA data sets were used to determine 
whether or not obstructive arterial lesions were present within the 
peripheral vascular tree of most symptomatic extremity. 
Flow analysis 
Modulus and phase images were reconstructed from the cine 
phase-contrast data. A quantitative flow analysis package (QFlow) 
included with the software release (R11.4.14, Philips Medical Systems) of 
the MRI hardware was used for analysis of the flow data directly after the 
acquisition. Using this software, a region of interest (ROI) covering the 
entire visible cross-section of the artery of interest was accurately drawn 
manually using a reconstructed modulus image during peak systole and 
then automatically propagated to the remaining cardiac phases using an 
active contour algorithm. Although the peak systolic phase is sufficient 
to calculate the APF, ROI’s were propagated to all cardiac phases to 
obtain flow wave forms, which were visually analyzed to reassure the 
chosen cardiac phase indeed was at peak systole and to detect possible 
aliasing effects directly after the acquisition. If detected, the measure-
ment was repeated with sufficient higher phase encoding velocity. 
APF was preferred over mean flow for analysis, as peak flow is 
known to be more reproducible and may exhibit large differences 
between patients and healthy controls (30). Given the high inter-reader 
reproducibility of the APF, all flow measurements were analyzed by a 
single blinded, well-experienced radiologist (27). 
ABI measurements 
ABI data were retrieved from patient records. All ABI measure-
ments were performed by well-trained operators at our vascular func-
tion laboratory, using an automated Doppler system (Nicolet VasoGuard, 
VIASYS healthcare, Madison, WI). If the ABI could not be determined due 
to arterial stiffness or other circumstances, this was mentioned in the 
report by the operators. The ABI was acquired within 2 months prior to 
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the MRI exam for all patients, and patients did not receive invasive 
treatment between the two exams. 
Statistical analysis 
For statistical analysis only APF and ABI data obtained in the 
(most) symptomatic leg were used. If both legs were equally sympto-
matic, the right leg was analyzed. Statistical analysis was performed with 
commercially available statistical software (SPSS 16.0, SPSS Inc., Chicago, 
IL). The proportions of patients with successful APF and ABI measure-
ments were compared and tested for statistical significance using 
McNemar’s test for paired proportions. A chi-square test was used to 
test between group differences in proportions and a  
t-test for independent samples was used to test between-group differ-
ences in continuous variables. 
The ability of APF and ABI measurements to discriminate between 
patients with intermittent claudication and critical ischemia was com-
pared using receiver operating characteristic (ROC) curves and the area 
under the curve (AUC). Differences in AUCs were tested for statistical 
significance using the method described by Hanley et al, which accounts 
for the fact that AUCs were derived from the same sample of patients 
(32). In all analysis, p-values < 0.05 were considered to indicate statis-
tical significance. 
Results 
APF and ABI 
The APF measured in the (most) symptomatic leg as well as ABI is 
presented in table 1. Typical flow waveforms of patients with intermit-
tent claudication and critical ischemia are presented in figure 2. Both the 
APF and ABI were significantly lower in patients with critical ischemia 
compared to patients with intermittent claudication (p < 0.01). In all 
patients with obstructive arterial lesions below the level of the PA 
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regardless the severity of the clinical symptoms (i.e. both patients with 
intermittent claudication and critical ischemia; n = 103), APF was signif-
icantly lower (3.9 ± 2.7 mL/s) compared to patients without arterial 
lesions below the PA (5.2 ± 3.3 mL/s; p < 0.01). Comparable differ-
ences were found for the ABI measurements (0.56 ± 0.23 and 0.68 ± 
0.25, respectively; p < 0.01). 
 
Figure 2. Flow waveforms in patients with intermittent claudication (A) and critical 
ischemia ( B). Note the bi-phasic flow waveform and a higher peak flow value in intermit-
tent claudication compared to the mono-phasic flow waveform with a lower peak flow 
value in critical ischemia. 
Success rates of APF and ABI measurements 
Success rates of APF and ABI measurements are presented in ta-
bles 2 and 3. Success rates of APF measurements were significantly 
higher compared to ABI measurements (91% versus 71%, p < 0.01). APF 
and ABI measurements were successful with both methods in 121 (66%) 
patients, whereas in 96% of the patients either APF or ABI measurements 
were successful. In 45 (25%) patients only the APF could be determined 
and in 9 (5%) patients only the ABI could be determined. 
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 Successful APF Successful ABI p-value 
All patients 91% (166/183) 71% (130/183) < 0.01 
Disease severity:    
 IC 95% (89/94) 80% (75/94) < 0.01 
 CI 87% (77/89) 62% (55/89) < 0.01 
Diabetes mellitusa    
 Yes 95% (76/80) 69% (55/80) < 0.01 
 No 90% (77/86) 71% (61/86) < 0.01 
Obstruction below PAb    
 Yes 88% (91/103) 68% (70/103) < 0.01 
 No 96% (72/75) 78% (59/75) < 0.01 
Table 2. Success rates of APF and ABI measurements. 
APF, arterial peak flow; ABI, ankle-brachial index; IC, intermittent claudication; CI, critical 
ischemia, PA, popliteal artery. a Diabetic status could be determined in 166 out of 183 
patients. bIn 5 out of 183 the PA or main arteries of the lower leg could not be assessed 
due to severe image artifacts caused by metallic knee prostheses. 
Factors influencing measurement success rate 
There were large differences in the proportions of subjects in 
whom APF and ABI could be obtained between patients with intermittent 
claudication and critical ischemia (table 2, disease severity). The success 
rates were highest in patients with intermittent claudication (p = 0.06 
and p = 0.01 for APF and ABI measurements, respectively) compared to 
those with critical ischemia. 
As can be seen in table 3, approximately half of patients with dia-
betes mellitus in our population had intermittent claudication. No 
significant differences in success rates were found between patients 
with and without diabetes mellitus for both APF and ABI measurements 
(p = 0.19 and p = 0.64 for APF and ABI measurements, respectively). 
However, ABI measurements were significantly more often successful in 
diabetic patients with intermittent claudication (table 3, 84%) than in 
those with critical ischemia (61%, p < 0.01). No further significant  
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differences were found between the subgroups of diabetes mellitus and 
disease severity in table 3. 
Patients without arterial obstructive pathology below the level of 
the APF measurement showed a trend of higher success rates in APF  
(p = 0.07) and ABI (p = 0.11) measurements. 
Main causes of failure of the APF measurements (n = 17, 9%) were 
hardware failure (n = 7), occlusion of the PA (n = 7) and irregular heart 
rate (n = 1). In 2 patients the cause of failure remained unknown. 
Main causes of failure for ABI measurements (n = 53, 29%) were 
non-compressible arteries due to arterial stiffness (n = 42) and pres-
ence of PAD-related ulcers or wounds, making it impossible to use a 
cuff to measure the systolic pressure at the level of the ankle (n = 7). In 
4 patients no cause of failure was reported in the patient records. 
 
Discriminative capability 
Figure 3 shows ROC 
curves for both APF and ABI 
measurements in 122 
patients with intermittent 
claudication or critical 
ischemia, in whom both APF 
as well as ABI measurement 
were successfully obtained. 
The AUC of the APF was 
0.74 (95% confidence 
interval (CI), 0.66 – 0.83) 
and 0.75 (95% CI, 0.65 – 
0.83) for ABI, respectively, 
and were not statistically 
significant (p = 0.90). 
 
 
 
Figure 3. ROC curves for arterial peak flow (APF) 
and ankle-brachial index (ABI) in 122 patients with 
successful APF and ABI measurements. The curves 
show comparable discriminative capability for 
determination of disease severity (intermittent 
claudication versus critical ischemia) between APF 
and ABI measurements. 
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Discussion 
Objective assessment of vascular function is important in the di-
agnostic work-up and follow-up of patients with PAD. The most widely 
used measure for this purpose is the ABI. Although the ABI has a high 
sensitivity to detect PAD, we found that the ABI could not be determined 
in up to 29% of the patients included in this study. Alternative functional 
measurements would therefore be desirable to objectively characterize 
the peripheral vascular status in these patients. The results of this study 
show that popliteal arterial peak flow (APF), measured with MRI in 
clinical PAD patients scheduled for MRA, has a success rate of up to 
91%, which was significantly higher compared to ABI measurements 
(71%), with similar discriminative capability. 
Success rates 
ABI measurements were unsuccessful in up to 29% of the patients. 
This is markedly worse than the 5 – 10% known from previous literature 
(12, 15, 18). The most likely explanation for this discrepancy is the 
specific population for this study, which comprises only PAD patients 
referred for a clinical CE-MRA exam, rather than the general population 
of PAD patients. This means our population is likely to harbor more 
severe disease compared to patients with PAD who do not require a CE-
MRA for diagnosis or treatment planning. 
Although in 91% of the patients functional information could be 
obtained by performing APF measurements, combined measurement of 
ABI and APF resulted in a slight improvement to 96% (n = 176) in the 
proportion of patients with usable functional information. Therefore, 
APF measurements should not be considered as a replacement for ABI 
measurements, but rather as a useful addition. 
Factors influencing success rate 
ABI measurements could be determined more often in patients 
with intermittent claudication compared to patients with critical ische-
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mia. This can be explained by the higher number of patients with 
ulceration and tissue loss as well as the more pronounced arterial 
stiffness in these patients with more severe state of PAD. 
The presence of arterial lesions in the lower leg showed a trend 
towards lower success rates in both APF and ABI measurements. As far 
as the APF is concerned, this was due to the presence of popliteal 
occlusions, whereas for the ABI measurements this was due to the 
presence of skin ulcera/wounds and more pronounced arterial stiffness. 
As the APF is measured in the PA, while the ABI is acquired at ankle-
level, a direct comparison between quantitative measures might not be 
reliable, especially in patients with arterial lesions in the lower leg. 
However, analysis of the APF data revealed significantly lower flow 
values for patients with significant arterial lesions in the lower leg. 
Therefore, flow measurements of the PA seem to be influenced by 
obstructive lesions in both in- and outflow trajectories. These results 
were concordant with the ABI data. 
Another factor associated with a trend towards lower success rates 
of both APF and ABI measurements was the presence of arterial lesions 
at the level of and below the knee. In this patient group, APF could not 
be determined in case of popliteal occlusions. ABI measurements on the 
other hand, were hard to obtain in the patients with ischemic wounds 
and more pronounced arterial stiffness. 
Discriminative capability 
Determination of APF with PCI has been shown to have good re-
producibility and discriminative capabilities before (27). In this study we 
found that APF in patients with critical ischemia was significantly lower 
compared to patients with intermittent claudication. AUCs of the ROC 
curves for both APF and ABI measurements were comparable. This 
indicates that there is no relevant difference in discriminative capability 
of APF and ABI measurements to distinguish PAD patients with intermit-
tent claudication from those with critical ischemia. Therefore, APF 
measurements are a reliable alternative to ABI measurements in patients 
in whom the ABI cannot be determined. 
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APF 
APF, defined as the maximum systolic flow, is an attractive arterial 
flow measure. Although quantitative MRI-based flow measurements can 
also be used to measure mean flow, we chose to measure the APF, only. 
This is an important determinant of the systolic blood pressure (28), 
that shows relatively large differences between PAD patients and control 
subjects and is more reproducible than the mean flow (30). 
For this study only patients scheduled for MRA were included. Alt-
hough a selected population was used, as far as APF measurements are 
concerned this is clinically the most relevant patient population, as MRI-
based APF measurements are not (yet) suitable for screening purposes 
due to the limited availability of MRI systems or magnet time and asso-
ciated costs. Also, as the selected study population comprised consecu-
tive patients undergoing CE-MRA, it is a clinically representative group 
as far as disease severity and presence of diabetes mellitus is con-
cerned. Nevertheless, this implies that current findings do not neces-
sarily apply for all PAD patients. We do see an increasing number of PAD 
patients undergoing multiple MRA examinations during lifetime for 
treatment planning and/or therapy monitoring. A fast and simple 
functional MRI measurement, such as the APF, is therefore a valuable 
addition to MRA in order to objectively quantify the vascular status and 
to monitor the progression of PAD over time, especially in patients in 
whom the ABI cannot reliably be determined. 
This study and our previous work (27) demonstrate that the APF is 
a reproducible measure that can be acquired in almost every PAD 
patient scheduled for MRA and can discriminate between non-PAD 
patients and PAD patients with intermittent claudication or critical 
ischemia. Further research will be required to determine the most 
suitable location to assess the APF, to determine normative values and 
to demonstrate the clinical relevance of APF, ie. Its influence on therapy 
and clinical course of PAD. 
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Conclusion 
Compared to assessment of PAD severity with ABI, the success 
rate of APF measurements is 20% higher, with similar discriminatory 
capacity for disease severity. Therefore, APF is a valuable ancillary 
method to assess PAD severity in patients referred for MRA, especially if 
ABI cannot be reliably determined. 
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Abstract 
Objectives 
The aim of this study was to provide reference values for popliteal 
arterial peak flow (APF) and to assess the influence of disease severity, 
and presence of diabetes mellitus in patients with peripheral arterial 
disease (PAD). 
Materials and Methods 
239 patients with varying degrees of PAD, 45 patients without PAD 
and 28 healthy subjects were included. All subjects underwent quantita-
tive 2D cine MR phase-contrast velocity imaging at the level of popliteal 
artery (PA). APF values of PAD patients were compared with a reference 
population consisting of non-PAD subjects. Furthermore, average APF 
values were compared between subgroups of PAD patients with inter-
mittent claudication and critical ischemia and with or without diabetes 
mellitus. The ability to discriminate between PAD and non-PAD subjects 
was evaluated by using a receiver operating characteristic (ROC) curve with 
corresponding area under the curve (AUC). 
Results 
Average APF values in PAD patients (mean ± SD, 4.6 ± 3.0 mL/s) 
were 58% lower compared to non-PAD subjects (11.0 ± 3.5 mL/s, p < 
0.01). APF was significantly lower in PAD patients with critical ischemia 
(4.1 ± 3.2 mL/s) compared to PAD patients with intermittent claudica-
tion (5.1 ± 2.9 mL/s, p = 0.02). The presence of diabetes mellitus did 
not appear to be a factor of significant influence. The ability of APF to 
discriminate between patients with and without PAD, expressed as AUC, was 
0.90 (95% CI: 0.86-0.95). 
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Conclusions 
This study provides MRI derived reference values for APF in pa-
tients with clinically manifest PAD as well as a control sample of patients 
referred for non-PAD indications and healthy subjects. These reference 
values may aid in objective functional quantification of PAD severity and 
follow-up after intervention. 
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Introduction 
The diagnosis of peripheral arterial disease (PAD) is made based 
on the typical pattern of complaints, palpation of pedal pulses and 
measurement of the ankle-brachial index (ABI) (1, 2). Non-invasive 
imaging is typically only requested when the need for invasive interven-
tion arises. A frequently used modality in the pre-interventional workup 
is magnetic resonance angiography (MRA). There is a large body of 
evidence that MRA is a highly accurate non-invasive diagnostic imaging 
method for the assessment of the location and severity of obstructions 
in peripheral conduit arteries in patients with PAD (2-5). 
Currently used MR imaging protocols are exclusively focused on 
morphological evaluation of the vascular tree. There remains a need, 
however, for a fast and simple functional measure that can serve as a 
proxy for the hemodynamic severity of vascular obstructions visualized 
with MRA. For this purpose, MRI derived arterial peak flow (APF) may be 
a simple and valuable addition to standard MRA protocols (6, 7). Alt-
hough numerous other non-invasive functional diagnostic tools are 
available for this purpose such as ABI, duplex ultrasonography and laser 
Doppler measurements (8-11), APF measurements have the advantage 
of being relatively fast and reproducible and can easily be added to 
existing MRA-protocols (6, 7, 12-14). This is of interest as the afore-
mentioned conventional functional measures might not always yield 
reliable results, for instance in the presence of non-compressible 
arteries in the case of the ABI, or a poor acoustic window in the case of 
duplex ultrasonography. 
The simplest way to measure MRI derived APF is by two-
dimensional (2D) cine phase contrast imaging. Previous studies have 
demonstrated good reproducibility of this method and lower APF values 
in PAD patients relative to healthy control subjects (6, 7). The 2D nature 
of the protocol enables fast imaging, but comes at the expense of 
anatomical coverage, as it is limited to interrogation of a single anatom-
ical location at once. It is desirable, therefore, to identify a standard 
location in the peripheral vascular tree that combines high sensitivity 
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with high specificity for detection of hemodynamically significant PAD. 
However, little is known at present about absolute APF values, both in 
healthy subjects, as well as in various categories of patients with PAD. 
Consequently, the aims of the current study were to establish reference 
values for 2D MRI derived resting APF in PAD patients. In addition, we 
evaluated the influence of disease severity (intermittent claudication 
versus critical ischemia), presence of diabetes mellitus and age upon the 
APF. To this end, we determined the APF at the level of the popliteal 
artery (PA) in a large group of PAD patients referred for lower extremity 
MRA, as well as a control sample of patients undergoing MRA of the 
peripheral vascular tree for non-PAD indications and healthy subjects. 
APF was measured at the level of the PA, as the PA is the most distally 
located large peripheral artery, reflecting all proximal obstructive 
arterial lesions. 
Materials and Methods 
Study population 
259 PAD patients were referred for contrast-enhanced MR angi-
ography (CE-MRA) of the peripheral arteries at our institution between 
January and December 2010. In 20 patients the APF could not be ob-
tained at the level of the PA (table 3, chapter 3), these patients were 
excluded from this study. Otherwise there were no exclusion criteria. 
Therefore, 239 patients were analyzed in this study. Non-patients 
referred for CE-MRA of the peripheral arterial tree to rule out deep vein 
thrombosis or in the pre-operative workup for reconstructive surgery 
using lower extremity tissue flaps with no signs of PAD on CE-MRA and 
with successful APF measurements (n = 45), were used as reference in 
this study. Patient characteristics were retrieved from the patients’ 
records and are summarized in table 1. The ethics committee waived the 
need for informed consent for patients, as flow measurements are part 
of the standard clinical imaging protocol at our institution. In addition, 
flow data were obtained in 28 healthy subjects. Non-PAD patients and 
healthy subjects were clustered together and referred to as non-PAD 
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subjects. The institutional medical ethics committee approved this part 
of the study and all volunteers provided signed informed consent prior 
to inclusion. 
    
 PAD patients  Non-PAD patients   Healthy subjects 
Number 239 45 28 
Males (%) / Females (%) 139 (58%) / 100 (42%) 21 (47%) / 24 (53%) 6 (21%) / 22 (79%) 
Age ( years) 66 ± 13.5  52 ± 16.1 * 24 ± 7.5 * 
IC/CI 128 (54%) / 111 (46%) 0 (0%) 0 (0%) 
Diabetics (%) 106 (52%)a 5 (14%)b 0 (0%) 
Table 1. Patient characteristics. 
Values are presented as mean ± SD. PAD, peripheral arterial disease; IC, intermittent 
claudication; CI, critical ischemia. 
*  p < 0.01. 
a Diabetic status could only be retrieved in 202 out of 239 PAD patients. bDiabetic status 
 could only be retrieved in 35 out of 45 non-PAD patients. 
MRI protocol 
All patients underwent a three-station CE-MRA protocol of the pe-
ripheral arteries (15), followed by quantitative MR cine phase-contrast 
imaging flow measurements at the level of the popliteal artery. Flow 
data were used to obtain absolute APF values in PAD and non-PAD 
patients as well as healthy subjects (16). All examinations were per-
formed using a 1.5-T MRI system (Intera, R11.4.14, Philips Healthcare, 
Best, The Netherlands). For signal reception we used a dedicated 12-
element phased-array peripheral vascular coil with a craniocaudal 
coverage of 128 cm (Philips Healthcare). Patients were imaged in supine 
position and had been in this position for approximately 30 minutes 
before flow measurements were started. Prior to flow measurements the 
CE-MRA examination was performed, using a fixed dose of 10 mL 
gadofosveset trisodium (Ablavar®, Lantheus Medical Imaging, Billerica, 
MA) as contrast agent. 
Survey. A non-enhanced time-of-flight (TOF) scan of the pelvic, 
upper and lower leg station was performed to prescribe the imaging 
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volumes of interest for morphological and functional imaging. A turbo 
field echo pulse sequence was used with a 180° inversion prepulse to 
suppress stationary tissues. Thirty-one axial slices per station were 
acquired with 3.3-mm slice thickness and 11-mm interslice gap, and an 
inferiorly concatenated saturation band was used to suppress signal 
from veins. The standard quadrature body coil was used for signal 
transmission and reception. To facilitate positioning of the 3D CE-MRA 
volumes maximum intensity projections (MIP) were generated in 3 
orthogonal directions. 
CE-MRA. A three-station 3D gradient-echo (fast field echo) MRA 
sequence was performed as previously described (4, 15). Acquisition 
parameters were as follows: TR 4.8 ms, TE 1.45 ms, flip angle 40°, FOV 
470 mm, matrix 480, and voxel dimensions (reconstructed) 0.92 x 0.92 
x 1.20 mm3. Prior to contrast agent administration, a non-enhanced 
‘mask’ image data set was acquired with exactly the same acquisition 
parameters as the CE-MRA, enabling background tissue suppression by 
image subtraction. 
Flow MRI. For quantitative cine phase-contrast imaging we used a 
2D gradient-echo (fast field echo) scan technique was used with the 
following acquisition parameters: TR 9.7 ms, TE 5.8 ms, flip angle 30°, 
FOV 380 mm, matrix 384, and reconstructed voxel dimensions of 0.99 x 
0.99 x 6.00 mm3. Fifteen dynamic phases were acquired during the 
cardiac cycle. Measurements were performed at the level of the P2 
segment of the popliteal artery. The phase encoding velocity was set to 
standard values of 60 cm/s in the craniocaudal direction (6, 16). Vector 
cardiography (VCG) triggering was used for retrospective cardiac syn-
chronization. Parallel imaging was applied to reduce scan time (accel-
eration factor 2 in the anterior-posterior direction) (17). At a mean heart 
rate of 60 beats per minute, the nominal acquisition time of this se-
quence was 1 minute. Coronal and sagittal maximum intensity projected 
reconstructions of CE-MRA recordings were used for accurate angula-
tion of the slice, perpendicular to the direction of the PA. 
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CE-MRA 
For this study, CE-MRA data were used to determine the presence 
and severity of obstructive arterial lesions in PAD and to exclude pres-
ence of obstructive arterial lesions or arterial malformations in the 
group of non-PAD subjects. All CE-MRA datasets were analyzed by one 
well-trained radiologist with over 5 years of experience in MRA of the 
peripheral vasculature. 
Flow analysis 
Modulus and phase images were reconstructed from the cine flow 
data. A quantitative flow analysis package (QFlow) included with the 
software release (R11.4.14) of the MRI hardware was used for analysis of 
the flow data directly after the acquisition. Using this software, a region 
of interest (ROI) covering the entire visible cross-section of the artery of 
interest was manually drawn using a modulus image at peak systole and 
then automatically propagated to the remaining cardiac phases using an 
active contour algorithm. Although the peak systolic phase only is 
sufficient to calculate the APF, ROI’s were propagated to the remaining 
cardiac phases to obtain flow wave forms, which were visually analyzed 
to reassure the chosen cardiac phase was indeed at peak systole and to 
detect possible aliasing effects. If aliasing artifacts were detected, the 
measurement was repeated with sufficiently higher phase encoding 
velocity. 
APF analysis 
APF was determined in the more symptomatic leg in patients with 
PAD and in the right leg in non-PAD subjects. If both legs were equally 
affected in patients with PAD, the right leg APF was used for analysis. 
Using CE-MRA data, patients with PAD were divided into two subgroups, 
i.e. patients with and without relevant arterial stenoses in the peripheral 
arterial tree. A relevant stenosis was defined as > 50% luminal narrow-
ing in the common or external iliac or common or superficial femoral or 
popliteal arteries, independent of the extensiveness and location of the 
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lesion. In addition, > 50% stenosis in at least two out of three main 
arteries of the lower leg were considered relevant. If the maximum 
stenosis grade anywhere in the peripheral arterial tree was  
< 50%, these lesions were considered not to be hemodynamically 
relevant. A comparison of APF values was made between PAD patients 
with and without relevant stenoses in the peripheral arterial tree and 
non-PAD subjects as well as healthy controls. Furthermore, APF values 
in subgroups of PAD patients with intermittent claudication and critical 
ischemia as well as with or without diabetes mellitus were compared and 
the ability to discriminate between PAD ad non-PAD subjects was 
evaluated. In non-PAD subjects, the influence of gender and age on APF 
was evaluated. 
Statistical analysis 
Statistical analysis was performed with commercially available sta-
tistical software (SPSS 16.0, SPSS Inc., Chicago, IL) and STATA (11.2, 
StataCorp LP., Texas). Mean values between groups were tested for 
statistical significance using a t-test for independent samples. The 
ability of APF measurements to discriminate between PAD and non-PAD 
subjects was compared using receiver operating characteristic (ROC) 
curves and area-under-curve (AUC) values. In all analyses, p-values  
< 0.05 were considered to indicate statistical significance. 
  
PAD patients Non-PAD subjects 
Relevant stenosis No relevant stenosis   
APF (mL/s) n APF (mL/s) n APF (mL/s) n 
4.6 ± 3.0 218 8.7 ± 3.8 21 11.0 ± 3.5 73 
Table 2. Arterial peak flow in PAD and non-PAD subjects. 
Values are presented as mean ± SD. PAD, peripheral arterial disease; APF, arterial peak 
flow. 
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Results 
Relevant stenoses were present within the peripheral arterial tree 
in 218 out of 239 patients (91%) with PAD according to CE-MRA, where-
as no relevant stenoses were found in 21 (9%) patients initially diag-
nosed with PAD (see table 2, chapter 4). 
Typical flow waveforms obtained in a patient with intermittent 
claudication and critical ischemia are presented in figure 1. APF values 
in patients with PAD with and without relevant stenoses and non-PAD 
subjects are listed in table 2. Average APF values in PAD patients with 
relevant stenoses (mean ± SD, 4.6 ± 3.0 mL/s) were 58% lower com-
pared to non-PAD subjects (i.e. non-PAD patients and healthy subjects) 
(11.0 ± 3.5 mL/s, p < 0.01). APF was significantly lower in PAD patients 
with relevant stenosis compared to PAD patients without relevant steno-
ses (p < 0.01). In PAD patients without relevant stenosis APF was 21% 
lower compared to non-PAD subjects (p = 0.01). Within the group of 
non-PAD subjects, no difference was found in absolute APF values 
between non-PAD patients (11.3 ± 3.8 mL/s) and healthy subjects (10.5 
± 3.1 mL/s, p = 0.35). Relevant stenoses were present in the lower leg 
 
Figure 1. Flow waveforms in a healthy subject without peripheral arterial disease (A), a 
patient with intermittent claudication (B) and critical ischemia (C). Note the tri-phasic flow 
waveform in the healthy subject, the bi-phasic flow pattern in a patient with intermittent 
claudication and mono-phasic flow waveform in a patient with critical ischemia. The APF is 
lowest in the patient with critical ischemia and highest in the healthy control. 
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in only 14 PAD patients. In these patients, APF was 7.6 ± 4.4 mL/s, 
which was significantly lower compared to non-PAD subjects (p < 0.01). 
Average APF values in different subgroups of PAD patients are 
listed in table 3. APF was significantly lower in PAD patients with critical 
ischemia (4.1 ± 3.2 mL/s) compared those with intermittent claudication 
(5.1 ± 2.9 mL/s, p = 0.02). The difference in average APF values be-
tween PAD patients with diabetes mellitus and without diabetes mellitus 
was not statistically significant (p = 0.13). However, the subgroup of 
PAD patients with critical ischemia and diabetes mellitus had a signifi-
cantly higher APF (4.9 ± 3.9 mL/s) compared to the non-diabetic pa-
tients with critical ischemia (3.4 ± 2.3 mL/s, p = 0.04). 
    
 Intermittent claudication Critical ischemia Total 
Diabetes mellitus APF (mL/s) n APF (mL/s) n APF (mL/s) n 
 Yes 5.1 ± 3.2 48 4.9 ± 3.9 49 5.0 ± 3.5 97 
 No 5.0 ± 2.8 46 3.4 ± 2.3 42 4.3 ± 2.7 88 
 Unknown 5.0 ± 2.2 19 3.1 ± 1.7 14 4.2 ± 2.2 33 
 Total 5.1 ± 2.9 113 4.1 ± 3.2 105 4.6 ± 3.0 218 
Table 3. Arterial peak flow in subgroups of patients with PAD with relevant stenosis. 
Values are presented as mean ± SD. PAD, peripheral arterial disease; APF, arterial peak 
flow. 
The distribution of APF values in the (most) symptomatic leg of 
PAD patients with relevant stenosis and the right legs of non-PAD 
subjects at the level of the PA is graphically presented in figure 2. In 
general, APF values in PAD patients were lower compared to non-PAD 
subjects, although a certain degree of overlap was observed. 
The ability of APF to discriminate between PAD patients and non-
PAD subjects is visualized in the ROC curves shown in figure 3. The 
area-under-the-curve (AUC) value for all PAD patients was 0.90 with a 
95% confidence interval (CI) between 0.86 - 0.95. For PAD patients with 
intermittent claudication and critical ischemia, AUC’s were 0.92 (95% CI 
0.89 - 0.96) and 0.93 (95% CI 0.90 - 0.97), respectively. The ability to 
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differentiate between PAD patients with intermittent claudication and 
critical ischemia revealed a AUC of 0.63 (95% CI 0.56 - 0.71). 
  
Figure 2. Histogram showing the 
distribution of arterial peak flow values 
at the level popliteal artery among a 
PAD patients with intermittent claudica-
tion and critical ischemia and a non-
PAD subject population. 
Figure 3. Receiver operating characteristic 
(ROC) curves showing ability of APF values to 
discriminate between PAD.  
No correlation was found between APF and age (R = 0.0022) in the 
non-PAD subjects of this study. 
Discussion 
The presence of PAD results in decreased flow to the affected low-
er extremity. However, the exact impact of various degrees of PAD on 
absolute MR derived flow values is not known. For this reason we sought 
to establish reference values for resting APF in a large sample of pa-
tients with PAD as well as patients referred for MRA of the lower ex-
tremities for non-PAD indications, and a sample of healthy control 
subjects. To the best of our knowledge, this study is the first to report 
such data of APF values in patients with PAD. 
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Literature about resting APF in the peripheral vascular tree in pa-
tients with PAD is sparse. Most studies providing MR derived APF used 
young, healthy subjects (6, 7), whereas others mainly focused on flow 
waveform analysis and/or blood velocity or mean flow rather than (peak) 
flow (16, 18). Other imaging techniques such as duplex ultrasonography 
also focus on blood velocity, but are mostly measured in and directly 
adjacent to stenotic areas (i.e. peak systolic velocity ratio) (9, 19). 
Therefore, no direct comparison of our results with other studies seems 
possible. 
Although MRA is a highly reliable test to determine the location 
and severity of peripheral vascular lesions, it remains difficult to draw 
conclusions with regard to their hemodynamic significance based on 
anatomical information alone. In our opinion the APF provides relevant 
complementary functional information on vascular status that can 
measured in a fast, simple and reproducible way. 
Here we demonstrate a standardized and simple approach in 
which APF was measured in the PA of patients with PAD (regardless of 
the location of arterial narrowing), and in non-PAD subjects. Mean APF 
values in PAD were significantly lower compared to non-PAD subjects. 
Mean APF was 58% lower in PAD patients with a clinical relevant stenosis 
compared to non-PAD subjects. A simple explanation for this finding is 
that PA arterial peak flow reflects – to a certain extent - all proximal 
obstructive arterial lesions. 
The APF in PAD patients with critical ischemia was significantly 
lower compared to patients with intermittent claudication. This was 
expected, as critical ischemia is clinically the most severe form of PAD 
where perfusion under resting conditions is not able to meet metabolic 
needs. No difference was found in APF of PAD patients with and without 
diabetes mellitus. However, for patients with critical ischemia, APF was 
higher in the diabetic subpopulation. Higher flow values in these pa-
tients with severe PAD are possibly due to severely calcified arteries 
which are known to exhibit decreased vascular compliance, resulting in 
an impaired ‘windkessel’ function of the lower leg arteries (20). 
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As we showed in the population of non-PAD subjects, the APF is 
not correlated with age. This is advantageous, as this indicates that age 
is not likely to be a relevant confounding factor. 
Discriminative value 
The discriminative ability of APF measurements to differentiate 
patients with peripheral vascular stenoses exceeding 50% reduction in 
luminal diameter versus non-PAD subjects as expressed by the area 
under the ROC curves was excellent (figure 3). Although the AUC was 
largest for the distinction between PAD patients with critical ischemia 
and non-PAD subjects (0.93), PAD patients with intermittent claudica-
tion could also be distinguished with high accuracy from those not 
suffering from PAD as well as patients with lower degrees of stenosis 
(AUC, 0.92). The APF is less suitable to distinguish between patients 
with intermittent claudication and critical ischemia (AUC, 0.63). 
Clinical implications 
Objective assessment of the functional consequences of obstruc-
tive PAD is a necessity in diagnosis and longitudinal follow-up and/or 
therapy monitoring of these patients. We believe APF could be a useful 
adjunct to morphological evaluation of the peripheral vasculature with 
CE-MRA, especially in patients with intermediate degrees of stenosis 
and equivocal results at standard functional testing. Currently, the 
ankle-brachial index (ABI) measurement is the most recognized and 
most widely applied functional measurement used for diagnosis and 
therapy monitoring (2, 21, 22). ABI measurements, however, are ham-
pered by poor reproducibility and cannot be determined accurately in 
patients with heavily calcified arteries (23-25). Other known techniques 
to determine vascular function are Doppler-based flow measurements, 
plethysmography, skin perfusion pressure measurements, positron 
emission tomography (PET), contrast-enhanced ultrasound (CEUS) and 
intra-arterial pressure and/or flow measurements (26-35). These 
techniques, however, may lack spatial resolution or coverage, or are 
unfavorable for repeated measurements for instance in the context of 
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therapy monitoring due to time constraints, invasiveness, use of ioniz-
ing radiation, or large interobserver variability (8). 
Study Limitations 
The most important limitation of this study is that as far as PAD 
patients were concerned, only patients scheduled for MRA were includ-
ed. Although this resulted in a selected study population, this popula-
tion was considered to be clinically the most relevant as far as APF 
measurements are concerned, as MRI-based APF measurements are not 
used for screening purposes due to the limited availability of MRI sys-
tems or magnet time and associated costs. Nevertheless, because the 
study sample comprised consecutive patients undergoing CE-MRA over 
a period of 1 year, it is a representative group with regard to the case-
mix one is likely to encounter in every day clinical practice. This also 
implies that current findings do not necessarily apply to all PAD pa-
tients. A second limitation is that although the group of non-PAD 
patients who were used as control subjects were free from PAD (accord-
ing to both clinical history as well as findings at CE-MRA), they were not 
entirely free from cardiovascular disease, as the majority of the non-
PAD patients had experienced prior deep venous thrombosis. Neverthe-
less, APF measures of these non-PAD patients were comparable with 
healthy controls from previous studies (6, 7). Finally, we did not meas-
ure APF in arteries below the knee. This was because limitations in 
spatial and temporal resolution in the acquisition protocol used in this 
study precluded sufficiently accurate APF measurements in these small 
arteries (14, 36, 37). Yet, as our results have shown, APF measurements 
at the level of the PA are sensitive enough to detect arterial stenosis in 
the lower leg. 
In conclusion, this study provides MRI derived reference values for 
resting APF in patients with clinically manifest PAD as well as a control 
sample of patients referred for non-PAD indications and healthy sub-
jects. These reference values may aid in objective functional quantifica-
tion of PAD severity and follow-up after intervention. We found that 
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absolute flow values allow diagnosis of clinically relevant PAD with high 
accuracy. 
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Abstract 
Objectives 
The purpose of the current study was to determine whether super-
vised exercise therapy (SET) leads to measurable vascular adaptations in 
patients with intermittent claudication using contrast-enhanced MR 
angiography (CE-MRA) and flow measurements. 
Materials and Methods 
Ten patients with clinical symptoms of intermittent claudication 
and proven obstructive arterial lesions of the superficial femoral artery 
were included and underwent SET for a period of six months. At base-
line, all patients underwent a treadmill test to assess pain free walking 
distance, ankle-brachial pressure index (ABI) measurement and MR 
imaging to determine the number of arteries in the upper leg using CE-
MRA and arterial peak flow (APF) in the popliteal artery using cine phase 
contrast angiography. All examinations were repeated after three and 
six months of SET, respectively, to evaluate vascular responses relative 
to baseline. 
Results 
After six months of SET, mean pain free walking distance (395 ± 
46 m) was improved by 71% compared to baseline (230 ± 42 m, p < 
0.01). No statistically significant changes were found for mean values of 
ABI (81 ± 4 and 77 ± 4 at respectively baseline and after six months of 
SET), number of arteries at the level of the arterial lesion (18 ± 2 and 19 
± 2, respectively) nor arterial peak flow (5.3 ± 0.6 and 5.3 ± 0.8 mL/s, 
respectively). 
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Conclusions 
Supervised exercise therapy in patients with intermittent claudica-
tion results in an increase in pain free walking distance, whereas with 
MRI no macrovascular adaptations in terms of additional collateral artery 
formation or flow increases could be observed. 
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Introduction 
Peripheral arterial disease (PAD) is a major health care problem 
among the elderly in the Western society (1, 2), affecting up to 7% of the 
general population over the age of 70 years (2). Symptoms in these 
patients range from intermittent claudication (Fontaine stage II, Ruther-
ford stage 1-3 (3)) to critical limb ischemia (1). 
The primary aim of treatment, in symptomatic patients with PAD 
without signs of critical ischemia, is relief of symptoms by improving 
exercise performance. Structured or supervised exercise therapy (SET) 
has been shown to be an effective conservative therapeutic approach to 
achieve this aim (2, 4-7). Improvement in exercise performance with SET 
is well established (5-8), but the magnitude of the response to SET 
varies according to literature. 
Although SET is the primary choice of treatment in intermittent 
claudication, the exact physiological mechanisms by which clinical 
improvement is accomplished are still subject of debate (6). Stimulating 
collateral artery formation to increase muscle perfusion is thought to be 
a potentially contributing biological mechanism (2, 6, 7, 9-12), which is 
generally thought to be a response to exercise induced elevated vessel 
wall shear stress (13, 14). Collateral artery formation is a complicated 
process and is thought to involve both adaptation of existing arteries 
and the formation of novel collateral arteries over time (15). To date the 
exact conditions under which collateral formation take place in patients 
with PAD, as well determinants of variations in extent of collateral 
formation among patients are still poorly understood. 
Magnetic resonance imaging is an ideal modality to study the pro-
cess of vascular adaptations in the context of SET because it is highly 
reliable for depiction of the peripheral vascular tree (16-18) and the 
ability to quantitatively study physiological phenomena such as vascular 
flow. 
The purpose of this study was to assess the morphological and 
functional macrovascular adaptations in response to SET in patients with 
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intermittent claudication. Morphological effects were evaluated with 
contrast-enhanced MR angiography (CE-MRA), whereas functional 
effects were assessed using quantitative flow measurements. 
Materials and Methods 
Study population 
Patients with newly diagnosed symptoms of PAD (Fontaine stage II; 
intermittent claudication with no signs of critical ischemia (3)) were 
eligible for participation in this study if obstructive arterial lesions (i.e. 
significant stenosis (> 50%) and/or occlusion) of the superficial femoral 
artery (SFA) were detected by duplex ultrasonography (peak systolic 
velocity (PSV) ratio > 2.0 (19)). Focus in this study was on patients with 
SFA disease as these patients are known to respond best to SET, where-
as patients with obstructive lesions within the iliac arteries are more 
often referred for invasive therapy and more likely to drop out of SET. 
Patients with lower leg stenosis are more prone to have diabetes melli-
tus, in which collateral artery formation might be impaired (20-22). 
Therefore, diabetic patients and patients with significant arterial lesions 
in the aorta, iliac arteries or arteries below the knee were excluded. If 
significant arterial lesions were detected in either the infra-renal aorta 
or severe lesions were detected in the lower leg on CE-MRA after initial 
inclusion of a patient, they were excluded from further participation 
from this study, however, this scenario did not occur during the entire 
study. Additional exclusion criteria were: prior treatment for PAD and 
presence of chronic or acute critical ischemia. Patients scheduled for 
vascular surgery or percutaneous transluminal angioplasty were also 
excluded from participation, as well as patients with contra-indications 
to MRI, including claustrophobia, known gadolinium based contrast 
agent allergy, and low estimated glomerular filtration rate (< 30 
mL/kg/1.73 m2) or patients with contra-indications for SET. The study 
was approved by the institutional medical ethics committee and all 
patients gave written informed consent before inclusion. 
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Study design 
Upon entry in the study, all patients underwent a treadmill test, 
ankle-brachial pressure index (ABI) measurement and MRI as described 
below to establish baseline values. MRI was acquired first, followed by 
the ABI measurements and the treadmill test on the same day (figure 1). 
All exams were repeated after three and six months of SET, respectively. 
Patients did not receive other (invasive) therapy than SET during this 
period, nor were there any alterations in prescribed medicaments. After 
six months of SET, patients returned to their vascular surgeon for 
evaluation and to discuss further treatment options (i.e. (dis)continuing 
SET and/or invasive therapy). Participation in this study had no impact 
on the course of treatment for the patients. MRI data were not used in 
the clinical evaluation of the participants. 
 
Figure 1. Overview of the imaging protocol. The MRI examination was performed first, 
followed by the ABI measurement and treadmill test for each visit of the patient. During 
the MRI examination, a first-pass contrast-enhanced MR angiography (CE-MRA) was 
performed of the entire muscular volume of the upper leg. CE-MRA was followed by 
quantitative cine phase-contrast imaging (PCI) to measure the arterial peak flow. 
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SET and treadmill testing 
A standardized and graded treadmill protocol was used during 
both the treadmill tests as well as the subsequent SET, as previously 
described by Gardner et al. (23). In this widely accepted and validated 
protocol (23), a constant speed of 3.2 km/h was applied, whereas 
during the exercise the slope of the treadmill was increased by 2% every 
two minutes starting at 0% inclination, thereby gradually increasing the 
metabolic demand for the patient. SET consisted of walking exercises on 
a treadmill 2-3 times per week, supervised by a physiotherapist. In 
addition, patients were given instructions for individual walking exercis-
es. 
To assess the effect of SET on pain free walking distance, treadmill 
tests were performed after three and six months at the vascular labora-
tory of our institution. 
MRI protocol 
MRI was performed to determine morphological and functional 
vascular effects during SET. Morphologic effects were studied using 
contrast-enhanced MR angiography (CE-MRA), whereas functional 
effects were studied using quantitative 2D cine MR phase-contrast 
imaging (PCI) to determine the arterial peak flow (APF) of the popliteal 
artery both at rest and after provoking reactive hyperemia to determine 
the maximum hyperemic flow as described before (24, 25). Postischemic 
reactive hyperemia in the lower leg was provoked using an inflatable 
cuff, ensuring total arterial occlusion (Medrad, indianola, PA). The cuff 
was placed at mid-thigh level and manually inflated to suprasystolic 
values (> 50 mmHg above brachial systolic blood pressure) during 6 
minutes. During cuff inflation, flow in the PA was measured with cine 
PCI to check that total arterial occlusion of the upper leg was achieved. 
A schematic overview of the study and MRI measurements is given in 
figure 1. 
All examinations were performed on a 1.5-T MRI system (Intera, 
Philips Medical Systems, Best, The Netherlands). For signal reception we 
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used a dedicated 12-element phased-array peripheral vascular coil with 
a craniocaudal coverage of 128 cm (Philips Medical Systems). Patients 
were imaged in supine position and were in this position for approxi-
mately 30 minutes before the flow measurement was started to mini-
mize any confounding history of physical effort. During this time the 
CE-MRA was acquired, using a fixed dose of 10 mL gadofosveset triso-
dium (Ablavar®, Lantheus Medical Imaging, Billerica, MA) as contrast 
agent. 
Survey. A non-enhanced time-of-flight (TOF) scan of the pelvic, 
upper and lower leg station was acquired to prescribe the imaging 
volumes of interest for morphological and functional imaging. For this, a 
turbo field echo (TFE) pulse sequence was used with a 180° inversion 
prepulse to suppress stationary tissues. Thirty-one axial slices per 
station were acquired with 3.3-mm slice thickness and 11-mm interslice 
gap, and an inferiorly concatenated saturation band. The standard 
quadrature body coil was used for signal transmission and reception. 
For positioning of the 3D CE-MRA volumes maximum intensity projec-
tions (MIP) were generated in 3 orthogonal directions. 
Angiography. A one-station 3D gradient-echo sequence was used 
for first-pass CE-MRA as previously described (16, 26). Whereas clinical 
CE-MRA examinations are usually limited to the visualization of a thin 
anteroposterior imaging volume only including the large conduit arteries 
in the upper leg (i.e. SFA and PA), for this study the entire muscular 
volume of the upper leg was imaged to visualize all the arteries includ-
ing any collateral branches within the upper leg. Acquisition parameters 
were as follows: TR 4.8 ms, TE 1.45 ms, flip angle 40°, FOV 470 mm, 
matrix 480 x 480, and voxel dimensions (reconstructed) 0.92 x 0.92 x 
1.20 mm. Prior to contrast medium administration, a non-enhanced 
‘mask’ image data set was acquired with exactly the same acquisition 
parameters as the CE-MRA, enabling background tissue suppression by 
image subtraction. 
After the first-pass sequence, a three station non-subtracted 
high-resolution steady-state acquisition was applied to visualize the 
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entire peripheral vascular tree to exclude iliac and lower leg arterial 
obstructions. 
Flow MRI. For quantitative flow measurements we used a 2D gra-
dient-echo cine phase contrast angiographic scan technique with the 
following acquisition parameters: TR 9.7 ms, TE 5.8 ms, flip angle 30°, 
FOV 380 mm, matrix 384, and reconstructed voxel dimensions of 0.99 x 
0.99 x 6.00 mm. Fifteen dynamic phases were acquired to obtain flow 
waveforms over the cardiac cycle. The phase encoding velocity (VENC) 
was set to 100 cm/s in the craniocaudal direction (17, 24). Vector 
cardiography triggering was used for retrospective cardiac synchroniza-
tion. Parallel imaging (sensitivity encoding, SENSE) was applied to reduce 
scan time (SENSE acceleration factor 2 in the anterior-posterior direc-
tion) (27). At a mean heart rate of 60 beats per minute, the nominal 
acquisition time was 1 minute. 
ABI measurements 
All ABI measurements were performed by well-trained operators at 
our vascular function laboratory, using an automated Doppler system 
(Nicolet VasoGuard, VIASYS Healthcare, Madison, WI). If the ABI could 
not be determined due to arterial stiffness or other circumstances, this 
was mentioned in the report by the operators. 
Angiographic reading 
All angiographic data sets were analyzed by a well-trained radiol-
ogist with over 5 years of experience in CE-MRA of the peripheral 
vasculature. First-pass CE-MRA data sets were used to assess morpho-
logic vascular effects following SET. 
Image analysis of the first-pass acquisition to determine the num-
ber of arteries of the upper leg was performed on a dedicated  
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Figure 2. Example of the counting procedure of the arteries in the upper leg using first-
pass CE-MRA data set. Arteries are marked in the right panel by the gray dots. 15 arteries 
were counted in this axial view. 
image post processing workstation (MacPro, running OS X, version 
10.5.4, Apple Inc., Cupertino, CA). As contrast-enhanced source images 
have shown better reproducibility compared to subtracted images, 
source images were considered for analysis (17). The number of arteries 
was manually quantified by counting the total number of arteries cross-
ing transverse planes in the upper leg at three different levels: 5 cm 
above, exactly at and 5 cm below the location where the SFA was recon-
stituted distal to the occlusion (figure 2) (17). This method ensures 
complete coverage of the collateral re-entrance zone, which represents 
the level at which collaterals re-enter the large native conduit artery 
distal to an occluded segment of the arterial tree (distal superficial 
femoral or popliteal artery in our study). Arteries were counted using the 
open source DICOM viewer OsiriX (OsiriX, Geneva, Switzerland, version 
3.5.1, http://www.osirix-viewer.com/), using the original source images 
as well as coronal and sagittal multiplanar reconstructions (MPR). Identi-
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fication of the correct counting plane was ensured by cross-reference to 
the anatomical landmarks as described above. Subsequently, the total 
number of arteries intersecting the three planes was determined, in-
cluding conduit arteries (SFA or PA), terminal muscle branches and any 
visible collateral arteries (figure 2). Arteries were distinguished from 
veins by scrolling through source images and MPR stacks to find an 
upstream connection to a named artery. 
Flow analysis 
Modulus and phase images were reconstructed from the cine 
phase contrast data. A quantitative flow analysis package included with 
the software release (Qflow, R11.4.14, Philips Medical Systems) of the 
MRI hardware was used for analysis of the flow waveform data. Using 
this software, a region of interest (ROI) covering the entire visible cross-
section of the artery of interest was manually drawn using a recon-
structed modulus image during peak systole and then automatically 
propagated to the remaining cardiac phases using an active contour 
algorithm. Although the peak systolic phase is sufficient to calculate the 
APF, ROIs were propagated to all cardiac phases to obtain flow wave 
forms, which were visually analyzed to reassure that the chosen cardiac 
phase indeed was at peak systole and to detect possible aliasing effects 
directly after the acquisition. If detected, the measurement was repeated 
with sufficient higher phase encoding velocity. APF was preferred over 
mean flow for analysis, as peak flow previously proved much more 
reproducible and revealed large differences between patients and 
healthy controls (17, 24, 25). Given the good inter-reader reproducibil-
ity of the APF analysis, all flow measurements were anonymously ana-
lyzed by a single, experienced radiologist (17, 25). 
Statistical analysis 
For statistical analysis only data of the symptomatic leg was used. 
If both legs were equally symptomatic, only the right leg was analyzed. 
Statistical analysis was performed with commercially available statistical 
software (SPSS 16.0, SPSS Inc., Chicago, IL). Mean values derived from 
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baseline and follow-up measurements were compared and tested for 
statistical significance using a t-test for paired samples. P < 0.05 was 
considered statistically significant. 
Results 
Subjects 
Over a period of 6 months, 10 patients (mean age 72.8 ± 8.9 
years; range 60 to 84 years; 8 men and 2 women) were included. SET 
was well tolerated by all patients. Subjects underwent six months of SET 
and three MRI examinations as planned without experiencing side 
effects or adverse events. 
Effect of SET on pain free walking distance 
Mean baseline pain free walking distance, as well as pain free 
walking distances after three and six months of SET are listed in table 1. 
After three months of SET the average pain free walking distance was 
significantly higher (p < 0.01) compared to the baseline distance at 
group level. After six months SET, pain free walking distance improved 
by 71% on average compared to baseline values (p < 0.01). The increase 
at six month relative to three month was small and not significant (p = 
0.45). In 2 out of 10 patients, pain free walking distance did not in-
crease. 
MRA 
At baseline, a significant arterial stenosis (n = 6) or occlusion (n = 
4) was present in the SFA in all patients. Morphologically, the arterial 
lesions of most patients remained unchanged (figure 3), although in two 
patients there was evident progression of the arterial lesions after six 
months (figure 4), whereas clinical symptoms (i.e. pain free walking 
distance) in these patients remained unchanged. Collateral arteries were 
present in 6 out of 10 patients at baseline. The mean number of arteries 
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in the upper leg at three different levels before and after SET is listed in 
table 1. There was no change in the mean number of collateral arteries 
after three and six months of SET, respectively, when compared to 
baseline values. In one of the two patients in whom the pain free walk-
ing distance did not improve, collateral arteries were present at base-
line, while in the other no collateral arteries were present at baseline nor 
developed during SET. 
 
Figure 3. Example of a maximum intensity projection of CE-MRA (upper panels) and the 
arterial flow wave form (lower panels) of a responder to SET (pain free walking distance 
increased from 100 m to 333 m after six months of SET). The arterial obstruction in the 
SFA is indicated by the white arrow. The three white lines demarcate the three axial 
planes where arteries were counted. White dotted line represents the location of the APF 
measurement. No vascular morphologic or arterial peak flow (black arrows) changes were 
seen after six months of SET. 
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APF 
Results of APF measurements are also listed in table 1. As was the 
case with the number of collateral arteries, mean APF at rest did not 
change significantly from the baseline value after three and six months 
of SET. Figure 3 shows an example of the APF at the level of the poplite-
al artery before and after SET in a patient that responded well to SET. 
Measurement of the maximum hyperemic flow after provoking reactive 
hyperemia with a cuff paradigm succeeded in 6 patients, while in 4 
patients the cuff paradigm proved too painful and cuff inflation could 
not be maintained for 6 minutes. In those 6 patients with successful 
hyperemic measurements, the maximum hyperemic flow did not change 
significantly from baseline values either (table 1). 
    
 Baseline 3 months 6 months 
Supervised Exercise Therapy    
 Pain free walking distance (m) 230 ± 42 362 ± 53a 395 ± 46a 
Number of arteries    
 5 cm above lesion 23 ± 3 21 ± 3 20 ± 3 
 At lesion level 18 ± 2 18 ± 3 19 ± 2 
 5 cm below lesion 12 ± 1 12 ± 1 12 ± 1 
Arterial Peak Flow (mL/s)   5.3 ± 0.6   5.5 ± 0.8   5.3 ± 0.8 
Ankle-brachial index 81 ± 4 80 ± 4 77 ± 4 
Table 1. Baseline and follow-up results after three and six months of SET, respectively. 
Values are presented as mean ± SD. ap < 0.01 compared to baseline. 
ABI measurements 
ABI measures before and after three and six months of SET are 
listed in table 1. In two patients, the ABI could not be determined relia-
bly, due to uncompressible arteries at the level of the ankle. After three 
and six months of SET, the mean ABI did not differ significantly from the 
baseline value. 
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Discussion 
In this study we assessed the macrovascular effects of six months 
SET in patients with intermittent claudication using different MRI tech-
niques. The main finding of this study is that although pain free walking 
distance improved substantially and significantly, no vascular adapta-
tions in terms of development of newly visible collateral arteries and/or 
increase in arterial peak flow could be detected with MRI. 
Effect of SET on walking distance 
Many studies have shown the benefits of supervised exercise ther-
apy to increase pain free and maximum walking distance in patients 
with intermittent claudication (2, 4-8, 28-31). Our study corroborates 
prior work and provides further evidence in support of this highly 
effective and low-cost intervention. The strongest improvement was 
made during the first three months of therapy, during which the pain 
free walking distance increased significantly compared to baseline 
values. Between the third and sixth month there was a trend of further 
improvement in walking performance, but improvements were less 
pronounced. 
SET and collateral artery development 
No new collateral arteries were found in our study population 
when comparing both maximum intensity projections as well as artery 
counts using our standardized counting method at different time points. 
On the contrary, in two patients arterial lesions increased in severity 
over time (figure 4). 
Maximum intensity projections of CE-MRA data acquired at base-
line revealed that most patients already had collateral arteries before the 
start of SET. The aspect of these collateral arteries did not change on 
MRA after six months of SET. Conversely, patients without collaterals at 
the start of SET did not develop any new visible collaterals during SET. 
These findings are remarkable, as SET is thought to stimulate formation 
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of collateral arteries (6). Two patients in whom the pain free walking 
distance did not improve after SET, showed presence of collateral 
arteries at the start of SET already.  
 
Figure 4. Progression of arterial lesions (white arrow left panel) in the right leg of a 
patient with intermittent claudication. At the level of the popliteal artery a new stenosis 
has developed (right panel, small white arrows) as compared to the baseline MRA (left 
panel). 
APF 
As with MRA, the APF measured at the level of the popliteal artery, 
i.e. below the level of the arterial stenosis in the superficial femoral 
artery and below the level of the suspected collateral artery re-entrance 
zone, did not reveal any improvement after three nor six months of SET, 
both at rest and after provoking reactive hyperemia (maximum hypere-
mic flow (25)). Even though there were no morphologic vascular adapta-
tions, an increase in APF might still have been expected due to a 
possibly improved physical condition, especially were the hyperemic 
flow is concerned, yet APF results were in line with MRA findings. This 
means that clinical improvement of our patients cannot be explained by 
either morphologic or functional vascular changes, as far as could be 
detected with MRI at rest and after provoking hyperemia. 
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ABI 
The ABI was measured to correlate possible functional vascular 
improvements (i.e. increased arterial peak flow) with a well-established 
and clinically widely applied functional test. Results in this study show 
that although the pain free walking distance of patients did increase, 
there was no increase in ABI after respectively three and six months of 
SET, which is in line Watson et al (30), who did not find changes in ABI 
during SET either. These results are also comparable with MRI findings, 
where no vascular adaptations or collateral artery formation was detect-
ed either. 
Considerations 
Although the study population was relatively small, we found no 
signs of macrovascular adaptations with MRI whereas there was a 
significant improvement in pain free walking distance after six months 
of SET in a high proportion of the participants. It is unlikely we missed 
significant collateral artery formation or improvements in flow as CE-
MRA has a high sensitivity for detecting small arteries (17) and both CE-
MRA as well as phase-contrast flow imaging proved highly reproducible 
before (17, 25). Given the observation that collateral arteries were 
already present in the majority of the included patients, it is more likely 
that clinical symptoms in these patients came apparent after collateral 
arteries had already been developed to a maximum extend and started 
to fall short. 
Most patients in this study responded favorably to SET and im-
proved clinically. Nevertheless, the success of SET does not seem to be 
related to a (macro) vascular substrate. Many participating patients 
declared, that in their opinion the improved pain free walking distance 
was actually the result of ‘a better handling’ of pain. Although we did 
not investigate this aspect it could potentially explain the discrepancy 
between clinical and MRI findings in this study (32). 
This study demonstrates that active monitoring of SET with MRI is 
not helpful to unveil any contribution of marcovascular adaptations and 
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MRI cannot help at the early detection of possible non-responders. From 
a basic research point of view, it might be helpful to acquire MRI data of 
PAD patients in earlier stages of disease, during which no collateral 
arteries are present yet. 
Even though MRI in this study was not able to detect macrovascu-
lar changes, our technique might still be useful for the monitoring and 
follow-up of patients with PAD treated with other, new therapeutic 
options aiming to improve vascularization, such as with stem cells and 
endothelial growth factors (i.e. vascular endothelial growth factor (VEGF) 
and basic fibroblast growth factor (bFGF)), which are currently being 
developed for treatment of both intermittent claudication and critical 
ischemia (33-36). 
Finally, our study underscores the need for MR methods to study 
adaptations at tissue level. However, although some authors have 
investigated skeletal muscle oxygenation and perfusion (37-39) ques-
tions remain about the reproducibility of these techniques, at least at a 
magnetic field strength of 1.5T (17). 
Conclusion 
Supervised exercise therapy in patients with intermittent claudica-
tion results in an increase in pain free walking distance. Nevertheless, 
with the current approach MRI proved not able to detect macrovascular 
adaptations in terms of additional collateral artery formation or flow 
increases both at rest and during reactive hyperemia after six months of 
SET compared to baseline values. 
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Abstract 
Objectives 
The aim of this work was to develop a MRI method to determine 
arterial flow reserve in patients with intermittent claudication and to 
investigate whether this method can discriminate between patients and 
healthy control subjects. 
Methods 
Ten consecutive patients with intermittent claudication and 10 
healthy control subjects were included. All subjects underwent vector 
cardiography triggered quantitative 2D cine MR phase-contrast imaging 
to obtain flow waveforms of the popliteal artery at rest and during 
reactive hyperemia. Resting flow, maximum hyperemic flow and abso-
lute flow reserve were determined and compared between the two 
groups by two independent MRI readers. Also, interreader reproducibil-
ity of flow measures was reported. 
Results 
Resting flow was lower in patients compared to controls (4.9 ± 1.6 
and 11.1 ± 3.2 mL/s in patients and controls, respectively (p < 0.01)). 
Maximum hyperemic flow was 7.3 ± 2.9 and 16.4 ± 3.2 mL/s (p < 0.01) 
and the absolute flow reserve was 2.4 ± 1.6 and 5.3 ± 1.3 mL/s (p < 
0.01), respectively in patients and controls. The interreader coefficient 
of variation was below 10% for all measures in both patients and con-
trols. 
Conclusions 
Quantitative 2D MR cine phase-contrast imaging is a promising 
method to determine flow reserve measures in patients with peripheral 
arterial disease and can be helpful to discriminate patients with inter-
mittent claudication from healthy controls. 
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Introduction 
The hemodynamic significance of obstructive arterial lesions in 
peripheral arterial disease (PAD) can be assessed by blood flow velocity 
measurements (1-5). Nevertheless, in patients with intermittent claudi-
cation - stage II PAD according to the Fontaine classification - blood 
flow at rest might be near-normal depending on the severity of the 
obstructive lesion, or recover quickly to near-normal values after exer-
cise due to collateral artery formation (6-13). These (near-)normal 
resting flow values explain the absence of clinical symptoms at rest in 
intermittent claudication. Symptoms in these patients, however, charac-
teristically appear during physical exercise when the flow demands 
towards the lower extremity increase. Therefore the flow reserve, either 
defined as the absolute difference or relative value between maximum 
hyperemic flow and autoregulated resting flow, is expected to be com-
promised in patients with intermittent claudication (10, 14, 15). Arterial 
flow reserve correlates well with subjective severity of symptoms in 
intermittent claudication and is less hampered by day-to-day variations 
than resting flow (14). Also, flow reserve stays compromised for a 
prolonged period of time during the process of collateral formation (9). 
Moreover, it does not depend on the physical capabilities of the patient, 
such as with physical exercise tests and ankle-brachial index measure-
ments. Flow reserve might therefore be a valuable additional objective 
measure of disease severity in PAD in those patients with normal resting 
flow values, in order to discriminate between hemodynamically signifi-
cant and insignificant obstructive arterial lesions. Flow reserve could 
also be useful for therapy monitoring, since physical exercise tolerance 
is closely correlated with the flow reserve, in contrast to resting flow 
levels (7-9). 
Flow reserve is usually measured with duplex ultrasonography. 
This method, however, is limited for the peripheral arteries by a rela-
tively large interobserver variability during reactive hyperemic condi-
tions, which are needed to determine the flow reserve (16, 17). Other 
techniques to measure blood flow are Laser Doppler flowmetry, con-
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trast-enhanced ultrasound (CEUS) and intra-arterial catheter based flow 
measurements (1, 9, 10, 14, 18). Unfortunately, these methods either 
lack the ability to directly measure flow in large, non-superficial, con-
duit arteries, are prone to poor interobserver variability, or are not 
suitable for repeated measurements, as in the context of therapy moni-
toring (9, 14, 16). A promising alternative method to measure flow in 
the peripheral arteries, is MRI-based quantitative cine phase-contrast 
imaging (PCI) (2-4, 19, 20). Cine PCI can easily be combined with stand-
ard contrast-enhanced MR angiograpy (CE-MRA) of the peripheral 
vasculature and therefore has the major advantage to provide highly 
accurate morphologic information (21, 22) together with relevant func-
tional information in a single examination. 
The purpose of the current study was (i) to develop a MRI method 
for the determination of vascular flow reserve in the popliteal artery 
(PA), using quantitative velocity encoded 2D MR cine PCI flow waveform 
measurements at rest and during reactive hyperemia, (ii) to evaluate the 
potential value of this method to discriminate patients with intermittent 
claudication from healthy control subjects, and (iii) to determine the 
reproducibility of measuring resting flow and flow reserve with cine PCI. 
Material and methods 
Subjects and Ethics statement 
Ten consecutive non-diabetic patients (mean age ± SD: 66.5 ± 9.9 
years; 8 males and 2 females) with clinical symptoms of PAD (Fontaine 
stage II; intermittent claudication with no signs of critical ischemia (23)) 
with suspected arterial lesions of the superficial femoral artery (SFA) by 
duplex ultrasonography (peak systolic velocity (PSV) ratio > 2.0 (24)) 
were included, as well as 10 healthy control subjects with no known PAD 
symptoms (age 24.1 ± 2.2 years; 3 males and 7 females). Exclusion 
criteria were hemodynamic instability, contraindications for MRI (i.e. 
claustrophobia, known gadolinium based contrast agent allergy, or low 
estimated glomular filtration rate (< 30 mL/kg/1.73 m2)). The institu-
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tional medical ethics committee (METC azM/UM) approved the study and 
all subjects gave written informed consent before inclusion. 
 
Figure 1. Overview of the imaging protocol. Three flow measurements were acquired at 
rest, before provoking reactive hyperemia to determine the average resting flow and 
reproducibility of resting flow. Reactive hyperemia was provoked by a cuff paradigm. 
After cuff deflation, 10 flow measurements were acquired during reactive hyperemia to 
determine the listed flow reserve measures. 
* CE-MRA was performed in patients only. In healthy controls flow measurements started 
 10 minutes after the survey was completed. 
** Nominal scan duration at a regular heart rate of 60 beats per minute. 
MRI protocol 
All subjects underwent cine PCI measurements in the PA to obtain 
flow waveforms. Cine PCI was combined with CE-MRA of the peripheral 
arteries as part of the clinical routine examination. A schematic overview 
of the scan protocol is given in figure 1. All examinations were per-
formed on a 1.5-T MRI system (Intera, Philips Medical Systems, Best, 
The Netherlands). For signal reception we used a dedicated 12-element 
phased-array peripheral vascular coil with a craniocaudal coverage of 
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128 cm (Philips Medical Systems, Best, The Netherlands). Subjects were 
imaged in the supine position. All subjects were in this position for 
approximately 30 minutes before the first flow measurement was 
started. During this time a three-station CE-MRA was acquired in 
patients, using a fixed dose of 10 mL gadofosveset trisodium (Ablavar®, 
Lantheus Medical Imaging, Billerica, MA) as contrast agent. 
In patients, flow was measured in the PA of the most symptomatic 
lower extremity. In all healthy controls flow was measured in the right 
PA. Postischemic reactive hyperemia in the lower leg was provoked 
using an inflatable cuff, ensuring total arterial occlusion (Medrad, 
indianola, PA). The cuff was placed at mid-thigh level and manually 
inflated to suprasystolic values (> 50 mmHg above brachial systolic 
blood pressure) during 6 minutes. During cuff inflation, flow in the PA 
was measured with cine PCI to check that total arterial occlusion of the 
upper leg was achieved. PA was chosen as the vessel of interest as the 
PA is the most distal artery with sufficiently large caliber to measure 
flow by PCI with a spatial resolution that enables fast cine PCI measure-
ments (19, 20). 
Survey. A non-enhanced time-of-flight (TOF) scan of the pelvic, 
upper and lower leg station was acquired to prescribe the imaging 
volumes of interest for morphological and functional imaging. A turbo 
field echo (TFE) pulse sequence was used with a 180° inversion prepulse 
to suppress stationary tissue. Thirty-one axial slices per station were 
acquired with 3.3-mm slice thickness and 11-mm interslice gap, and an 
inferiorly concatenated saturation band. The standard quadrature body 
coil was used for signal transmission and reception. For the positioning 
of the 3D CE-MRA volumes maximum intensity projections (MIPs) were 
generated in 3 orthogonal directions. 
CE-MRA. A three-station 3D FFE CE-MRA sequence was performed 
as previously described (21, 25). Acquisition parameters were as fol-
lows: TR 4.8 ms, TE 1.45 ms, flip angle 40°, FOV 470 mm, matrix  
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Figure 2. Coronal (A) and sagittal (B) reconstructions of CE-MRA of the upper leg of a PAD 
patient, showing the superficial femoral and popliteal artery. The cine PCI plane (line 
segments) was angulated perpendicular to the popliteal artery. 
480, and voxel dimensions (reconstructed) 0.92 x 0.92 x 1.20 mm. Prior 
to contrast medium administration, a non-enhanced ‘mask’ image data 
set was acquired with exactly the same acquisition parameters as the 
CE-MRA, enabling background tissue suppression by image subtraction. 
For cine PCI we used a 2D FFE scan technique with the following acquisi-
tion parameters: TR 9.7 ms, TE 5.8 ms, flip angle 30°, FOV 380 mm, 
matrix 384, and voxel dimensions (reconstructed) 0.99 x 0.99 x 6.00 
mm (26-28). Fifteen dynamic phases were acquired during the cardiac 
cycle. To focus on the peak velocity and flow, the phase encoding 
velocity (VENC) was set to 100 cm/s in the craniocaudal direction, as 
published before (2, 29). Vector cardiography (VCG) triggering was used 
for retrospective cardiac synchronization. Parallel imaging (sensitivity 
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encoding, SENSE) was applied to reduce scan time (SENSE factor 2 in the 
anterior-posterior direction). At a mean heart rate of 60 beats per 
minute, the nominal acquisition time was 1 minute per dynamic acquisi-
tion. Coronal and sagittal MIP reconstructions of CE-MRA images were 
used for accurate positioning and angulation of the slice, perpendicular 
to the direction of the PA (see figure 2), for cine PCI measurement. 
Flow analysis 
Two independent MRI readers, blinded for each other’s results, 
analyzed all datasets. Modulus and phase images were reconstructed 
from the cine PCI data. MRIcro (MRIcro, http://www.mricro.com/) was 
used as the image software application to manually draw a region of 
interest (ROI) covering the entire visible cross-section of the PA on each 
of the 15 reconstructed modulus images spanning the cardiac cycle. 
These regions of interest (ROIs) were analyzed, using self-written 
software code (Matlab, The Mathworks inc., Natick, MA) to obtain flow 
waveforms from the phase images (27). Phase images and flow wave-
forms were visually analyzed to detect possible aliasing due to a low 
phase encoding velocity. Flow waveforms were used to determine flow in 
mL/s by integrating the 2D velocity profile over the cross-section of the 
artery. For this study, we primarily focused on the vascular stress condi-
tion, and therefore the arterial peak flow (related to peak velocity) was 
the primary functional quantity measured, rather than mean flow or 
velocity, cross-sectional luminal area or other velocity measures, as 
peak flow is physiologically the most relevant quantity and known to be 
most reproducible (2). Mean flow, peak velocity and peak area were 
nevertheless determined and can be found in appendix 1. 
Resting flow was defined as the average flow of three consecutive 
acquisitions at rest prior to cuff inflation. Absolute flow reserve was 
defined as the absolute difference between maximum hyperemic flow 
after cuff release and resting flow, whereas the relative flow reserve was 
defined as the ratio between these two measures. Also the time-to-peak 
(TTP), defined as the time needed to reach maximum hyperemic flow 
after cuff release, and time-to-recovery (TTR), defined as the time 
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needed for flow to recover towards resting values after cuff release, 
were determined. An overview of the different flow parameters is illus-
trated in figure 3. Flow values were recorded as the average flow over a 
single dynamic measurement (approximately one minute at a heart rate 
of 60 beats per minute). For example, if the maximum hyperemic flow 
was observed during the first measurement after cuff release, a TTP of 
30 seconds was recorded. If the maximum hyperemic flow was observed 
during the second measurement, a TTP of 60 + 30 = 90 seconds was 
recorded. TTR was determined similarly. 
 
Figure 3. Overview of the different flow (reserve) measures. Absolute and relative flow 
reserve are defined as the absolute difference and the ratio between maximum hyperemic 
and resting flow, respectively. TTP, time-to-peak; TTR, time-to-recover. 
Statistical analysis 
Statistical analysis was performed with commercially available sta-
tistical software (SPSS 16.0, SPSS Inc., Chicago, IL). For the small groups 
a non-parametric 2-samples test (Mann-Whitney test) was applied to 
compare measures between patients and healthy controls.  
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P < 0.05 was considered statistically significant. Data of both MRI 
readers were averaged for the comparison between patients and healthy 
controls. 
The variation of consecutive flow measurements at rest and the 
interreader reproducibility of resting flow and flow reserve measures 
were calculated. To determine interreader reproducibility, two measures 
of agreement were determined, being the coefficient of variation (CV in 
%) and the repeatability coefficient (RC). In addition, the intraclass 
correlation coefficient (ICC) was determined as a parameter of reliability. 
The CV represents the relative variation within subjects and was derived 
by dividing the overall within-subject standard deviation (SDws) by the 
mean measurement value over all subjects. The RC gives the smallest 
noticeable difference that can be detected beyond measurement error 
and is defined as 1.96⋅√2⋅SDws (30, 31). In other words, the difference 
between 2 measurements in the same subject is expected to be less 
than the RC in 95% of the observations in cases where the measured 
quantity remains unchanged over time. A value of RC lower than the 
absolute difference between mean values in patients and healthy con-
trols indicates good agreement. The ICC, the fraction of total variance 
due to variation between subjects, rather than measurement error, was 
calculated using a 1-way random model, according to ICC = SDbs2 / 
(SDbs2 + SDws2), where SDbs represents the standard deviation between 
subjects. If the measurement error is small compared to the variation 
between subjects, the ICC approaches 1, i.e. reliability is very high. 
Interreader reproducibility was determined for the resting flow and both 
flow reserve measures. 
Results 
Subjects 
All subjects included underwent cine PCI to obtain flow waveforms 
as planned and without experiencing side effects or adverse events. 
Total arterial occlusion during cuff compression could be confirmed by 
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cine PCI measurements in all subjects. All cine PCI images were of 
sufficient quality for quantitative analysis and no aliasing was detected. 
The average heart rate (mean ± SD) in patients was 67 ± 9 beats per 
minute (bpm), versus 62 ± 11 bpm in healthy controls (no significant 
difference, p = 0.23). 
CE-MRA 
CE-MRA revealed significant stenosis (> 50%) of the SFA in 6 out 
of 10 patients, whereas long occlusions of the SFA were found in the 
remaining patients. Large collateral arteries were found in those patients 
with SFA occlusions, whereas in patients with significant stenosis of the 
SFA there were no prominent collateral arteries. Iliac artery vessel wall 
irregularities were found in 3 out of 10 patients. The remaining patients 
had no signs of obstructive lesions of the iliac arteries. At least 2 out of 
3 main conduit arteries of the lower leg were free from obstructive 
lesions in all patients. CE-MRA revealed no signs of PAD in any of the 
control subjects. 
Patients versus healthy controls 
Representative phase-contrast images (modulus and phase), cross 
sectional velocity 2D velocity profiles and flow waveforms at rest and 
during reactive hyperemia in a patient and healthy control subject are 
shown in figure 4 and 5 respectively. Flow increased during reactive 
hyperemia in both patients and healthy controls. Flow waveforms under 
resting conditions were either tri- (n=2), bi- (n=2) or monophasic (n=6) 
in patients and triphasic in all healthy controls. During reactive hypere-
mia flow waveforms became monophasic for all patients, as seen in 
figure 5, while flow waveforms remained triphasic for all healthy con-
trols. Figure 6 shows temporal variations in flow before and after pro-
voking reactive hyperemia in a patient and a healthy control. 
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Figure 4. Example of PCI modulus images (left corner panel A and B) and phase images 
(right corner panel A and B) and the correspondingly measured 2D velocity profiles of a 
PAD patient (panel A) and healthy control (panel B). The brightest pixels of the modulus 
images represent the popliteal artery and is located within the white box on the phase 
images. 2D velocity profiles represent peak systolic velocity across the popliteal artery. 
Maximum peak velocity values were 24.3 cm/s and 92.6 cm/s respectively for the patient 
and healthy control, respectively. 
 
Figure 5. Flow waveforms in a PAD patient (panel A) and a healthy control (panel B) at 
rest and during maximum hyperemia. Note the mono-phasic flow waveform in the 
patient, both at rest and during reactive hyperemia. 
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   Resting flow 
   Patients Healthy controls 
   (n = 10) (n = 10) 
Value mL/s 4.9 ± 1.6 11.1 ± 3.2 
Interreader reproducibility   
 CV % 4.0 4.3 
 RC mL/s 0.5 1.0 
 ICC (95% CI) 0.99 (0.96 - 0.99) 0.99 (0.96 - 0.99) 
   Maximum hyperemic flow 
  Patients Healthy controls 
Value mL/s 7.3 ± 2.9 16.4 ± 3.2 
Interreader reproducibility   
 CV % 4.6 3.5 
 RC mL/s 0.9 1.6 
 ICC (95% CI) 0.99 (0.95 - 0.99) 0.97 (0.89 - 0.99) 
   Absolute flow reserve 
  Patients Healthy controls 
Value mL/s 2.4 ± 1.6 5.3 ± 1.3 
Interreader reproducibility   
 CV % 9.8 8.7 
 RC mL/s 0.6 1.2 
 ICC (95% CI) 0.98 (0.93 - 0.99) 0.89 (0.63 - 0.97) 
   Relative flow reserve 
  Patients Healthy controls 
Value % 149 ± 31 151 ± 19 
Interreader reproducibility   
 CV % 3.1 3.4 
 RC % 12.5 14.0 
 ICC (95% CI) 0.98 (0.93 - 0.99) 0.93 (0.76 - 0.98) 
Table 1. Flow measures and reproducibility in patients with intermittent claudication and 
healthy controls. 
Values are presented as mean ± SD. CV, coefficient of variation; RC, repeatability coeffi-
cient; ICC, intra-class correlation coefficient. 
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Absolute flow values at rest and during reactive hyperemia are 
given in table 1. On average, resting flow in patients was less than half 
of the values measured in healthy controls (p < 0.01). Maximum hyper-
emic flow and absolute flow reserve in patients were also less than half 
the values found in healthy controls (p < 0.01). For relative flow reserve, 
on the other hand, there were no significant differences between pa-
tients and healthy controls (p = 0.81). 
Figure 7 shows the distribution of resting flow and absolute flow 
reserve values in patients. The upper and lower limits represent mean 
values ± 2SD in healthy controls. Resting flow was lower than the lower 
limit of healthy controls (i.e. mean – 2SD) in 4 patients. Absolute flow 
reserve revealed lower values than the lower limit in 6 patients, of whom 
2 patients had normal resting flow values (see cross-table of figure 7). 
In 4 patients both resting flow and flow reserve values were within the 
upper and lower limits as encountered in control subjects. 
 
 
Figure 6. Peak flow in the popliteal artery before and after provoking reactive hyperemia 
by a cuff paradigm in a PAD patient (panel A) and a healthy control (panel B).The shaded 
bar represents the period of cuff compression to provoke reactive hyperemia. There is 
close agreement between the two MRI readers for both the patient and healthy control 
subject. 
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Figure 7. Resting flow (panel A) and absolute flow reserve (panel B) in PAD patients. The 
upper and lower limits in the graphics represent the mean value ± 2SD of resting peak 
flow (panel A) and absolute peak flow reserve (panel B) of healthy controls. The cross-
table (right C) shows the number of patients with flow and flow reserve values within 
(normal values) or below (impaired values) the lower limits. 
TTP was 65 ± 52 (mean ± SD) seconds in patients and 35 ± 29 
seconds in healthy controls. TTR was 360 ± 212 and 254 ± 96 seconds 
in patients and healthy controls, respectively. These results for TTP and 
TTR indicate a trend towards slower responses in patients (p = 0.15 and 
p = 0.16 for TTP and TTR, respectively). 
Vascular lesions and flow measures 
Resting flow in patients with an occlusion of the SFA was signifi-
cantly lower compared to those with a significant stenosis (p = 0.02). 
Three out of 4 patients with an occlusion of the SFA had resting flow 
values lower than the lower limit of healthy controls. 
Maximum hyperemic flow, absolute and relative flow reserve 
measures did not differ significantly between patients with occlusions 
and significant stenosis (p = 0.15, p = 0.72 and p = 0.63 respectively). 
Absolute flow reserve was lower than the lower limit of healthy controls 
in 3 out of 4 patients with a SFA occlusion and 3 out of 6 patients with a 
significant stenosis of the SFA. 
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Reproducibility 
The variation between the three consecutive resting flow meas-
urements was 4.2 % in patients and 6.6 % in healthy controls. Interreader 
reproducibility values of the flow measures are given in table S1. In-
terreader reproducibility for resting flow and flow reserve measures was 
high in both patients and healthy controls, with a CV below 10% for all 
flow measures in both groups (table 1). The RC values were smaller than 
the difference between PAD patients and healthy controls for the resting 
flow, maximum hyperemic flow, and the absolute flow reserve 
measures, but not for relative flow reserve. 
Discussion 
In this study we describe a simple MRI-based cine phase contrast 
imaging method that can be used to determine flow reserve measures in 
the popliteal artery in a vascular stress condition. Our initial results 
indicate that this a stable method that seems to be more sensitive in 
detecting peripheral arterial disease than resting flow measurements 
only. 
Objective assessment of the functional consequences of stenoses 
and occlusions in the peripheral arterial tree remains an area of high 
interest for physicians dealing with PAD patients. Currently, the ankle-
brachial index (ABI) measurement is the most recognized and most 
widely applied functional measurement used for diagnosis and therapy 
monitoring (5, 32, 33). ABI measurements, however, are hampered by 
poor reproducibility (14, 34). Besides, in patients with heavily calcified 
arteries in the lower leg, as frequently seen in patients with PAD, the ABI 
cannot be determined accurately or not be determined at all (14, 34, 
35). 
The current study demonstrates that it is feasible to combine the 
ability of MRI to depict peripheral vascular anatomy with functional 
information (i.e. hemodynamic consequences) of popliteal artery flow 
reserve. Combining these two measurements in one examination is of 
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high clinical interest, as it would potentially enable more objective 
assessment of PAD in patients suspected of having PAD, but also in the 
context of evaluating novel therapeutic strategies for PAD. 
Patients versus healthy controls 
Maximum hyperemic flow and absolute peak flow reserve were 
approximately 50 % and significantly lower in patients compared to 
healthy controls. This shows that flow reserve measures can be used to 
determine the hemodynamic consequences of obstructive arterial 
lesions in the superficial femoral artery in PAD patients. These results 
are in line with previous studies and prove that the concept of blood 
flow reserve, originally introduced by Coffman and Gregg in 1960 for 
the coronary arteries (15), also seem to apply to peripheral arteries (9, 
10, 14, 36, 37). Lower flow reserve in the popliteal artery of PAD pa-
tients can be explained by the presence of obstructive arterial lesions, 
resulting in a decrease of the pressure gradient distal to the vascular 
lesion and thereby a decrease of the maximum hyperemic flow distal to 
these lesions (37). 
An important observation is that, at group level, resting flow in 
this study was significantly reduced in patients with intermittent claudi-
cation, which concurs with previous studies (2, 29). This might suggest 
that resting flow alone already provides sufficient functional information 
on the hemodynamic significance of obstructive arterial lesions in 
intermittent claudication, without the need for flow reserve assessment. 
However, when looking at the resting flow values of individual patients 
(figure 7), it becomes clear that only four patients (40%) had resting flow 
values below the mean flow -2SD in healthy controls. Three out of 
these four patients had a long occlusion of the SFA at CE-MRA. Regard-
less of the small number of patients, these initial results show that the 
type of vascular obstruction (i.e. stenosis or occlusion) affects resting 
flow. Although resting flow of these patients was lower than the lower 
limit in healthy controls, flow was still sufficient to sustain minimal 
perfusion of the lower leg as there were no clinical signs of ischemia at 
rest. Absolute flow reserve, on the other hand, was below the mean 
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value in healthy controls – 2SD in six (60%) patients and was therefore 
able to identify two more patients with PAD compared to resting flow 
alone. Of these six patients, three suffered from an occlusion of the SFA 
and three had a significant stenosis of the SFA on CE-MRA. In the four 
remaining patients both resting flow and flow reserve appeared normal. 
This suggests that either no hemodynamically significant obstructive 
arterial lesions were present, or flow through the collateral arteries 
mitigated the effects of the stenoses. 
Our initial results also indicate that for patients with (near-)normal 
resting flow values, assessment of the flow reserve might provide 
important additional functional information with respect to the hemody-
namic significance of the arterial lesions, allowing to discriminate 
patients with intermittent claudication from healthy controls. Further 
studies with larger populations will be needed to determine the addi-
tional clinical value of flow reserve in the assessment of the hemody-
namic significance of obstructive arterial lesions, both in patients with 
intermittent claudication and more severe stages of PAD. 
Relative flow reserve, also known as the dimensionless flow re-
serve ratio in literature (37), was not significantly different between 
patients and healthy controls in this study, although we expected it to 
be impaired in patients. This discrepancy can be explained by the fact 
that resting and maximum hyperemic flow in patients as well as volun-
teers were reduced to approximately the same extent, resulting in a 
ratio for patients comparable to that in healthy controls. Based on our 
results there seems no clinical value of the relative flow reserve. 
TTP and TTR did not significantly differ between patients and vol-
unteers. However, when looking at the absolute values, it becomes clear 
that TTP and TTR are prolonged in patients, as we expected. However, 
the fact that we did not find significant differences in TTP and TTR 
between patients and healthy controls might be due to the relative small 
number of subjects. In addition, the low temporal resolution of approx-
imately one minute per acquisition probably had a negative influence 
upon the discriminative ability for TTP and TTR as well. Previous studies 
on microvascular reactions during reactive hyperemia found prolonged 
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peak and recovery times for microvascular flow between PAD patients 
and controls and the same phenomenon might be expected for macro-
vascular flow (38-40). 
Reproducibility 
Flow at rest was measured three times to determine an average 
resting flow. The variation between consecutive flow measurements at 
rest was very low in both patients (4.2%) and healthy controls (6.6%). 
This means that resting flow in a lying subject is relatively stable over 
time. 
Resting flow and flow reserve measures (maximum hyperemic 
flow, absolute and relative flow reserve) all showed a high interreader 
reproducibility, with a interreader CV < 5% for most measures (with 
exception of the absolute flow reserve in patients with a CV < 10%). This 
indicates a low observer dependency of the measurements, which is 
desirable for clinical application in therapy monitoring and follow-up 
studies. The interreader CV is comparable to the variation of the (rest-
ing) flow measurements. 
Peak versus mean flow 
In this study peak flow values were preferred over mean flow val-
ues. Peak flow, the maximum flow during systole, is an attractive flow 
measure, as it correlates with the ABI and is an important determinant of 
the systolic blood pressure (41). The decision to use peak flow was 
based on previous results, suggesting that peak values are more repro-
ducible in cine PCI of the popliteal artery and show larger differences 
between PAD patients and healthy controls (2). Results on mean flow, 
peak velocity and peak area are presented in table 2 and discussed in 
appendix S1. 
It would be interesting to see how well MRI derived flow reserve 
correlate and reproducibility measures compare with duplex ultrasonog-
raphy derived flow measurements. Such a comparison, however, was 
beyond the scope of the current feasibility study and requires a larger 
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sample size and patient population. Besides, at present flow reserve is 
not yet routinely used in clinical practice for establishing the diagnosis 
and severity of PAD, neither using duplex ultrasonography nor MRI. 
Spatiotemporal resolution 
Previously published cine PCI protocols that measure flow reported 
a temporal resolution of 2 minutes or more (2, 42-44). We believe that 
this temporal resolution would have been insufficient to accurately 
measure the maximum flow during reactive hyperemia, as it is known 
that the maximum flow after cuff release is reached within one minute 
(45). Therefore, the temporal resolution of cine PCI measurements in the 
current study was improved by using parallel imaging (sensitivity encod-
ing, SENSE (46, 47)). Prakash et al (47) found good agreement between 
conventional cine PCI measurements and flow measurements with a 
parallel imaging acceleration factor of 2, resulting in approximately 50% 
reduction in scan time. The results of our study show that in healthy 
controls the maximum hyperemic flow indeed was reached within one 
minute for every subject. To accurately measure the time-to-peak value 
in healthy subjects, and probably patients with less severe forms of PAD, 
further improvement of the temporal resolution is required. In PAD 
patients however, the time-to-peak was markedly longer, and in most 
patients the maximum hyperemic flow was not reached during the first 
measurement after cuff deflation. The currently used temporal resolu-
tion therefore seems to be sufficient for the application of this method 
in patients. Nevertheless, further improvement of the temporal resolu-
tion might result in more accurate (and possibly higher, as the measured 
value is an average flow measure over the entire duration of the meas-
urement) flow reserve values in healthy persons, which will increase the 
ability to discriminate more patients from healthy controls. With our 
current equipment, however, parallel imaging acceleration factors above 
2 results in a strong decrease in image quality. 
Along the same vein, the temporal resolution of the waveform ac-
quisition and the accuracy of the flow values can be improved, particu-
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larly in healthy controls, by applying faster image sampling. However, a 
present drawback is that spatial resolution will consequently decrease. 
Conclusion 
This exploratory study demonstrates that quantitative 2D MR cine 
PCI flow waveform measurement in the popliteal artery is a simple and 
stable method to assess the functional severity of arterial stenoses in 
patients with intermittent claudication. A strong reduction in maximum 
hyperemic flow and absolute flow reserve was found in patients with 
intermittent claudication compared to healthy controls. Therefore, 
assessment of flow reserve might be a valuable addition to MR angi-
ography to objectively determine the hemodynamic consequences and 
disease severity in PAD patients. 
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Appendix 
In addition to arterial peak flow also mean flow, peak velocity and 
area were determined and are listed in table 2. 
Mean flow. No significant differences for mean flow were found 
between patients and healthy controls (table 2). The results in table 2 
also confirm that interreader reproducibility is markedly lower for mean 
flow as compared to peak flow. Previous studies already revealed better 
discriminative capabilities and reproducibility for arterial peak flow over 
mean flow, which is confirmed in the current study (2, 29). Poor in-
terreader reproducibility for mean flow is probably induced by low 
contrast between the lumen of the popliteal artery during diastole and 
static tissue, which makes it difficult to correctly identify vessel con-
tours. Also, the applied acquisition settings, especially the relatively 
high phase encoding velocity (VENC) of 100 cm/s is less suitable to 
accurately measure low flow velocities during diastole in the popliteal 
artery. Nevertheless, we choose this VENC value as we were primarily 
focused on peak flow. A venc value of 100 cm/s was approx. 30-40% 
above the highest peak velocity values we found at rest in healthy 
controls in a previous study (29), and we expected this value to be high 
enough to measure the maximum hyperemic peak velocity. We decided 
to use a fixed (i.e. predefined and constant) phase encoding velocity for 
both patients and controls as we (i) we did not know the optimal phase 
encoding velocity for each patient (especially during hyperemia) prior to 
the study, and (ii) in clinical practice, a fixed phase encoding velocity 
would be highly desirable for reasons of time efficiency, and also (iii) by 
using a constant phase encoding velocity the methodology was identical 
for each subject. 
Peak velocity. Peak velocity results are concordant to peak flow re-
sults, with resting peak velocity, maximum hyperemic peak velocity and 
absolute peak velocity reserve being significantly lower in patients (p < 
0.01), whereas no significant difference was found for relative peak 
velocity reserve. Interreader reproducibility is excellent, which is hardly 
surprising, as during data analysis it is easy to identify the intraluminal 
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voxel with the highest velocity (i.e at the vessel’s center). Nevertheless, 
in clinical practice the use of peak velocity might be problematic. Arteri-
al peak velocity is known to increase over hemodynamically significant 
stenotic vessel segments (an increase that is measured clinically by 
determining the peak systolic velocity (PSV)-ratio by ultrasound (48)). As 
far as peak flow is concerned, the increase in arterial peak flow is largely 
neutralized by the decrease in area at the stenosis. Moreover, during 
hyperemia, the arterial peak velocity only measures the increase in 
velocity, but not the influence of vasodilation. By measuring arterial 
peak flow, both the increase in velocity and vasodilatation are consid-
ered, which makes peak flow a more robust and physiologically more 
relevant measure. In addition peak velocity is much more sensitive to 
errors in angulation between imaging plane and vessel axis. Small errors 
in non-perpendicular orientation between vessel and imaging plane will 
have no impact upon flow as cross-sectional area increases compensate 
the decreases in the axial velocity component. 
Cross-sectional area. Vessel cross-sectional area showed no sig-
nificant differences between patients and healthy controls and is there-
fore not useful to discriminate patients with PAD from healthy controls 
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Abstract 
Objectives 
The aim of the current study was to describe a method that as-
sesses the hyperemic microvascular blood plasma volume of the calf 
musculature. The reversibly albumin binding contrast agent gadofos-
veset was used in dynamic contrast-enhanced magnetic resonance 
imaging (DCE MRI) to assess the microvascular status in patients with 
peripheral arterial disease (PAD) and healthy controls. In addition, the 
reproducibility of this method in healthy controls was determined. 
Materials and Methods 
Ten PAD patients with intermittent claudication and 10 healthy 
control subjects were included. Patients underwent contrast-enhanced 
MR angiography of the peripheral arteries, followed by one DCE MRI 
examination of the musculature of the calf. Healthy control subjects 
were examined twice on different days to determine normative values 
and the interreader and interscan reproducibility of the technique. The 
MRI protocol comprised dynamic imaging of contrast agent wash-in 
under reactive hyperemia conditions of the calf musculature. Using 
pharmacokinetic modeling the hyperemic fractional microvascular blood 
plasma volume (Vp, unit: %) of the anterior tibial, gastrocnemius and 
soleus muscles was calculated. 
Results 
Vp was significantly lower for all muscle groups in PAD patients 
(4.3 ± 1.6 %, 5.0 ± 3.3 % and 6.1 ± 3.6 % for anterior tibial, gas-
trocnemius and soleus muscles, respectively) compared to healthy 
control subjects (9.1 ± 2.0 %, 8.9 ± 1.9 % and 9.3 ± 2.1 %). Differences 
in Vp between muscle groups were not significant. The coefficient of 
variation of Vp varied from 10 - 14 % and 11 - 16 % at interscan and 
interreader level, respectively. 
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Conclusions 
Using DCE MRI after contrast-enhanced MR angiography with 
gadofosveset enables reproducible assessment of hyperemic fractional 
microvascular blood plasma volume of the calf musculature. Vp was 
lower in PAD patients than in healthy controls, which reflects a promis-
ing functional (hemodynamic) biomarker for the microvascular impair-
ment of macrovascular lesions. 
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Introduction 
Functional measurements in peripheral arterial disease (PAD) are 
used for diagnostic purposes and for quantifying the hemodynamic 
consequences of obstructive arterial lesions (1-4). Among these func-
tional measurements, the ankle brachial index (ABI) is the most recog-
nized and widely applied test for diagnosis and therapy monitoring in 
PAD (1-9). ABI measurements only represent macrovascular functionali-
ty, whereas PAD is known to affect the microcirculation as well, particu-
larly in patients with diabetes mellitus(10, 11). Functional assessment of 
the microvascular status of the lower extremities could therefore be a 
valuable addition to the current diagnostic work-up in PAD to objective-
ly determine disease severity and might be useful in evaluation of 
therapeutic efficacy in PAD (12-15). MRI is well-suited for comprehen-
sive diagnostic imaging of both macrovascular morphology of the 
peripheral vascular tree using contrast-enhanced MRA (CE-MRA) (16-
18) and the microvascular functionality by dynamic contrast-enhanced 
(DCE) MRI (14, 19-21). 
Commonly used functional measures in DCE MRI are the rate con-
stant (k) and the transfer constant (Ktrans), which both describe the wash-
in of a contrast agent. These measures reflect a combination of the rate 
of microvascular reactivity and permeability, both of which may be 
significantly impaired in patients with PAD (14, 19, 22, 23). The rate of 
vascular reactivity, as determined by rate constant k and transfer con-
stant Ktrans, however, decreases with age, mainly due to slow progression 
of vascular resistance as reflected by an increased intima thickness 
versus luminal diameter ratio (24). Therefore, the clinical relevance of 
these measures in PAD patients is questionable. In mild PAD, i.e. inter-
mittent claudication, symptoms generally arise and progress slowly 
during exercise (impaired active hyperemia). Critical ischemia, on the 
other most severe end of the pathophysiological spectrum, is a chronic 
condition characterized by hypoperfusion of the distal lower extremity 
at rest. It is conceivable that in both of these conditions, the absolute 
degree of microvascular dilatation, rather than its rate, is of more 
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clinical relevance and a better reflection of clinical severity of microvas-
cular disease in PAD compared to rate and transfer constants. We 
hypothesize that maximum microvascular dilatation can be assessed by 
determining the hyperemic fractional microvascular blood plasma 
volume (Vp) using DCE MRI. Microvascular blood plasma volume, howev-
er, is hard or even impossible to measure using extracellular contrast 
agents, as clinically applied low-molecular weight (i.e. small-sized) 
contrast agents extravasate rather rapdily into the interstitial space (22, 
25, 26). Recently introduced blood pool agents are largely prevented 
from leaking into the interstitial space by a strong, reversible albumin 
binding and therefore theoretically allow a more reliable assessment of 
microvascular blood plasma volume with DCE MRI (27, 28). 
The main purpose of the current study was to describe a method 
to assess hyperemic microvascular blood plasma volume of the calf 
musculature and to investigate its ability to discriminate between PAD 
patients and healthy control subjects using the blood pool contrast 
agent gadofosveset in dynamic contrast-enhanced (DCE) MRI. Also, the 
interreader and interscan reproducibility of this method was determined 
in healthy control subjects. 
Materials and Methods 
Study population 
Ten patients (age mean ± SD: 66.5 ± 9.9 years; 8 males and 2 fe-
males) with proven PAD (intermittent claudication, Fontaine stage II, (5)), 
diagnosed by the vascular surgeon, and 10 healthy control subjects 
without signs and symptoms of PAD (age 24.1 ± 2.2 years; 3 males and 
7 females) were included in this study. Exclusion criteria were diabetes 
mellitus, hemodynamic instability, contra-indications for MRI (i.e. 
claustrophobia, known gadolinium based contrast agent allergy, and 
estimated glomular filtration rate < 30 mL/kg/1.73 m2. The institutional 
medical ethics committee approved the study and all subjects gave 
written informed consent before inclusion. 
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MRI protocol 
An overview of the imaging protocol is given in figure 1. The en-
tire DCE MRI examination lasted approximately 15 minutes. All scans 
were performed on a 1.5-T commercially available MRI system (Intera, 
Philips Medical Systems, Best, The Netherlands). For all acquisitions a 
dedicated 12-element three-station peripheral vascular phased-array 
coil (4 elements/station) was used. Subjects were imaged in the supine 
position and care was taken not to deform calf muscle by calf-bed 
contact. All subjects were lying in this position for at least 30 minutes 
before the DCE MRI measurement was started. During this time a con-
ventional three-station contrast enhanced MR angiography (CE-MRA) 
 
Figure 1. Overview of the imaging protocol. DCE MRI was preceded by conventional three-
station contrast-enhanced MR angiography (CE-MRA) for which a dose of 8 mL gadofos-
veset was administered. CE-MRA was followed by ‘pre-contrast’ T1 determination. A 6-
minute cuff compression of the thigh was used to provoke reactive hyperemia within the 
calf musculature. Directly after cuff inflation a single dose of 2 mL gadofosveset was 
injected. Half a minute before cuff deflation the dynamic contrast-enhanced (DCE) MRI was 
started. 
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exam was performed in the subject. Therefore, prior to the start of the 
DCE MRI measurement, all subjects had already received 8 mL of 
gadofosveset (Ablavar®, Lantheus Medical Imaging, Billerica, MA). 
PAD patients were examined once, whereas in healthy control 
subjects the entire exam was repeated on a different day (interval mean 
± SD: 9.3 ± 3.5 days) to determine normative values and the reproduci-
bility of the technique. 
Survey. A non-enhanced time-of-flight (TOF) scan of the pelvic, 
upper and lower leg station was acquired to prescribe the imaging 
volumes of interest for subsequent morphological and functional imag-
ing. A turbo field echo (TFE) pulse sequence was used with a 180° 
inversion prepulse to suppress stationary tissues. Thirty-one transverse 
slices per station were acquired with 3.3-mm slice thickness and  
11-mm interslice gap, and an inferiorly concatenated saturation band. 
The standard quadrature body coil was used for signal transmission and 
reception. For positioning of the 3D angiography volumes, maximum 
intensity projections (MIP) were generated in 3 orthogonal directions. 
CE-MRA. A three-station 3D CE-MRA was performed as previously 
described (29). Prior to contrast medium administration, a non-
enhanced ‘mask’ image data set was acquired with exactly the same 
acquisition parameters as the CE-MRA, enabling background tissue 
suppression by image subtraction. 
DCE MRI. A dynamic 3D T1-weighted spoiled gradient echo se-
quence was used for DCE MRI with the following acquisition parameters: 
TR 8.0 ms, TE 0.91 ms, flip angle 30°, FOV 400 mm, matrix 128 x 128, 
NSA 1 and a parallel imaging (SENSE) reduction factor of 2 (right-left 
direction). Slice thickness was 6.00 mm; 12 transverse slices were 
imaged. Acquired voxel dimensions were 3.13 x 3.13 x 6.00 mm. 
Dynamic scan time was 2.6 seconds. Slices were centered at the maxi-
mum diameter of the calf. A series of 80 dynamic scans were acquired in 
approximately 3.5 minutes. A cuff paradigm was applied to provoke 
reactive hyperemia (14, 30). A fixed dose of 2 mL gadofosveset was 
injected directly after cuff inflation, using an automated power injector 
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(Medrad Spectris, Indianola, PA). Cuff inflation was directly followed by 
contrast injection to allow systemic contrast equilibration in the arterial 
blood pool during cuff compression and to ensure that DCE MRI data 
were acquired during the steady state, at which gadofosveset was 
maximally bound to albumin (27, 28, 31). The acquisition started 330 
seconds after cuff inflation. The cuff was then rapidly deflated at the 
start of the 6th dynamic scan. 
Before the cuff inflation of the dynamic sequence, a series of 
spoiled fast gradient echo scans with identical contrast and geometry 
parameters with respect to the dynamic sequence, but with varying flip 
angles (2, 5, 10, 15, 25 and 35°) were acquired (figure 1). These variable 
flip angle scans were used for T1 baseline determination (after contrast 
agent administration for CE-MRA) and subsequent conversion of signal 
changes to T1 relaxation time changes and contrast agent concentration 
time-courses (12, 32). 
Image analysis 
Only the most symptomatic leg was analyzed in patients, whereas 
for healthy control subjects the measures were determined for both legs 
separately and subsequently averaged. Two independent MRI readers, 
blinded for each other’s results and acquisition order, analyzed the data 
sets of healthy control subjects. Patient datasets were analyzed by one 
observer, foreshadowing the good interreader reproducibility we found 
in healthy control subjects, which were concordant to previous results 
(33). 
The image software application MRIcro (MRIcro, 
http://www.mricro.com/) was used to manually draw regions of interest 
(ROI’s) of 3 x 3 pixels in the anterior tibial, gastrocnemius and soleus 
muscles for all 12 slices, resulting in a ROI volume of 6.3 mL. Also, a 
larger ROI covering the entire cross-section of the calf musculature in 
four successive slices was drawn. These ROI’s were subject to relatively 
large inter-individual differences in volume due to large variations in 
calf size in the subjects. An arterial ROI was drawn within the tibiofibular 
trunk to obtain the arterial input function (AIF). Self-written software 
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code (Matlab, The Mathworks inc., Natick, MA) was used for the analysis 
of T1-weighted signal intensity time-courses for each ROI. Matlab was 
also used to calculate the functional microvascular parameters as 
represented by figure 1. 
The T1-value, prior to the contrast injection of the DCE-MRI but 
after that of the CE-MRA, were determined from the variable flip angle 
series for each ROI (34). To calculate the T1-value, the signal curve as a 
function of the flip angle was fitted to the signal formula for the spoiled 
fast gradient echo pulse sequence using a non-linear (Levenberg-
Marquardt) optimization algorithm, which corrects for the inherent non-
linearity in the relation between changes in MRI signal, T1, and contrast 
agent concentration. Any possible T2* effects were negated by the short 
TE used. The dynamic sequence was used to calculate the following 
functional measures: hyperemic fractional microvascular blood plasma 
volume (Vp, unit: %), rate constant (k, unit: min-1) and the area-under-
the-curve in the first 90 seconds after contrast arrival (AUC90s, unit: 
mM⋅s). Individual signal time-courses were normalized with respect to 
resting values, measured prior to contrast agent arrival and converted to 
contrast agent concentration, using the relation between T1 relaxation 
time and the signal intensity for a spoiled gradient echo pulse sequence 
(12). 
The concentration time-course in muscle tissue ( )tC t after cuff 
deflation was empirically modeled by the relation 
max( ) (1 )kt mt
t p p
C t V C e e− −= −  
where Vp is the fractional hyperemic blood plasma volume in muscle 
tissue, 
max
p
C is the maximum concentration of contrast agent in blood, k 
is the rate constant describing the speed of muscle enhancement after 
cuff deflation, and m represents the tissue clearance rate. The parame-
ters Vp and k were calculated by non-linear curve fitting, using a Leven-
berg-Marquadt optimization algorithm (35). 
max
p
C was determined from 
the asymptotic concentration level in the femoral artery. The concentra-
tion time-courses were used to calculate the area-under-curve for the 
first 90 seconds after cuff deflation (AUC; mMs). The functional measure 
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Vp is related to the degree of (total) microvascular dilatation, whereas 
the functional measures k and AUC reflect the rate of microvascular 
reactivity. 
Statistical analysis 
A two-samples t-test was used to determine the significance of 
differences in the functional parameters between patients and healthy 
control subjects. P < 0.05 was considered statistically significant. 
Statistical analysis was performed with commercially available statistical 
software (SPSS 16.0, SPSS Inc., Chicago, IL). 
For healthy control subjects the reproducibility of the measures 
was calculated, both at interscan and interreader level. Reproducibility 
of each parameter was expressed as coefficient of variation (CV in %) 
and the repeatability coefficient (RC). The CV is derived by dividing 
overall mean within-subject standard deviation (SDws) by the mean 
measurement value over all subjects. The RC is the smallest noticeable 
difference that can be detected beyond measurement error and is 
defined as 1.96⋅√2⋅SDws (36, 37). 
Assuming that interscan reproducibility was mainly influenced by 
scan and time related varariabilities (e.g. variations in slice positioning 
and day-to-day variations in physiology) it was calculated by averaging 
results of both MRI readers for each scan (mean of MRI 1 for reader A 
and B versus the mean of MRI 2 for reader A and B). Conversely, in-
terreader reproducibility is an indicator of the image reading error (e.g. 
positioning and delineation of ROI’s) and is primarily influenced by 
reader experience. Interreader reproducibility was calculated by averag-
ing the results of both scans for each MRI reader (mean of reader A for 
MRI 1 and MRI 2 versus the mean of reader B for MRI 1 and MRI 2). 
 
Results 
HYPEREMIC FRACTIONAL MICROVASCULAR BLOOD PLASMA VOLUME IN PERIPHERAL ARTERIAL DISEASE 
189 
All included subjects underwent DCE MRI as planned without ex-
periencing side effects or adverse events. 
CE-MRA 
CE-MRA revealed stenosis (> 50%) of the SFA in 6 out of 10 pa-
tients, whereas an occlusion of the SFA was found in the remaining 4 
patients. In 3 out of 10 patients there were slight vessel wall irregulari-
ties in the iliac arteries. The remaining patients had no signs of obstruc-
tive lesions in the iliac arteries. At least 2 out of 3 main arteries of the 
lower leg were free from obstructive lesions in all patients. CE-MRA 
revealed no signs of PAD in any of the control subjects. 
DCE MRI 
Examples of DCE MRI derived time-courses of the entire cross-
section of the calf musculature and arterial blood are presented in figure 
2. Muscle tissue enhancement was generally less strong in patients 
compared to healthy control subjects (figure 2). Signal time-courses of 
the individual muscle groups showed similar results. Strongest en-
hancement was found in the soleus muscle. 
An AIF was obtained for each individual subject within the most 
prominent arterial structure visible, which was either the tibiofibular 
trunk or posterior tibial artery in most patients. Quality of the AIF was 
lower in patients in comparison with the AIF of healthy control subjects. 
There was a trend (p = 0.07) towards higher maximum concentration of 
the AIF in patients compared to the healthy control subjects. 
CHAPTER 8 
190 
 
Figure 2. Coronal maximum intensity projection (MIP) of a CE-MRA examination of the 
peripheral arterial tree of a patient with PAD (left panel) and examples of axial cross-
sectional CE-MRA and DCE images of a patient with PAD (center panel) and a healthy 
control subject (right panel), respectively. The comparison for DCE MRI between patients 
with PAD and healthy control subjects was made for the tibial anterior (A), gastrocnemius 
(B) and soleus (C) muscle, as well as the entire cross-section of the calf musculature (area 
within the black dotted lines). The lower center and right panels show representative 
examples of the relative signal change in blood and the entire cross-section of the calf 
musculature before and after cuff release in a patient with PAD and healthy control, 
respectively. 
Patients versus healthy control subjects 
Table 1 lists the values of DCE MRI measures obtained in patients 
and healthy control subjects. Vp was significantly lower for all muscle 
groups in PAD patients compared to healthy control subjects. Differ-
ences in Vp between patients and controls ranged from 3.2 - 4.8 % (p < 
0.01). For both patients and controls the differences in Vp between 
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muscle groups were not significant (p = 0.49 and p = 0.15, respective-
ly). Vp of the entire cross-section of the calf musculature was signifi-
cantly higher compared to the Vp of individual muscle groups, both for 
patients and healthy control subjects (p < 0.01). The rate constant k was 
significantly lower in PAD patients for all muscle groups (range differ-
ences 5.5 - 7.9 min-1, p < 0.01). The AUC only was significantly lower in 
PAD patients for the anterior tibial muscle (p < 0.01). Vp, k or AUC were 
not consistently higher or lower in PAD patients with stenosis (n = 6) 
compared to PAD patients with an occlusion (n = 4) of the SFA. 
      
   Patients Healthy controls  
   (n = 10) (n = 10)  
Anterior tibial muscle    
 Vp % 4.3 ± 1.6  9.1 ± 2.0*  
 K min-1 2.3 ± 1.6 11.2 ± 5.6*  
 AUC90s mMs 0.35 ± 0.22   0.64 ± 0.19*  
Gastrocnemius muscle    
 Vp % 5.0 ± 3.3  8.9 ± 1.9*  
 K min-1 4.1 ± 4.1  9.6 ± 4.0*  
 AUC90s mMs 0.49 ± 0.26  0.55 ± 0.14 (p = 0.50) 
Soleus muscle    
 Vp % 6.1 ± 3.6  9.3 ± 2.1**  
 K min-1 5.1 ± 3.7 12.3 ± 4.1*  
 AUC90s mMs 0.64 ± 0.28  0.65 ± 0.15 (p = 0.90) 
Cross-section calf musculature   
 Vp % 7.2 ± 4.3 12.0 ± 2.4*  
 k min-1 5.5 ± 3.6 10.4 ± 4.1*  
 AUC90s mMs 0.78 ± 0.17  0.87 ± 0.17 (p = 0.18) 
Table 1. DCE MRI of the calf musculature in patients with PAD and healthy control sub-
jects. 
Values are presented as mean ± SD. Vp, fractional microvascular blood plasma volume; k, 
rate constant; AUC90s, area under the curve for the first 90 seconds after cuff release. 
*p < 0.01, ** p < 0.05 
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   T1pre* 
Anterior tibial muscle 688 ± 29 ms 
Interscan   
  CV 3.4 % 
  RC 63 ms 
Interreader   
  CV 1.2 % 
  RC 22 ms 
Gastrocnemius muscle 722 ± 56 ms 
Interscan   
  CV 5.4 % 
  RC 108 ms 
Interreader   
  CV 6.4 % 
  RC 131 ms 
Soleus muscle 667 ± 32 ms 
Interscan   
  CV 5.0 % 
  RC 91 ms 
Interreader   
  CV 5.9 % 
  RC 109 ms 
Cross-section calf musculature 625 ± 28 ms 
Interscan   
  CV 4.9 % 
  RC 84 ms 
Interreader   
  CV 2.6 % 
  RC 44 ms 
Table 2. Reproducibility of T1 determination in healthy control subjects 
Values are presented as mean ± SD. T1pre,T1 before administration of contrast agent; CV, 
coefficient of variation; RC, repeatability coefficient. 
* Pre-contrast T1 values were actually obtained after a prior injection of 8 mL  gadofos-
veset, as used for contrast-enhanced MR angiography of the lower extremities. 
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   Vp k AUC90s 
Anterior tibial muscle 9.1 ± 2.0 % 11.2 ± 5.6 min-1 0.64 ± 0.19 mMs 
Interscan     
  CV 12.5 % 48.8 % 36.5 % 
  RC 3.1 % 15.1 min-1 0.64 mMs 
Interreader     
  CV 13.0 % 22.8 % 16.2% 
  RC 3.3 % 7.1 min-1 0.29 mMs 
Gastrocnemius muscle 8.9 ± 1.9 % 9.6 ± 4.0 min-1 0.55 ± 0.14 mMs 
Interscan     
  CV 9.7 % 37.8 % 25.5 % 
  RC 2.4 % 10.0 min-1 0.39 mMs 
Interreader     
  CV 16.0 % 22.1 % 27.3 % 
  RC 3.9 % 5.9 min-1 0.41 mMs 
Soleus muscle 9.3 ± 2.1 % 12.3 ± 4.1 min-1 0.65 ± 0.15 mMs 
Interscan     
  CV 13.3 % 19.9 % 23.3 % 
  RC 3.4 % 6.8 min-1 0.42 mMs 
Interreader     
  CV 11.2 % 18.7 % 12.0 % 
  RC 2.9 % 6.3 min-1 0.22 mMs 
Cross-section calf musculature 12.0 ± 2.4 % 10.4 ± 4.1 min-1 0.87 ± 0.17 mMs 
Interscan     
  CV 16.3 % 34.8 % 20.3 % 
  RC 5.4 % 9.9 min-1 0.49 mMs 
Interreader     
  CV 2.1 % 8.4 % 1.8 % 
  RC 0.7 % 2.4 min-1 0.04 mMs 
Table 3. Reproducibility of DCE MRI in healthy control subjects. 
Values are presented as mean ± SD. A, maximum concentration; Vp, fractional microvas-
cular blood plasma volume; k, rate constant; AUC90s, area under the curve for the first 90 
seconds; CV, coefficient of variation; RC, repeatability coefficient. 
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Reproducibility 
Values and reproducibility measures of the pre-contrast T1 as-
sessment in healthy control subjects are given in table 2. T1 assessment 
showed interscan and interreader CV’s below 6 and 7% respectively. 
Reproducibility of the DCE MRI measurements in healthy control 
subjects is listed in table 3. CV and RC of Vp for the different muscle 
groups were below 17% and 6%, respectively, at interscan level and 
below 16% and 6%, respectively, at interreader level. Interreader and 
interscan reproducibility of Vp were comparable for most muscle groups. 
Reproducibility values of Vp were comparable for the different muscles. 
Interscan reproducibility of k and AUC showed CV values as high as 49% 
and 37%, respectively. Interreader reproducibility was markedly better 
with a maximum CV of 22% and 27% for k and AUC, respectively. In-
terreader CV was lowest for the entire muscle group (8.4% and 1.8% for 
k and AUC, respectively). 
Discussion 
In this study we found that gadofosveset, a reversible albumin 
binding (blood pool) contrast agent, can be used in DCE MRI to repro-
ducibly determine a functional surrogate of the hyperemic microvascular 
blood plasma volume in the calf. Using this functional measure, the 
fractional microvascular blood plasma volume Vp, patients with PAD 
revealed a reduced Vp for all muscle types in the calf relative to healthy 
controls. Moreover, patients with PAD could be discriminated from 
healthy subjects on the basis of Vp. Measures that quantified the rate of 
vasodilation (k and AUC) were also reduced in patients with PAD com-
pared to healthy controls. However, interscan and interreader reproduc-
ibility of Vp were better compared to those of measures that reflect the 
vasodilation rate (k and AUC). We also found that functional DCE MRI 
with a blood pool contrast agent can easily be combined with clinical 
CE-MRA to assess both macrovascular morphology and microvascular 
functionality in patients with PAD. 
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Pathophysiologic effect in PAD 
The fractional microvascular blood plasma volume Vp of the calf 
musculature in PAD patients with intermittent claudication was signifi-
cantly lower than in healthy control subjects. A lower Vp in patients with 
PAD can possibly be explained by impaired microvascular dilatative 
capacity, which is the result of endothelial dysfunction (38-43). This 
means that DCE MRI can be used to determine the fractional microvas-
cular blood plasma volume of each large muscle group of the calf and as 
such can identify patients with reduced Vp as compared to healthy 
controls. 
Vp did show consistent differences between PAD patients with ste-
nosis or occlusions. This can be explained partly by the small sample 
size (respectively six PAD patients with stenosis and four with occlusion 
of the SFA), but also by the fact that most of the patients with an occlu-
sion of the SFA revealed well developed collateral arteries at CE-MRA 
and both patients with stenosis and occlusion had the same clinical 
symptoms (i.e. intermittent claudication). 
There were no significant differences between individual muscle 
groups within patients or controls. This indicates that this method does 
not distinguish different muscles of the calf. In healthy control subjects, 
Vp of the entire cross-section of the calf musculature showed signifi-
cantly higher values when compared to Vp of the individual muscles. In 
patients a similar trend was observed. A higher Vp for the entire cross-
section of the calf musculature can be explained by the inclusion of 
relatively large arterial and venous structures (in comparison to mi-
crovessels) in these regions of interest, increasing the average amount 
of contrast agent within the ROI which results in a higher Vp. To avoid 
relatively large blood vessels, assessment of Vp of individual muscles is 
preferred over the Vp of the entire cross-section of the calf musculature. 
The measures k and the AUC both reflect the initial speed of signal 
enhancement during reactive hyperemia and were lower in patients 
compared to healthy controls. This finding indicates lower vascular 
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reactivity in patients with PAD, which is in line with the results of previ-
ous studies (14, 19). 
Reproducibility 
Interscan reproducibility of Vp in DCE MRI was good compared to k 
and the AUC. The interscan CV in healthy control subjects of all muscle 
groups was lower than the relative difference between patients and 
healthy control subjects. This implies that the reproducibility of the 
measurement is sufficient to discriminate patients with PAD from 
healthy controls. The RC for the anterior tibial and gastrocnemius 
muscles was lower compared to the absolute difference between pa-
tients and healthy controls. The RC for the entire cross-section of the 
calf musculature and the soleus muscle was comparable to the absolute 
difference between patients and healthy control subjects. A poor RC is 
probably the result of our small study population and these results 
might improve with a larger group of subjects. 
Reproducibility of Vp was in general much higher than the repro-
ducibility of k and the AUC, both at interscan and interreader level. This 
is clearly reflected by the large RC values for k and AUC, which are 
comparable or even higher than the measured values for k and AUC in 
healthy control subjects. These findings are in line with those found by 
Galbraith et al. concerning the extravasation rate constant Ktrans, using 
low molecular weight (i.e. small-sized) extracellular contrast agents 
(19). For a blood pool acting contrast agent, k mainly represents the 
speed of the filling of the microvasculature in the time period of the 
measurement, rather than the extravasation of contrast agent into the 
interstitial space. This rapid filling phase did not prove reproducible and 
is therefore not suitable as a monitoring measure in clinical practice. 
T1 mapping showed good interscan and interreader reproducibil-
ity of T1 values for each muscle group. High interreader reproducibility 
indicates that the technique is relative insensitive for the exact location 
at which a ROI is drawn within a muscle group and that the technique is 
highly reader-independent. This is especially desirable for monitoring 
purposes, as in clinical routine it is likely that follow-up examinations 
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will be assessed by different readers. Good reproducibility of T1 map-
ping suggests that our scan and analysis method is reliable and that the 
moderate reproducibility we found for Vp is the result of biologic factors 
and/or the cuff paradigm. 
Clinical relevance 
Functional assessment of muscle perfusion of the lower extremi-
ties with dynamic contrast-enhanced (DCE) MRI, could be a valuable 
addition to the diagnostic work-up in PAD to objectively determine 
disease severity. An added advantage is that DCE MRI can be combined 
with the standard morphological assessment of PAD with CE-MRA. Also, 
DCE-MRI could be of value in non-invasive assessment of the efficacy of 
novel therapeutic strategies such as stem cell and gene therapy. DCE 
MRI of calf musculature may indicate the contribution of macrovascular 
blood flow on muscle perfusion and provide an objective diagnostic tool 
to determine the influence and severity of microvascular dysfunction in 
PAD (13-15, 19). 
Commonly used extracellular contrast agents rapidly extravasate 
into the interstitial space and are therefore less suitable to determine 
biomarkers of the microvascular blood plasma volume (25). 
Study considerations 
Although we found large differences between patients with PAD 
and healthy control subjects for Vp and the reproducibility of Vp was 
good, the number of subjects in this study is relatively small and further 
research will be needed to confirm our results by blinded analysis in 
more patients and compare them with age and gender matched control 
subjects. The observed differences between patients with PAD and the 
controls is expectedly smaller for age-matched, thus older, controls. In 
addition, it would be clinically relevant to include patients with different 
symptoms of PAD to assess variations in the involvement of microvascu-
lar impairment in PAD. 
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In all subjects a three-station CE-MRA of the peripheral arteries 
was performed, prior to the DCE MRI. For CE-MRA the first bolus injec-
tion of gadofosveset was used. This means all subjects already had 
gadofosveset in their systemic circulation at the start of the DCE MRI. 
The residual presence of contrast agent in the circulation affects the T1 
determination and its variability. However, a combination of both exams 
is highly desirable for clinical practice and our results prove the possi-
bility to discriminate patients from control subjects and provided good 
reproducibility of Vp (and T1), despite the previous bolus injection for 
angiography. 
Although in reality a small fraction (± 15%) of unbound gadosfos-
veset is available for extravasation into the interstitial space, the influ-
ence of this fraction upon the outcome can be neglected as the relative 
relaxivity of albumin-bound gadofosveset is much higher compared to 
the unbound fraction (r1 of respectively 19 and 5.2 Lmmol-1s-1 in 
blood plasma at 37 °C at 1.5 T) and the total fraction of albumin-bond 
gadofosveset (± 85%) is much larger as compared to the unbound 
fraction (27, 28, 31). In this study, gadofosveset proved to be a usable 
contrast agent for DCE MRI of muscle tissue in PAD to obtain a surrogate 
functional measure of microvascular blood plasma volume in patients 
with PAD. 
Conclusion 
DCE MRI after CE-MRA using a blood pool contrast agent is able to 
determine the hyperemic microvascular blood plasma volume Vp of the 
calf musculature and to identify patients with PAD as compared to 
healthy control subjects. In addition, the reproducibility of Vp was good 
in healthy control subjects. Together with the ability to acquire DCE MRI 
data combined with CE-MRA during a single examination makes DCE 
MRI with a blood pool acting agent a valuable addition to CE-MRA to 
assess both the macrovascular morphology and functional (hemody-
namic) status of the calf microvasculature in patients with PAD. 
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Peripheral arterial disease (PAD) is an expression of generalized 
arteriosclerosis, an inflammatory disease of the vessel wall of arteries, 
caused by well-known noxious stimuli like smoking, diabetes mellitus, 
hypertension, dyslipidemia and hyperhomocysteinemia (1, 2). Despite 
progress in cardiovascular risk management and treatment, peripheral 
arterial disease (PAD) remains a major health care problem among the 
elderly, affecting up to 20% of the worldwide population of 70 years and 
older (1, 2). Clinical symptoms associated with PAD range from intermit-
tent claudication to critical ischemia, and are the result of compromised 
arterial flow towards the lower extremities due to obstructive arterial 
lesions at the macrovascular level and/or microvascular disease (1). 
Collateral artery formation is one of the potential physiological 
mechanisms by which the human body attempts to compensate for the 
ischemia induced by these obstructive arterial lesions (3). However, 
collateral formation is a complicated and incompletely understood 
process, thought to involve both adaptation of existing arteries and 
formation of novel collateral arteries. 
Early imaging of PAD might be beneficial to determine a reliable 
starting point for patient monitoring and the best therapeutic options. In 
addition, imaging is potentially useful to monitor the effects of novel 
vessel-stimulating therapies, to increase our knowledge concerning 
these processes and perhaps to help in the early identification of possi-
ble non-responders to therapy. MRI is a highly attractive imaging mo-
dality for this purpose because it is virtually the only clinically available 
modality that can be used to reliably assess vascular morphology as well 
as function in a single examination. 
This thesis addresses the development and clinical utility of mor-
phologic and functional vascular MRI in patients with PAD. The main 
objectives were to assess the suitability of quantitative MRI techniques 
in diagnosis and longitudinal follow up of patients with peripheral 
arterial disease. Different morphologic and functional vascular MRI 
techniques were tested for reproducibility and discriminative capability, 
and based on these results improvements to existing techniques are 
proposed to better differentiate between diseased and healthy vascula-
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ture. Also, a standardized approach to acquire quantitative morphologic 
and functional vascular information was developed. The results of this 
thesis are placed in a broader context for which the role of MRI is 
related to other diagnostic (imaging) tools in PAD. 
Current diagnostic work-up of patients with PAD 
PAD is foremost a clinical diagnosis, based upon the symptoms of 
patients. The typical patient history and physical examination are often 
sufficient to diagnose PAD and to grade the severity of disease, accord-
ing to the Rutherford and Fontaine classification (1, 2, 4-6). History 
taking should be focused on the presence of risk factors, relation 
between physical activity and complaints, pain free and/or maximum 
walking distance and presence or absence of rest pain. Physical exami-
nation should encompass a comparison between the affected and 
unaffected extremity as far as color changes, hair loss, toenails (thick-
ened and brittle toenails may appear in patients with PAD), muscular 
volume (affected skeletal muscle groups may show atrophy), venous 
filling time and temperature differences are concerned. Patients with 
PAD often exhibit diminished or absent arterial pulsation as well as 
bruits during palpation in the presence of a stenosis (6, 7). Abnormal 
femoral pulsations have proven to be highly specific and offer a high 
positive predictive value for the presence of PAD, although the sensitivi-
ty is low (8). 
Because many patients with PAD are asymptomatic, history and 
physical examination alone are not entirely reliable for detection of PAD 
(1, 6, 9, 10). However, a variety of diagnostic tests are available for early 
diagnosis in asymptomatic subjects and objective confirmation of the 
diagnosis in symptomatic patients with suspected PAD. One of the most 
widely used means of objectively documenting the presence and severity 
of PAD is measurement of the ankle-brachial index (ABI). ABI is a fast, 
widely available and cost-effective test for this purpose. Sensitivity of 
ABI measurements for diagnosing PAD is high and the ABI can be used 
to determine the severity and progression of PAD over time (13, 15-17). 
Determination of ABI is also suitable as a screening tool in the high-risk, 
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asymptomatic population to confirm the presence of suspected PAD (1, 
18, 19). If the ABI at rest is normal, repeating the measurement after a 
treadmill test might further increase the sensitivity, as a systolic pres-
sure gradient might arise after exercise in patients with hemodynami-
cally significant stenoses. 
Despite the clear advantages there are also drawbacks to ABI 
measurement. There are several well-known limitations such as relative-
ly poor interobserver variability and inability to reliably acquire the ABI 
in many patients with stiff and uncompressible ankle arteries due to 
severe arterial wall calcifications (20-22). In this latter category of 
patients, ABI may be incongruently high. In fact, an abnormally high ABI 
(> 1.4) has also been associated with the presence of PAD. Studies have 
shown that the ABI cannot be (reliably) measured in at least  
5 – 10% of the diabetic patients, as these patients are most prone to 
develop severely calcified artery walls, especially regarding small arter-
ies, such as at the level of the ankle and the pedal arteries (14, 17, 22-
27). 
Once the presence of PAD is confirmed, the next step in the rou-
tine diagnostic workup of patients with PAD is to determine the exact 
location and extent of obstructive arterial lesions. Segmental pressure 
measurements are most often used for this purpose. Plethysmographic 
cuffs placed over the brachial arteries and at different distinct locations 
around the lower extremity are used to measure systolic blood pressure 
with a Doppler device, comparable to ABI measurements (6, 28). In 
general, a gradient difference of more than 20 mmHg between two 
adjacent levels is considered indicative for the presence of hemodynam-
ically significant obstructive arterial lesions. 
Often, segmental pressure measurements are combined with pulse 
volume recordings. The combination of segmental systolic pressures 
and pulse volume recordings results in a diagnostic accuracy of 97% (30, 
31). The technique of segmental pressure measurements is very compa-
rable to ABI measurements. Not surprisingly, these measurements suffer 
from the same limitations related to uncompressible arteries. Moreover, 
pulse waveform measurements are a subjective (qualitative) rather than 
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an objective (quantitative) functional measurement, with limitations in 
heavily calcified arteries. Pulse waveform measurements are less accu-
rate than duplex ultrasonography for localizing lesions (28). 
Segmental pressure measurements are often followed by duplex 
ultrasonography (DUS). DUS combines Doppler waveform analysis and 
Doppler velocities. DUS is mainly used for determining the exact loca-
tion of the obstructive arterial lesion and for differentiating between 
stenosis and occlusion. A normal arterial flow waveform is triphasic, 
which in the presence of obstructive arterial lesions will become either 
bi- or monophasic. An increase of more than 100% of the peak systolic 
velocity relative to the proximal normal arterial segment indicates the 
presence of significant arterial lesions. DUS is used to determine the 
degree of stenosis, which is done by a combination of flow waveform 
analysis and the peak systolic velocity (28, 32). Besides diagnostic 
purposes and treatment planning, DUS is also used for the follow-up of 
patients with (treated) PAD. 
DUS is an accurate non-invasive test to confirm the presence of 
PAD. However, it requires the technical skill of an experienced vascular 
technologist and the accuracy is operator and patient dependent (32). A 
complete duplex examination of both legs is rather time consuming 
(over 40 minutes). Also, the accuracy for the aortoiliac vessels is limited, 
amongst others due to body habitus and bowel gas. The sensitivity and 
specificity for the detection of hemodynamically significant arterial 
stenosis are lower than for CT angiography (CTA) or MR angiography 
(MRA) (32, 33). In line with other ultrasonographic techniques, DUS is 
unable to measure flow within heavily calcified arteries and the accuracy 
of the technique diminishes when there are multiple obstructive arterial 
lesions within close proximity (28). Although DUS is relatively inexpen-
sive, in up to 43% of the patients there is need for additional imaging 
according to the DIPAD trial (34), which in the end results in significantly 
higher costs for DUS when compared to CT angiography and comparable 
costs when compared with MR angiography. Also, it has been proven 
that if patients do have a preference for either MRA or DUS in the diag-
nostic work-up for PAD, MRA is preferred over DUS (35). 
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Imaging of PAD 
None of the above mentioned diagnostic tests provide adequate 
morphologic information. Although functional information suits the 
purpose of diagnosing and monitoring, vascular morphology is required 
to determine the location and severity of stenosis and plays an im-
portant role in choosing the appropriate therapy (i.e. conservative 
management, percutaneous intervention or surgery). Imaging of the 
peripheral arteries in PAD is preserved for patients being considered for 
invasive therapy only in order to localize arterial lesions and to plan the 
correct approach of the intervention (1, 18, 36). Radiological imaging 
techniques comprise invasive digital subtraction angiography (DSA), 
which is considered the ‘gold standard’ for the diagnosis of PAD, and 
non-invasive CTA and MRA. The introduction of CTA and MRA has made 
it possible to obtain highly accurate morphologic data on the macrovas-
cular morphologic vascular status in PAD patients and to assess the 
suitability of arterial lesions for intervention, without the need for 
invasive angiography (37-39). The rapid development of multidetector 
CT (MDCT) technology has motivated the clinical use of CTA to examine 
the peripheral vasculature, and allows fast visualization of the complete 
peripheral arterial tree with high accuracy. The overall sensitivity and 
specificity for the assessment of significant arterial stenosis are 95-97% 
and 91-98%, respectively (40). Major advantages of CTA are high spatial 
and contrast resolution and fast acquisition times, whereas the im-
portant disadvantages of CTA are the potentially harmful contrast 
agents and radiation. Furthermore, CTA has limited diagnostic accuracy 
in (heavily) calcified arteries when compared to DSA and MRA (32). 
Over the last decade contrast-enhanced MRA (CE-MRA) has estab-
lished itself as a highly accurate non-invasive diagnostic imaging meth-
od for the morphological evaluation of the large conduit arteries in PAD 
patients. Sensitivity and specificity of CE-MRA are comparable with 
invasive intra-arterial digital subtraction angiography (DSA) (33, 38, 41). 
In chapter 2 of this thesis we have demonstrated that CE-MRA is an easy 
and reproducible method to quantify arteries with a detection limit of 
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0.5 mm and to assess the diameter of the collateral re-entrance zone in 
the upper leg (42). 
Recently introduced blood pool contrast agents, which reversely 
bind with blood plasma albumin molecules, thereby limiting extravasa-
tion of contrast agent into the interstitial space, increase the temporal 
imaging window for CE-MRA. This allows high-resolution CE-MRA 
acquisitions and whole-body CE-MRA examinations to be performed 
with even better diagnostic accuracy (43-47). MRA has important ad-
vantages over DSA and CTA. MRA is a non-invasive imaging modality as 
compared to DSA and there is no need for iodinated contrast agents nor 
usage of ionizing radiation in MRA. Compared to CTA, the ability of MRA 
for stent assessment is generally poor. On the other hand, MRA is better 
suited to accurately visualize the arterial lumen of heavily calcified 
arteries when compared to CTA (32). 
DSA, CTA and MRA are all suitable to accurately depict vascular 
morphology in patients with PAD. Morphologic images, however, pro-
vide little or no information on the hemodynamic consequences of 
obstructive vascular lesions in PAD patients, whereas above mentioned 
functional tests provide little or no morphologic information. To sup-
plement morphologic information, it is therefore highly desirable to 
have quantitative non-invasive imaging tools available, that can be 
easily combined with existing morphologic imaging tools. MR imaging 
has the potential to overcome these limitations and can facilitate a 
variety of functional measurements at both the macro- and microvascu-
lar level in patients with PAD, as is shown in this thesis. The hemody-
namic significance of obstructive arterial lesions can be determined, as 
well as the impact of vascular adaptations resulting from different 
treatment strategies. Combined morphologic and functional methods to 
visualize and quantify the vascular status in PAD patients are useful in 
several ways. For example to confirm the diagnosis and to grade the 
severity of PAD. However, morphological and functional data are also 
suitable for patient follow-up and therapy monitoring, for studying the 
mechanisms underlying vascular adaptations, such as collateral artery 
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formation, and for studying the effect of established and novel therapies 
aimed at ameliorating PAD. 
Functional MRI 
MRI enables comprehensive diagnostic imaging of both the anat-
omy of the peripheral vascular tree as well as functionality in terms of 
macrovascular flow and surrogate parameters of tissue perfusion and 
oxygenation (48-54). In this thesis the reproducibility, discriminative 
capability and clinical usage of different MRI techniques able to depict 
macro- and microvascular function were evaluated. Macrovascular 
function was assessed by measuring arterial peak flow (APF) in the 
popliteal artery with quantitative 2D cine MR phase contrast imaging 
(PCI) (50, 55-58). Microvascular function was determined by perfusion 
measurements in calf musculature using dynamic contrast-enhanced 
(DCE) MRI (49, 53, 59), as well as the oxygenation measurements using 
dynamic blood oxygen level-dependent (BOLD) MRI (48, 52, 60-64). 
Arterial peak flow (APF), defined as the maximum systolic flow, is 
an attractive arterial flow measure that can be obtained with PCI meas-
urements. APF measurements have the advantage of being a fast MRI 
technique, with acquisition times well below one minute, which can 
easily be added to existing MRA protocols. In other words, in patients 
scheduled for MRA both morphologic and functional vascular status can 
be assessed at the same time (42, 65-68). Reproducibility of APF is 
high, as was shown in chapter 2 and 6 of this thesis (42, 68). The APF is 
an important determinant of the systolic blood pressure (69), that 
exhibits large differences between PAD patients and control subjects, 
which has been shown in chapter 2, 4 and 6 (42, 68). In chapter 4 we 
also demonstrated that the APF is able to differentiate between patients 
with intermittent claudication and critical ischemia, with high reliability, 
which is comparable with ABI measurements. However, APF measure-
ments could be determined in up to 91% of 183 PAD patients, as op-
posed to a success rate of just 71% for ABI measurements. Although 
quantitative flow measurements can also be used to measure mean flow 
and peak velocity, the results of chapter 6 of this thesis indicate that 
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reproducibility and discriminative capability are best for peak flow (50, 
68). 
DCE MRI is an example of a functional MRI test to assess micro-
vascular function. DCE MRI is able to determine regional blood perfusion 
in skeletal muscle tissue, and therefore measures the influence of the 
presence of peripheral arterial disease at end-organ level (59, 70). By 
dynamically recording enhancement of muscle tissue after injection of 
contrast medium and concurrently measuring arterial signal, quantita-
tive information on the microcirculation can be obtained. When a small 
molecular contrast agent (e.g. gadopentate dimeglumine) is used for 
DCE-MRI the wash-in rate of the tissue is relatively fast and primarily 
determined by microvascular flow. Using a two-compartment pharma-
cokinetic model that relates arterial concentration to the tissue concen-
tration, the dynamic transfer of the contrast agent from the blood space 
to the tissue can be quantified in terms of the unidirectional influx Ki 
(unit: min-1), which is a surrogate quantity for microvascular flow. 
Unfortunately, skeletal muscle perfusion is highly variable and rel-
atively low under resting conditions and does not represent perfusion 
during physical exertion (53, 71). To mimic the vascular response to an 
active muscle use in a standardized way, a cuff inflation-deflation 
paradigm can be used to provoke reactive hyperemia (72). Besides 
provoking reactive hyperemia, the cuff paradigm also results in a 
stepped arterial input function of contrast agent concentration (53, 72). 
Although DCE MRI has proven to be a promising technique in 
highly perfused organs, such as brain and kidney tissue, the results of 
chapter 2 in this thesis indicate that perfusion of the calf musculature 
cannot be determined reproducibly with DCE MRI (42). Reproducibility 
studies in skeletal muscle are unfortunately scarce, but our work cor-
roborates to prior DCE MRI studies in various tumor types and skeletal 
muscle performed under resting conditions, which also reported unfa-
vorable reproducibility measures, particularly for muscle tissue (49, 53). 
In the study by Galbraith et al. flow in resting state muscle was low and 
variable. Large day-to-day variations in endothelial function due to 
variations in endothelial permeability and bioavailability of nitric oxide 
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might explain these results (49, 73). Although DCE-MRI allows very 
interesting insights into vascular (patho)physiology, the results of 
chapter 2 indicate a lack of discriminatory power for DCE MRI, as the 
differences in Ki between patients with PAD and healthy controls were 
not significant. 
In contrast to DCE MRI, BOLD MRI is a non-contrast enhanced 
functional MRI technique to measure perfusion. The BOLD phenomenon 
is based on local susceptibility changes due to changes in blood oxy-
genation and BOLD imaging is sensitive to the concentration of para-
magnetic deoxyhemoglobin (endogenous contrast). Its presence in 
blood results in a mismatch between the magnetic susceptibility of 
tissue and blood and thereby shortening of the T2* of blood and its 
immediate surroundings (52, 60). The disproportionally high inflow of 
oxygenated blood during postischemic reactive hyperemia, results in an 
initially rapidly increasing T2*, as the concentration of deoxyhemoglobin 
will decrease and the mismatch is reduced (52, 60, 61, 74-78). 
As is the case with DCE MRI, BOLD techniques have shown promis-
ing results in tissues with a high perfusion rate, such as brain and tumor 
tissue. However, the results in chapter 2 of this thesis indicate poor 
reproducibility for BOLD imaging as far as calf muscle perfusion is 
concerned. Besides, there was no significant difference between patients 
with PAD and healthy controls in this study (42). 
In summary, we demonstrated that macrovascular flow can be re-
producibly determined by MRI, whereas methods used to measure 
microvascular function were subject to large variations. Our observation 
of poor microvascular reproducibility is remarkable given the reproduci-
bility of the APF at the level of the popliteal artery (i.e. blood supply to 
calf muscle). There are two likely underlying reasons for this apparent 
discrepancy. First, the microcirculation of the calf muscle itself is likely 
more prone to day-to-day variations than macrovascular flow as the 
microcirculation and endothelial function are influenced by many intrin-
sic (i.e. hormonal and circadian cycles, insulin supply, shunting and 
rerouting of blood) and extrinsic (i.e. outside temperature, season, time 
of the day, food, pharmacologic) factors (79). Many of these factors are 
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susceptible to day-to-day variations and will therefore inevitably nega-
tively impact reproducibility of microvascular function. A second factor 
that might partly explain our findings is that microvascular function was 
assessed under reactive hyperemic conditions, whereas flow was meas-
ured under resting conditions. 
New developments 
The results of this thesis indicate, that currently APF is the most 
promising MR derived functional vascular measurement for use in 
clinical practice. APF measurements are much more reproducible and 
are best able to identify patients with PAD compared to other functional 
vascular MRI measurements evaluated in this thesis. Besides, APF has 
the major advantage that it is a fast MRI technique, with acquisition 
times well below one minute, which can easily be added to existing 
MRA-protocols, so that for those patients scheduled for MRA both 
morphologic and functional vascular status can be interrogated at the 
same time (42, 65-68). This may be especially useful, when other 
techniques, such as ABI measurements, have failed. APF measurements 
might eventually even serve as a replacement for other functional 
measurements, at least in patients with an indication for MRA. 
However, one of the strengths of other functional tests, especially 
ABI measurements, is a high degree of standardization. The ABI is 
measured at the same location using the same technique in every 
patient. Such a standardized protocol is a necessity for a functional 
measurement in order to be suitable for longitudinal follow-up or 
therapy monitoring in patients and will further increase the discrimina-
tive capability of a technique. As APF measurements are relatively new 
and not widely accepted, currently no such standardized protocol does 
exist for APF measurements, nor are there normative values known for 
APF measurements. Although APF measurements are relatively fast, it 
would be desirable to have a single, predefined location to measure the 
APF in all patients with PAD, at which the ability to differentiate between 
a diseased and non-diseased vasculature is highest. In chapter 4 of this 
thesis we demonstrated a standardized approach in which the APF was 
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measured in the proximal common femoral artery, proximal superficial 
femoral artery and the popliteal artery in patients with PAD, independent 
from the location of obstructive arterial lesions, and in non-PAD pa-
tients. The results of this study indicate that measurement of APF at the 
level of the popliteal artery shows the largest difference between PAD 
and non-PAD patients, best discriminative capability and highest suc-
cess rates of the measurement as compared to the APF acquired at the 
level of the common femoral artery and superficial femoral artery, even 
though differences with the superficial femoral artery are small. The 
popliteal artery therefore seems to be the most suitable predefined 
location for a standardized measurement of the APF in PAD patients. 
Although APF measurements at the level of the popliteal artery can be 
used to differentiate between patients with and without PAD, there 
remains an overlap in APF values between patients and healthy subjects, 
as can be seen in the histograms of chapter 4. Especially in PAD patients 
with intermittent claudication blood flow at rest might be - as expected 
- near-normal depending on the severity of the obstructive lesion, or 
recovers fast to near-normal values after exercise due to collateral 
artery formation (80-87). These (near-)normal resting flow values 
explain the absence of clinical symptoms at rest in intermittent claudi-
cation. Symptoms in these PAD patients, however, characteristically 
appear during physical exercise, when the flow demands towards the 
lower extremity increases. In an attempt to increase the sensitivity of 
APF measurements in these patients, we therefore developed a method 
to measure the flow reserve and tested its ability to discriminate pa-
tients with intermittent claudication from healthy control subjects 
(chapter 6). 
The results of this study revealed that flow reserve is severely 
compromised in patients with PAD compared to healthy controls. This 
indicates that flow reserve therefore is able to determine the hemody-
namic consequences of obstructive arterial lesions in PAD patients and 
to discriminate between patients with intermittent claudication and 
healthy controls. So, the concept of blood flow reserve, originally intro-
duced by Coffman and Gregg in 1960 for the coronary arteries (88), also 
seems to apply to the peripheral circulation (83, 84, 89-91). Lower flow 
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reserve in the popliteal artery of PAD patients can be explained by the 
presence of obstructive arterial lesions, resulting in a decrease of the 
pressure gradient distal to the vascular lesion and thereby a decrease of 
the maximum hyperemic flow distal to these lesions (91). 
Although the APF already provides useful functional information 
on the hemodynamic significance of obstructive arterial lesions in 
intermittent claudication, by measuring the flow reserve, we were able to 
identify more patients with PAD compared to resting APF measurements 
alone. These initial results also indicate that for suspected PAD patients 
with (near-)normal resting APF values, assessment of flow reserve might 
provide important additional functional information with respect to the 
hemodynamic significance of the arterial lesions, allowing better differ-
entiation between diseased and non-diseased vasculature. Further 
studies in larger populations will be needed to determine the true 
additional value of flow reserve in the assessment of the hemodynamic 
significance of obstructive arterial lesions, both in patients with inter-
mittent claudication and more severe stages of PAD. 
Microvascular function as measured with conventional DCE MRI is 
poorly reproducible and has limited discriminative capability. Neverthe-
less, microvascular function remains an interesting phenomenon to 
study, as PAD is known to affect the microcirculation as well, particularly 
in patients with diabetes mellitus(92, 93). Functional assessment of 
microvascular status of the lower extremities could therefore be a 
valuable addition to the current diagnostic work-up in PAD to objective-
ly determine disease severity and might be useful in evaluation of 
therapeutic efficacy in PAD (53, 59, 70, 94). Commonly used functional 
measures in DCE MRI, the rate constant (k) and the transfer constant 
(Ktrans), reflect a combination of the rate of microvascular reactivity and 
permeability, both of which may be significantly impaired in patients 
with PAD (49, 53, 95, 96). The rate of vascular reactivity, however, 
decreases with age, mainly due to slow progression of vascular re-
sistance as reflected by an increased intima thickness versus luminal 
diameter ratio (97). Therefore, the clinical relevance of these measures 
in PAD patients is questionable. In mild PAD, i.e. intermittent claudica-
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tion, symptoms generally arise and progress slowly during exercise (i.e. 
impaired active hyperemia). Critical ischemia, on the other, most severe 
end of the pathophysiological spectrum, is a chronic condition charac-
terized by hypoperfusion of the distal lower extremity at rest. It is 
conceivable that in both of these conditions, the absolute degree of 
microvascular dilatation, rather than its rate, is of more clinical rele-
vance and a better reflection of clinical severity of microvascular disease 
in PAD compared to both the rate and transfer constant. In chapter 7 of 
this thesis we therefore hypothesized that DCE MRI may better be used 
to measure the maximum microvascular dilatation by determining the 
hyperemic fractional microvascular blood plasma volume (Vp). Microvas-
cular blood plasma volume, however, is hard or even impossible to 
measure using extracellular contrast agents, as clinically applied low-
molecular weight (i.e. small-sized) contrast agents extravasate rather 
rapidly into the interstitial space (95, 98, 99). Blood pool contrast 
agents, however, are largely prevented from leaking into the interstitial 
space by a strong, reversible albumin binding and therefore theoretically 
allow a more reliable assessment of microvascular blood plasma volume 
with DCE MRI (100, 101). The results of this study indeed indicated that 
DCE MRI using a blood pool contrast agent is able to determine the 
hyperemic microvascular blood plasma volume Vp of the calf muscula-
ture and to identify patients with PAD as compared to healthy control 
subjects. In addition, the reproducibility of Vp was better as compared to 
conventional DCE MRI. Together with the ability to acquire DCE MRI data 
combined with CE-MRA during a single examination makes DCE MRI 
with a blood pool contrast agent a valuable addition to CE-MRA to 
assess both the macrovascular morphology and functional (hemody-
namic) status of the calf microvasculature in patients with PAD. Espe-
cially in diabetic patients we expect this method to be of value, although 
this remains to be investigated. 
Future developments 
The results of this thesis indicate that MRI is capable of assessing 
both vascular morphology and vascular function in the same examina-
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tion. The APF is a fast and easy to use MRI technique, that can be added 
to existing MRA-protocols. In its current state, APF measurements may 
already be useful in PAD patients, when other techniques, such as ABI 
measurements, have failed. APF measurements, however, might eventu-
ally even serve as a replacement for other functional measurements. 
Although imaging in PAD is currently only applied in those pa-
tients who are considered for invasive therapy, it can be argued whether 
or not this is the most cost-effective approach in the near future. In the 
present-day situation, the most suitable interventional approach in PAD 
patients is defined in most cases only after a patient has undergone 
physical examination, ABI measurement, segmental pressure measure-
ment, DUS and either MRA or CTA. This is a rather time consuming, 
patient unfriendly and costly approach. As many patients with PAD end 
up undergoing MRA anyway, early MRA with additional functional MRI 
may be a much more patient friendly and, at the end, cost-effective 
approach in the diagnostic work-up of PAD patients. Especially as 
vascular morphology and function can be assessed with a single MRI 
examination, while together taking less time than for example a full DUS 
examination. Results of the DIPAD trial already indicate that early 
imaging in PAD may be a more cost-effective approach than the current 
diagnostic work-up in PAD patients (34). 
Nevertheless, before functional vascular MRI, and especially APF 
measurements, are capable of replacing existing functional measure-
ments, more research is needed. As far as APF measurements are 
concerned, normative values need to be determined in large groups of 
PAD and non-PAD subjects. Besides, the influence of APF measurements 
or the correlation between APF and clinical outcome of PAD patients will 
have to be evaluated to determine the true clinical contribution of APF 
measurements in the diagnostic work-up of PAD patients in comparison 
with traditional functional measurements. Also, the cost-effectiveness of 
early MRA with additional functional measurements has to be evaluated. 
With these data available, MRA may play a much more prominent role in 
the diagnostic work-up of PAD patients in the near future. 
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Morphologic and functional vascular imaging in patients with PAD 
may in the future also play a role of importance in elucidating the 
biological mechanisms with which the human body compensates for 
local ischemia and to monitor the effects of established and novel 
vessel-stimulating therapies, to increase our knowledge concerning 
these processes and to perhaps help in the early identification of possi-
ble non-responders to therapy. In chapter 5 of this thesis we used MRA 
and APF measurements to evaluate the effect of supervised exercise 
therapy upon vascular status in PAD patients with intermittent claudica-
tion. Even though MRI in this study was not able to detect macrovascular 
changes, these imaging techniques can still be useful for the monitoring 
and follow-up of patients with PAD treated with other, new therapeutic 
options aiming to improve vascularization, such as with stem cells and 
endothelial growth factors (i.e. vascular endothelial growth factor (VEGF) 
and basic fibroblast growth factor (bFGF)), which are currently being 
developed for treatment of both intermittent claudication and critical 
ischemia (102-105). 
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Peripheral arterial disease (PAD) is an expression of generalized 
arteriosclerosis resulting in compromised arterial flow to the lower 
extremities due to obstructive peripheral arterial lesions. Symptoms 
range from intermittent claudication, commonly defined as pain and / or 
cramping of the calf musculature in response to exercise, relieved by a 
short period of rest, to critical limb ischemia, defined as ischemic rest 
pain, ulceration or gangrene. 
Arterial lesions can present at both the macro vascular level (i.e. 
lesions in large conduit arteries), and the micro vascular level, in which 
small arteries, arterioles and capillaries are affected. Microvascular 
disease is most pronounced in the subgroup of PAD patients with 
diabetic mellitus, whereas macrovascular disease is the major cause of 
symptoms in non-diabetic PAD patients. 
Collateral artery formation is one of the mechanisms by which the 
human body can compensate for the ischemia resulting from these 
obstructive arterial lesions. However, collateral formation is a complicat-
ed process, thought to involve both adaptation of existing arteries and 
the formation of novel collateral arteries, and to date the conditions 
under which collateral formation takes place in PAD are still poorly 
understood. 
Currently, the diagnosis of PAD is typically made on the basis of 
the typical clinical history, palpation of pedal pulsations and by meas-
urement of the ankle-brachial index (ABI). Consequently, imaging of the 
peripheral vascular tree is only preserved for those patients being 
considered for invasive therapy with the aim to localize arterial lesions 
and to plan the correct approach for the intervention. Although vascular 
imaging currently plays no clinical role of interest in the diagnosis of 
PAD, early imaging of PAD might be beneficial to determine a reliable 
starting point and the best therapeutic options for patients with PAD, 
but also to monitor the effects of vessel-stimulating therapies, to 
increase our knowledge concerning the biological processes and per-
haps to help in the early identification of possible non-responders to 
therapy. MRI might be an ideal imaging solution for such an approach of 
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patients with PAD, as MRI is a highly reliable tool to evaluate vascular 
morphology, but also vascular function during a single examination. 
This thesis addresses the development and usage of morphologic 
and functional vascular MRI in patients with PAD. The main objectives 
were to determine and optimize the suitability of morphologic and 
functional vascular MRI in diagnosis and longitudinal follow up of PAD 
patients. Therefore, in this thesis different morphologic and functional 
vascular MRI techniques were tested as far as reproducibility and dis-
criminative capability was concerned, and based upon these results 
improvements to existing techniques have been proposed and studied 
to increase reliability and to better differentiate between a diseased and 
healthy vasculature. Also, a standardized quantititive approach to 
acquire morphologic and functional vascular information was developed. 
In chapter 2 the reproducibility of morphologic and functional 
vascular MRI was evaluated in PAD patients and healthy control subjects. 
In this study, quantification of the morphological (macro)vascular status 
by contrast-enhanced MR angiography, as well as phase contrast MRI to 
assess macro vascular blood flow proved highly reproducible in both 
PAD patients and healthy volunteers. These MR techniques might there-
fore be helpful in studying the development of collateral arteries in PAD 
patients and in unraveling the mechanisms underlying this process. 
Functional assessment of the microvascular status using dynamic 
contrast enhanced (DCE) and dynamic blood oxygen level-dependent 
(BOLD) imaging MRI were not reproducible and are therefore currently 
not suitable for clinical application in PAD. 
In chapter 3 arterial peak flow (APF) measurements at different 
levels of the peripheral arterial vasculature in a large population of PAD 
and non-PAD patients were evaluated to determine the best location for 
APF measurements in order to facilitate clinical standardization. When 
measured at the level of the popliteal artery, the APF showed the largest 
differences between PAD and non-PAD patients, best discriminative 
capability and highest success rates of the measurement as compared to 
the APF acquired in the common or superficial femoral artery. Therefore 
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the popliteal artery seems to be the most suitable level for a standard-
ized flow measurement in PAD. 
In chapter 4 the success rates and discriminative capability of MRI 
derived APF measurements were compared with conventional ankle 
brachial index (ABI) measurements in a large clinical population of PAD 
patients. Compared to assessment of PAD severity with ABI, the success 
rate of MRI-based APF measurements was 20 % higher (91% versus 71% 
for APF and ABI measurements, respectively), with a similar discrimina-
tory capacity for disease severity. We conclude that APF is a valuable 
measure to objectively assess PAD severity in patients in whom ABI 
cannot be reliably determined, which is especially convenient in patients 
already scheduled to undergo MR angiography. 
In chapter 5 normative values for the APF in patients with PAD and 
non-PAD subjects were established and the influence of disease severity 
(intermittent claudication versus critical ischemia), presence of diabetes 
mellitus and age upon the APF were evaluated. Our reference values may 
aid in objective functional quantification of PAD severity and follow-up 
after intervention. We found that use of absolute flow values allows 
diagnosis of ≥50% luminal narrowing in the peripheral vascular tree with 
high accuracy. 
In chapter 6 the results of a longitudinal follow-up study using 
CE-MRA and quantitative phase contrast imaging to study the effect of 
supervised exercise therapy on vascular changes in PAD patients were 
presented. Supervised exercise therapy in patients with intermittent 
claudication resulted in an increase in pain free walking distance, 
whereas with MRI no macrovascular adaptations in terms of additional 
collateral artery formation or flow increases were observed. 
In chapter 7 a technique was presented to measure arterial flow 
reserve by quantitative PCI to improve the sensitivity of the APF to 
differentiate between PAD patients and healthy controls. Quantitative 2D 
MR cine PCI proved a promising method to determine flow reserve 
measures in patients with PAD and can be helpful to objectively discrim-
inate patients with intermittent claudication from healthy controls. 
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In chapter 8 we demonstrated the feasibility of DCE MRI of the calf 
musculature of PAD patients and healthy control subjects using a blood 
pool contrast agent. Using DCE MRI after contrast-enhanced MR angi-
ography with gadofosveset enables reproducible assessment of hypere-
mic fractional microvascular blood plasma volume of the calf 
musculature. This hyperemic fractional microvascular blood plasma 
volume was lower in PAD patients than in healthy controls, which re-
flects a promising functional (hemodynamic) biomarker in the study of 
microvascular impairment in patients with PAD. 
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Perifeer arterieel vaatlijden (PAV) is een expressie van algehele ar-
teriosclerose met een gecompromitteerde arteriële doorbloeding van de 
onderste extremiteiten als gevolg van obstructieve perifere arteriële 
laesies. De symptomen variëren van claudicatio intermittens, doorgaans 
gedefinieerd als pijn en/of kramp van de kuitspieren in reactie op 
inspanning welke verdwijnt na een korte periode van rust, tot kritische 
ischemie van de ledematen, gedefinieerd als ischemische rust pijn, 
zweren en gangreen. 
Arteriële laesies kunnen zich presenteren zowel op het macrovas-
culaire niveau (dat wil zeggen laesies in grote aanvoerende arteriën) als 
op het microvasculaire niveau, waarbij kleine arteriën, arteriolen en 
capillairen zijn aangedaan. Microvasculaire pathologie is het meest 
uitgesproken in de subgroep van patiënten met diabetes mellitus, terwijl 
macrovasculaire pathologie de belangrijkste oorzaak van de symptomen 
is bij niet-diabetische patiënten met PAV. 
De vorming van collateraal arteriën is een van de mechanismen 
waarmee het menselijk lichaam kan compenseren voor de ischemie die 
uit deze obstructieve arteriële laesies voortvloeit. Echter, collateraalvor-
ming is een ingewikkeld proces, waarvan men denkt dat het zowel de 
aanpassing van de bestaande arteriën als de vorming van nieuwe colla-
terale arteriën omvat. De omstandigheden waaronder deze collateraal-
vorming plaatsvindt bij patiënten met PAV is nog altijd een groot 
vraagstuk. 
Momenteel wordt de diagnose van PAV meestal gesteld op basis 
van de typische klinische voorgeschiedenis, palpatie van de enkel 
pulsaties en door de meting van de enkel-arm index (EAI). Beeldvorming 
van het perifere vaatstelsel wordt alleen toegepast op die patiënten bij 
wie invasieve behandeling wordt overwogen, met als doel arteriële 
laesies te lokaliseren en de juiste benadering voor de interventie te 
plannen. Hoewel vasculaire beeldvorming geen klinische rol van beteke-
nis speelt bij het diagnosticeren van PAV, kan vroege beeldvorming van 
PAV voordelig zijn om een betrouwbare uitgangsituatie vast te stellen en 
om de beste therapeutische opties te bepalen. Daarnaast is beeldvor-
ming ook geschikt voor het monitoren van deze patiënten om de invloed 
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van vaat stimulerende therapieën te evalueren en om onze kennis over 
de betrokken biologische processen te vergroten. Dit kan uiteindelijk 
misschien helpen bij de vroegtijdige identificatie van mogelijke non-
responders op therapie. MRI kan een ideale beeldvormende modaliteit 
zijn voor een dergelijke benadering van patiënten met PAV, aangezien 
MR angiografie een zeer betrouwbaar hulpmiddel is om de vasculaire 
morfologie evalueren en MRI daarnaast ook geschikt is om functionele 
metingen te verrichten. 
Dit proefschrift richt zich op de ontwikkeling en het gebruik van 
morfologische en functionele vasculaire MRI metingen bij patiënten met 
PAV. De belangrijkste doelstellingen waren het bepalen en optimaliseren 
van de geschiktheid van morfologische en functionele vasculaire MRI 
metingen in de diagnostiek en longitudinale follow-up van patiënten 
met PAV. Daartoe zijn in dit proefschrift verschillende morfologische en 
functionele vasculaire MRI technieken getest op gebied van reprodu-
ceerbaarheid en discriminerend vermogen tussen vaatstelsels met en 
zonder PAV en op basis van deze resultaten zijn verbeteringen doorge-
voerd aan de bestaande methoden om de betrouwbaarheid en het 
onderscheidend of discriminerend vermogen te verhogen. Ook werd een 
gestandaardiseerde, kwantitatieve methode voor het verkrijgen van 
morfologische en functionele vasculaire informatie ontwikkeld. 
In hoofdstuk 2 van deze thesis werd de reproduceerbaarheid van 
morfologische en functionele vasculaire MRI metingen geëvalueerd in 
patiënten met PAV en gezonde proefpersonen, en werd gekeken naar de 
verschillen tussen patiënten en gezonde proefpersonen. In deze studie 
werd de morfologische (macro)vasculaire status gekwantificeerd door 
het tellen van collateraalvaten die afgebeeld werden met contrast-
versterkte MR angiografie. Daarnaast werd het functioneren van de 
vaten gekwantificeerd met behulp van fase-contrast (bloedsnelheid 
sensitieve) MRI. Beide methoden bleken zeer reproduceerbaar, zowel bij 
patiënten met PAV als gezonde vrijwilligers. Deze MR technieken kunnen 
daarmee nuttig zijn bij het bestuderen van de ontwikkeling van collate-
raalarteriën in patiënten met PAV en hulp bieden bij het ontrafelen van 
de mechanismen die ten grondslag liggen aan dit proces. De functionele 
SAMENVATTING 
241 
kwantificatie van de microvasculaire status met gebruik van dynamische 
contrast-versterkte (DCE) en blood oxygen level-dependent (BOLD) MRI 
bleek slecht reproduceerbaar en is momenteel dan ook niet geschikt 
voor klinische toepassing in patiënten met PAV. 
In hoofdstuk 3 werden arteriële peak flow (APF) metingen op ver-
schillende fysieke niveaus van het perifere arteriële vaatstelsel in een 
grote populatie van patiënten met en zonder PAV geëvalueerd, om de 
beste locatie voor APF metingen te bepalen en zo standaardisatie van de 
meting te bevorderen. Hieruit bleek dat metingen op het niveau van de 
arterie poplitea resulteerden in de grootste verschillen tussen patiënten 
met en zonder PAV, het beste discriminerende vermogen en de hoogste 
slagingspercentages. Daarmee lijkt de arterie poplitea de meest ge-
schikte locatie voor een gestandaardiseerde flowmeting te zijn in pati-
enten met PAV. 
In hoofdstuk 4 werden de slagingspercentages en het discrimine-
rend vermogen van APF metingen vergeleken met conventionele EAI 
metingen in een grote klinische populatie van patiënten met PAV. Het 
slagingspercentage van APF metingen was 20 % hoger ( 91 % versus 71 
% voor respectievelijk APF en EAI metingen), met een vergelijkbaar 
discriminerend vermogen voor de ernst van de ziekte. APF is daarmee 
een waardevolle meting om objectief de ernst van de ziekte vast te 
stellen bij patiënten met PAV bij wie de EAI niet of niet betrouwbaar kan 
worden bepaald. 
In hoofdstuk 5 werden karakteristieke waarden voor de APF bij pa-
tiënten met en zonder PAV vastgesteld en de invloed van de ernst van 
ziekte (claudicatio intermittens versus kritische ischemie), de aanwezig-
heid van diabetes mellitus en de leeftijd op de APF geëvalueerd. De 
bepaalde referentiewaarden kunnen bijdragen aan de objectieve functi-
onele kwantificering van de ernst van het PAV en de follow-up na de 
interventie.  
In hoofdstuk 6 werden de resultaten gepresenteerd van een longi-
tudinale follow-up studie van patiënten met PAV die gesuperviseerde 
looptherapie ondergingen en waarbij met behulp van contrast-
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versterkte MR angiografie en kwantitatieve flow metingen het effect van 
deze therapie op de bloedvaten werd bestudeerd. Gesuperviseerde 
looptherapie bij deze patiënten met claudicatio intermittens resulteerde 
in een toename van de pijnvrije loopafstand, terwijl met MRI geen 
macrovasculaire veranderingen werden waargenomen. 
In hoofdstuk 7 werd een techniek gepresenteerd om de arteriële 
flowreserve te meten en zodoende gevoeligheid van de APF meting om 
te discrimineren tussen patiënten met PAV en gezonde personen te 
verbeteren.  
In hoofdstuk 8 toonden we de mogelijkheid om met behulp van 
een ‘blood pool’ contrastmiddel DCE MRI van de kuitspieren bij patiën-
ten met PAV en gezonde proefpersonen te verrichten. Door de DCE MRI 
meting te verrichten na contrast-versterkte MR angiografie met gado-
fosveset als contrastmiddel, werd het mogelijk om een reproduceerbare 
bepaling van het hyperemic fractional microvascular blood plasma 
volume van de kuitspieren te bepalen. Dit hyperemic fractional micro-
vascular blood plasma volume bleek bij patiënten met PAV lager dan bij 
gezonde personen, waarmee het een veelbelovende functionele (hemo-
dynamische) biomarker is voor de studie naar microvasculaire patholo-
gie bij patiënten met PAV. 
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De studies beschreven in dit proefschrift waren nooit mogelijk ge-
weest zonder de medewerking van vele patiënten en vrijwilligers, die 
bereid waren een (vaak) langdurig en een niet al te comfortabel MRI 
onderzoek te ondergaan, in veel gevallen zelfs meerdere malen. Daarom 
wil ik in eerste instantie al deze personen, die vaak belangeloos deelna-
men, danken voor hun belangrijke bijdrage aan de totstandkoming van 
dit proefschrift! 
 
(Prof?) Dr. Tim Leiner. Beste Tim, jij hebt mij de mooie kanten van 
wetenschappelijk onderzoek doen laten zien. Je hebt mij vanaf de eerste 
dag van onze samenwerking het gevoel van vertrouwen gegeven en ik 
ben je zeer dankbaar voor alle kansen die je me hebt geboden. Samen-
werken met zo’n gemotiveerd en gedreven persoon als jij was voor mij 
een hele prettige en leerzame ervaring. Ondanks je, destijds voor mij 
onverwachte, vertrek naar Utrecht stond dit onze samenwerking geluk-
kig niet in de weg. Wie weet zullen we in de toekomst nog vaker een 
project samen doen. 
 
Prof. Dr. Ir. Walter Backes. Beste Walter, na Tim’s vertrek naar 
Utrecht waren we voor dit onderzoek toch vooral op elkaar aangewezen. 
Een fysicus en een arts, die niet zelden anders tegen de onderwerpen 
aan keken. Desondanks hebben we het onderzoek tot een goed einde 
weten te brengen en ik ben je dankbaar voor de samenwerking in de 
afgelopen jaren. 
 
Dr. Patty Nelemans. Beste Patty, ook jouw bijdrage aan dit onder-
zoek was van groot belang. Niet zelden dachten we het ei van Columbus 
ontdekt te hebben, waarna jouw berekeningen en inzichten ons weer 
met beide benen op de grond zette. Hoewel dat nog wel eens wat 
frustratie met zich mee bracht, kwamen de manuscripten door jouw 
inbreng op een kwalitatief hoger niveau. Ik ben je daarom erg dankbaar 
voor je bijdrage aan dit proefschrift en ben blij dat je een van mijn co-
promotoren bent. 
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Prof. Dr. Joachim Wildberger. Beste Joachim, met uw komst naar 
Maastricht raakte u kort na de start van mijn onderzoek betrokken bij 
dit project. Hoewel er in het begin enige bedenkingen waren over de 
doelstellingen en haalbaarheid, heeft dit onderzoek mede dankzij uw 
inspanningen geleid tot een heel aantal mooie publicaties. Ik ben u erg 
dankbaar voor deze samenwerking en de waardering die u menigmaal 
heeft uit gesproken over mijn werk. 
 
Prof. Dr. Michiel de Haan. Beste Michiel, hoewel jij nooit direct be-
trokken bent geweest bij mijn studies, ben ik je dankbaar voor het 
vertrouwen dat je me hebt gegeven vanaf het eerste moment dat ik op 
de afdeling Radiologie van het azM rond liep. In de afgelopen jaren ben 
ik gemarineerd geraakt in de MRA’s en CTA’s en hebben we leuke 
verbeteringen aan protocollen en beeldkwaliteit op het gebied van MRA 
weten door te voeren. Je interesse in de voortgang van het onderzoek en 
je luisterend oor in de mindere tijden heb ik altijd zeer gewaardeerd. 
Hoewel onze wegen zich ondertussen waarschijnlijk gescheiden hebben, 
kijk ik met veel plezier terug naar onze samenwerking in de afgelopen 
jaren. 
 
MRI laboranten azM. Beste laboranten, ook zonder jullie medewer-
king was dit onderzoek niet mogelijk geweest. Thea en Etienne, langs 
deze weg wil ik jullie speciaal hartelijk danken voor het feit dat jullie 
altijd bereid waren mee te denken, nieuwe protocollen uit te testen en 
door te voeren, ook buiten werktijd.  
 
Afdeling vaatchirurgie azM. Ik wil de afdeling vaatchirurgie, en dan 
met name prof. dr. Schurink en dr. Daemen hartelijk danken voor de 
samenwerking en hun inspanningen om patiënten te werven voor 
deelname aan de verschillende studies. Zonder deze samenwerking was 
dit onderzoek niet mogelijk geweest. 
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Pap, mam, Peter, ik wil jullie hartelijk danken voor jullie interesse 
en medewerking (ook jullie zijn immers voor mij in die scanner gedo-
ken) in mijn onderzoek in de afgelopen jaren. Jullie hebben me zien 
veranderen van een heel gemotiveerde promovendus naar iemand die 
erg kritisch is geworden en van bepaalde keuzes spijt heeft gekregen; 
daar hebben we vele discussies over gevoerd. Nu dit hoofdstuk afgeslo-
ten is, is het tijd voor een nieuwe, totaal andere uitdaging in een totaal 
andere wereld.  
 
Michel, ik heb geen idee hoelang wij elkaar nu kennen (kan me in 
ieder geval nog een oude Dell & Carmageddon(?) herinneren, wat een 
tijd was dat…), maar onze vriendschap heeft de nodige vrouwen, studies 
en nog meer verhuizingen weten te doorstaan. Of het nu voor goed 
gesprek of een nieuw spel is (al dan niet met blauwe legers), we weten 
elkaar gelukkig altijd weer te vinden. Hoewel je eerste ervaring met de 
MRI niet helemal jouw ding bleek te zijn, ben ik blij dat mee wilde 
werken. Bedankt voor je vriendschap en je interesse in dit onderzoek. 
We zien elkaar snel weer in Veldhoven… of Nijmegen… of Veldhoven… 
of Nijmegen… (’t is altijd weer een verrassing waar je woont).  
 
Jeroen, een speciaal woord van dank voor jou, voor onze vriend-
schap, je belangstelling in mijn onderzoek, het mee denken en de vele 
discussies die we hebben gevoerd ‘ons wereldje’. Ik ken weinig mensen 
die zo enthousiast zijn in hun bezigheden, die zich zo (belangeloos) 
inzetten en zo in en in goed zijn als jij. Ik hoop dat onze vriendschap 
ook na mijn tijd in het Limburgse nog lang zal bestaan.  
 
Marloes... wat hebben wij een hectische tijd achter de rug. Wij 
leerden elkaar kennen op het moment dat bij mij de twijfels het grootst 
waren, maar jij wist me met je vlotte (en niet te stoppen) babbel altijd 
weer het positieve van dingen in te laten zien. Bedankt voor je steun, je 
vriendschap en de gezellige tijd die we hebben gehad en hopelijk nog 
gaan hebben! 
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Alice. Lieve Alice, ik kan niet beschrijven hoe mijn leven is veran-
derd sinds ik jou heb leren kennen en hoeveel vreugde jij hebt gebracht 
in mijn leven. Hoewel je dit bepaald niet als je grootste of beste daad 
beschouwt, heb jij mij doen beseffen dat er veel belangrijkere dingen 
zijn in het leven dan werk, maar vooral wat echte waardering is. Je bent 
mijn vriendin, mijn maatje, mijn geweten en sinds dit jaar ook nog eens 
mijn zakenpartner! Of het nu binnen de radiologie is of met ons eigen 
bedrijfje (manege?) of allebei, wij gaan het samen maken lieve schat, is 
het niet hier, dan wel in ons geliefde Zweden. Ik hou van je!  
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